Patent Abridgements Part 1 [2.2 MB PDF] - Intellectual Property ...

INTELLECTUAL PROPERTY OFFICE OF NEW ZEALAND 

Complete Specifications Accepted 

Copies of the specification and drawings (if any) can be obtained 

from the IPONZ website www.iponz.govt.nz. 

At any time within 3 months from the date of issue of this Journal, any 

person interested may give notice of opposition to the grant of a patent on 

any of the applications relating to the accepted complete specification 

shown hereunder, by filing form 15 in duplicate accompanied by a statement 

of the case in duplicate and a fee of $300 plus GST where applicable, 

provided that if an application for extension on form 16 is made within 

the said 3 months, the Commissioner may extend the prescribed period 

for opposition to 4 months from the date of issue of this Journal. The 

grounds for giving notice of opposition are specified in section 21 of the 

Act, and prospective opponents should also refer to regulations 48 to 56 

of the Patents Regulations 1954. 

(21) 540042 (22) 16 May 2005 

(54) Broccoli type adapted for ease of harvest having exserted head produced 

by traditional or selective breeding 

(51) IPC2010.01:A01H5/00,10 

(71) Seminis Vegetable Seeds, Inc. 

(72) van den Bosch G.J.M., Franciscus; Boon, Meinardus P; 

(31) 04 850077 (32) 19 May 2004 (33) US 

(74) SPRUSON & FERGUSON, St Martins Tower, Level 35, 31 Market 

Street, Sydney, New South Wales 2000, Australia 

(57) A broccoli cultivar and methods of producing the cultivar comprising 

the traits of a crown higher than the leaf canopy and having a harvestable 

head weight of at least about 200 grams when planted at a density 

of40,000 plants per hectare, wherein within at least 25 centimetres of the 

crown .said cultivar produces no leaves or petioles having a surface 

area each greater than about 30 square centimetres, wherein the foregoing 

traits have been introduced by plant breeding. 

Divisional filed as 584334 

(21) 540343 (22) 13 Nov 2003 

(54) Compositions and methods for the diagnosis and treatment of tumor 

(86) PCT/US2003/036298 (87) WO2004/045516 

(51) IPC2010.01:C07K16/30; C12N15/13; C12P21/02 

(71) GENENTECH, INC. 

(72) Ashkenazi, Avi J; Frantz, Gretchen; Goddard, Audrey; Gonzalez, Lino; 

Gurney, Austin L; Polakis, Paul; Polson, Andrew; Wood, William I; Wu, 

Thomas D; Zhang, Zemin; 

(31) 02 426847 (32) 15 Nov 2002 (33) US 

(31) 02 431250 (32) 6 Dec 2002 (33) US 

(31) 02 437344 (32) 31 Dec 2002 (33) US 

(74) A J PARK, 6th Floor, Huddart Parker Building, 1 Post Office Square, 

Wellington 6011, New Zealand 

(57) Provided is a method of diagnosing the presence of a tumor in a 

mammal, the method comprising (i) determining the level of expression 

ofa gene encoding a TAT 408 polypeptide with a specified sequence in a 

test sample of tissue cells obtained from the mammal, and (ii) comparing 

the level of expression of (i) with the level of expression of said nucleic 

acid in a control sample; wherein a significantly higher level of expression 

of the gene encoding the protein in the test sample, as compared to 

the control sample, is indicative of the presence of tumor. 

(21) 542258 (22) 6 Sep 2005 (23) 5 Sep 2006 

(54) A medical composition comprising honey or sugar syrup and a viscosity 

increasing agent for use on wounds 

(51) IPC2010.01:A23L1/08; A61L15/28; A61K47/38,36; A61K9/70; A61L26/ 

00 

(71) Comvita New Zealand Limited 

(72) Molan, Peter Charles; 

(74) CreateIP, Unit 1, 16 Bealey Avenue, Christchurch 8640, New Zealand 

(57) Disclosed is a paste for application to a wound comprising: honey or 

sugar syrup; and at least one viscosity increasing agent selected from 

guar gum, a methylcellulose compound, a hydroxyl ethyl cellulose com- 

pound, and combinations thereof; wherein the viscosity increasing agent 

or agents and honey or sugar syrup are mixed together at a ratio of 

approximately 0.75 to 2 parts viscosity increasing agent to 5 parts honey 

or sugar syrup; and, wherein the paste flows once mixed and attains an 

increased viscosity forming a semi-solid gel or solid on application to a 

moist wound environment. Also disclosed is a method for producing the 

above paste, and its use in treating wounds. 

(21) 543606 (22) 7 Apr 2005 

(54) Method of managing a plurality of electronic microcircuit chip readers 

and equipment for implementing said method 

(51) IPC2010.01:A63F3/00; G07F17/32; G06K7/016 

(71) Gaming Partners International 

(72) Vuza, Dan Tudor; 

(74) BALDWINS INTELLECTUAL PROPERTY, Level 14, Baldwins Centre, 

342 Lambton Quay, Wellington 6011, New Zealand 

(57) A method for coordinated management of a plurality of contactless 

radiofrequency readers of chips incorporating electronic microcircuits, is 

disclosed. The method comprises: (a) transmitting, in a first time interval, 

transmit operations from each of a plurality of active readers to the 

electronic microcircuits of the chips associated with each respective 

reader; and (b) receiving, in a second time interval, responses from the 

electronic microcircuits of the chips associated with each respective 

reader, where the first and second time intervals do not overlap. The 

active readers are synchronized to group their respective transmitting 

and receiving into distinct time intervals, where the synchronisation is 

such that it begins with the reader assigned instruction having the greatest 

duration, where a delay between executing one instruction and the 

next is equal to a difference between the durations of the transmit operations 

of the transmit/ receive cycle command instructions to be transmitted 

by the corresponding readers, up to executing the instruction associated 

with the shortest duration of the transmit operations. 

(21) 543685 (22) 14 May 2004 

(54) Rotor Blade connection for wind power plant 

(86) PCT/EP2004/005166 (87) WO2004/106732 

(51) IPC2010.01:F03D1/06 

(71) Aloys Wobben 

(72) Wobben, Aloys; 

(31) 03 0324166 (32) 28 May 2003 (33) DE 

(74) Pizzeys Patent and Trade Mark Attorneys, Level 2, Woden Plaza 

Offices, Woden Town Square, Woden, ACT 2606, Australia 

(57) The disclosure relates to a rotor blade for a wind power plant provided 

with several holes which are embodied in the base thereof and 

designed in the form of passage holes extending essentially vertically 

with respect to the longitudinal axis of said rotor blade which also comprises 

transversal bolts inserted into said holes and strength members 

connectable to the transversal bolts. Usually, the strength members extend 

in the base of a rotor blade thereby weakening material in said area. 

The aim of said invention is to solve the problem by simplifying the struc- 

PATENT OFFICE JOURNAL 1571 28 May 2010 Page 58 |BACK TO CONTENT


ture. For this purpose, the inventive rotor blade is characterised in that 

the strength members extends outwards the rotor blade base in such a 

way that said area is aerodynamically modified in a disadvantageous 

manner at a hub area without detrimentally affecting the acoustic behaviour 

and other properties of the device since the blade base is covered 

by a blade spinner or arranged at least in the low-rotating rotor area. 

(21) 545441 (22) 12 Nov 2004 

(54) Multi-layer blown film molding machine and method of molding multilayer 

blown film 

(86) PCT/JP2004/016846 (87) WO2005/046970 

(51) IPC2010.01:B29C55/28; B29C47/06,20,88 

(71) Shikoku Kakoh Co., Ltd. 

(72) Kitauji, Yoshiyuki; Nishida, Takahiro; Andou, Akitaka; Kometani, Hideo; 

Kitajima, Hidetoshi; Goma, Shinichiro; Nyuko, Masayuki; Yoshihara, 

Shigeru; Futagawa, Takashi; Hasegawa, Noritaka; 

(31) 03 382947 (32) 12 Nov 2003 (33) JP 

(31) 04 045474 (32) 20 Feb 2004 (33) JP 



(57) A multi-layer blown film molding machine, comprising an adapter installed 

to supply multiple types of resins, a molding die installed on the 

axial downstream side of the adapter, and a temperature control mechanism. 

The multiple types of molten resins are individually supplied to the 

molding die through the adopter. The molding die further comprises a 

body, a laminate of a plurality of single layer thin-film molding dies axially 

disposed in the body and generating the thin-film of the corresponding 

resin among the multiple types of molten resins and a first annular passage 

formed between the body and the laminate. A multi-layer thin-film 

formed of the plurality of thin-films laminated on each other is outputted 

as a multi-layer thin-film annular film through the first annular passage, 

and the temperature control mechanism independently controls the temperatures 

of the plurality of single layer thin-film molding dies. 

(21) 545442 (22) 17 Jul 2004 

(54) Medicaments for inhalation comprising betamimetics and an aclidinium 

salt known as 3-(2-hydroxy-2,2-dithiophen-2-yl-acetoxy)-1-(3phenoxypropyl)-l-azoniabicyclo[2.2.2]octane 

(86) PCT/EP2004/008030 (87) WO2005/014044 

(51) IPC2010.01:A61K45/06; A61K31/46; A61P11/00,06 

(71) BOEHRINGER INGELHEIM INTERNATIONAL GMBH 

(72) Pairet, Michel; Pieper, Michael P; Meade, Christopher John Montague; 

(31) 03 03017163 (32) 29 Jul 2003 (33) EP 



(57) Disclosed is a pharmaceutical composition of formula 1, wherein the 

substituents are as defined in the specification, combined with one or 

more betamimetics selected from the group consisting of formoterol, 

salmeterol, 3-(4-{6-[2-Hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)ethylamino]-hexyloxy}-butyl)-benzenesulfoneamide 

and 5-[2-(5,6- 

Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-lH-quinolin-2-one, 

optionally in the form of an enantiomer thereof, a mixture of enantiomers 

thereof or in the form of a racemate thereof, optionally in the form of a 

solvate or hydrate thereof and optionally together with a pharmaceutically 

acceptable excipient. 

(21) 545608 (22) 28 Sep 2004 

(54) Inert anode connections brazed during use in the production of aluminium 

by fused-salt electrolysis 

(86) PCT/FR2004/002451 (87) WO2005/033368 

(51) IPC2010.01:C25C3/12,16; B23K1/00 

(71) ALUMINIUM PECHINEY 

(72) Lamaze, Airy-Pierre; 

(31) 03 0311444 (32) 30 Sep 2003 (33) FR 



(57) Anode assembly (1) to be used in a fused bath electrolysis aluminium 

production cell is disclosed. The anode (1) has at least one inert anode 

(2) in the shape of a ladle, at least one connection conductor (3) and at 

least one brazed metallic joint (31) or brazing material that could form a 

brazed metallic joint (31). The inert anode (2) has a cavity (21) and an 

open end comprising at least one connection surface (20) with least one 

mechanical connection means (26, 34). The connection conductor has a 

connection end with at least one connection surface (40) and at least 

one mechanical connection (45) capable of cooperating with the mechanical 

connection means of the anode (26, 34) so as to set up a loose 

mechanical link between the conductor (3) and the anode (2). The brazed 

metallic joint (31) is already formed of is formed wholly or partly during 

use, the joint being located between all or part of the connection surface 

of the open end of the anode and all or part of the connection surface of 

the connection end of the conductor. 



(21) 546055 (22) 27 Aug 2004 

(54) Novel tricyclic nucleosides or nucleotides as therapeutic agents 

(86) PCT/US2004/027819 (87) WO2005/021568 

(51) IPC2010.01:C07H19/23; A61K31/7064; A61P31/12 

(71) Biota Scientific Management Pty Ltd 

(72) Cook, Phillip Dan; Ewing, Gregory; Jin, Yi; Lambert, John; Prhavc, 

Marija; Rajappan, Vasanthakumar; Rajwanshi, Vivek K; Sakthivel, 

Kandasamy; 

(31) 03 498425 (32) 27 Aug 2003 (33) US 

(74) DAVIES COLLISON CAVE - MELBOURNE, 1 Nicholson Street, Melbourne, 

Victoria, Australia 

(57) Disclosed is a compound of the formula (I) which may be a D- or Lnucleotide 

or nucleoside, wherein A is O, S, CH2, NH, CHF, or CF2; R1, 

R2, R2’, R3, R3’ and R4 are independently selected from the group consisting 

of H, F, Cl, Br, I, OH, SH, NH2, NHOH, NHNH2, N3, COOH, CN, 

CONH2, C(S)NH2, COOR, R, OR, SR, SSR, NHR, and NR2; provided 

that at least one of R2 or R2’ is not hydrogen; B is a base selected from 

the group of heterocycles as defined by formula (II) or formula (III), and 

wherein the other substituents are as defined herein. Also disclosed is 

the use of compounds including those defined above in the manufacture 

of a medicament for the treatment of a viral or bacterial infection, wherein 

the medicament optionally comprises one or more active anti-viral or 

anti-bacterial agents. 

(21) 546369 (22) 9 Sep 2004 

(54) Antibodies to M-CSF 

(86) PCT/US2004/029390 (87) WO2005/030124 

(51) IPC2010.01:C07K16/00; C12N15/00 

(71) Amgen Fremont Inc.; Warner-Lambert Company LLC 

(72) Bedian, Vahe; Devalaraja, Madhav Narasimha; Low, Joseph Edwin; 

Mobley, James Leslie; Kellermann, Sirid-Aimee; Foltz, Ian; Haak- 

Frendscho, Mary; 

(31) 03 502163 (32) 10 Sep 2003 (33) US 

(74) CULLEN & CO, Level 32, 239 George Street, Brisbane, QLD 4001, 

Australia 

(57) Provided is a human monoclonal antibody or an antigen-binding portion 

thereof that specifically binds to M-CSF, wherein the antibody or 

portion comprises: a) a heavy chain comprising the heavy chain CDR1, 

CDR2 and CDR3 of an antibody 8.10.3F, 8.10.3 (ATCC Hybridoma Accession 

No. PTA-5395), 8.1 0.3C-Ser, 8.10.3-CG2, 8.1 0.3-Ser, 

8.10.3CG4, or 8.10.3FG1; or b) the heavy chain of a) and a light chain 

comprising the light chain CDR1, CDR2 and CDR3 of the selected antibody. 

Further provided is the use of the compositions for the manufacture 

of a medicament to treat arthritis, asthma, cancer, inflammatory conditions 

and various other diseases. 


(21) 546575 (22) 15 Sep 2004 

(54) Plate-shaped cementitious product and production method 

(86) PCT/FR2004/002336 (87) WO2005/028773 

(51) IPC2010.01:E04C2/06; E04F13/14; C04B28/02,04 

(71) SAINT-GOBAIN MATERIAUX DE CONSTRUCTION S.A.S. 

(72) Famy, Charlotte; Cadoret, Gael; Houang, Paul; 

(31) 03 0310813 (32) 15 Sep 2003 (33) FR 



(57) A fiber-reinforced cementitious board product is prepared from a sheet 

material aqueous suspension that does not contain siliceous sand by 

superposition of thicknesses of the material on a filtration screen until 

the desired board thickness is obtained, the board then being autoclaved. 

The material of the matrix includes a hydraulic binder such as Portland 

cement, fibrous plant material such as wood fibre, and at least one 

pozzolan chosen from aluminosilicates, calcium aluminosilicates, amorphous 

silica, and material containing essentially amorphous silica that is 

capable of undergoing a pozzolanic reaction. In any case each of the 

materials has a particle size with mean diameter greater than 1 micrometer. 

(21) 547042 (22) 12 Oct 2004 

(54) Method for eliciting a T-cell response 

(86) PCT/US2004/033391 (87) WO2005/035779 

(51) IPC2010.01:A61K31/70; A61K39/00 

(71) POWDERJECT VACCINES, INC. 

(72) Braun, Ralph Patrick; Dong, Lichun; 

(31) 03 510086 (32) 10 Oct 2003 (33) US 

(31) 03 526571 (32) 4 Dec 2003 (33) US 

(31) 04 567771 (32) 5 May 2004 (33) US 



(57) Provided is the use of a nucleotide sequence of interest (NOI) encoding 

a T cell epitope; and a protein comprising the T cell epitope; in the 

manufacture of a medicament to be administered to a mammal to elicit a 

T cell response against a T cell epitope in a host mammalian subject for 

treating or preventing a disease or condition that would benefit from a Tcell 

response, wherein the medicament is formulated for administration 

according to a dosage regime providing: (i) a first immunisation that comprises 

at least two administrations to the subject, wherein all subsequent 

administrations are given at least 2 and no more than 6 days after the 

first administration, and wherein each administration comprises administering 

a nucleotide sequence of interest (NOI) encoding a T cell epitope, 

and (ii) a second immunisation that comprises at least one administration 

to the subject of a protein comprising the T cell epitope, wherein the 

time between the first administration of the first immunisation, and the 

first administration of the second immunisation, is from 21 to 365 days. 

(21) 547044 (22) 5 Nov 2004 

(54) Substituted triazoles as sodium channel blockers 



(86) PCT/US2004/037280 (87) WO2005/047270 

(51) IPC2010.01:A61K31/4196; A61P25/00; C07D249/10,08 

(71) MERCK SHARP & DOHME CORP. 

(72) Park, Min K; Chakravarty, Prasun K; Zhou, Bishan; Gonzalez, Edward; 

Ok, Hyun; Palucki, Brenda; Parsons, William H; Sisco, Rosemary; Fisher, 

Michael H; 

(31) 03 518890 (32) 10 Nov 2003 (33) US 



(57) Disclosed is a compound of formula (I) or (II) or a pharmaceutically 

acceptable salt thereof, wherein the substituents are disclosed within 

the specification. Also disclosed is the use of a compound of formula (I) 

or (II) for the preparation of a medicament for the treatment or prevention 

of pain. 

(21) 547071 (22) 19 Nov 2004 

(54) Preparation of palladium / gold catalyst on a support when prepared 

from halide free precursors 

(86) PCT/US2004/038815 (87) WO2005/065819 

(51) IPC2010.01:B01J23/52; B01J35/00; B01J37/02; C07C67/055; 

C07C69/12 

(71) Celanese International Corporation 

(72) Wang, Tao; Wade, Leslie E; Wong, Victor; Han, Jun; Hagemeyer, 

Alfred; Lowe, David; Sokolovskii, Valery; 

(31) 03 530937 (32) 19 Dec 2003 (33) US 



(57) Disclosed is a method of producing a catalyst or pre-catalyst suitable 

for assisting in the production of alkenyl alkanoates (such as vinyl acetate), 

comprising: a) contacting at least one catalytic precursor solution 

comprising palladium and gold to a support material wherein the at least 

one catalytic precursor solution is an aqueous solution that comprises 

one or more of Pd(NH3)2(NO2)2, Pd(NH3)4(OH)2, Pd(NH3)4(NO3)2, 

Pd(NH3)4(OAc)2, Pd(NH3)2(OAc)2, Pd(NH3)2(HCO3)2, NaAuO2, 

NMe4AuO2, HAu(NO3)4 in nitric acid or combinations thereof, wherein 

the aqueous solution is substantially free of chlorine; and b) reducing the 

palladium or gold by contacting a reducing environment to the support 

material. 

(21) 547072 (22) 19 Nov 2004 

(54) Zirconia containing support material for palladium / gold catalysts 

(86) PCT/US2004/039039 (87) WO2005/061107 

(51) IPC2010.01:B01J21/06; B01J23/52; B01J37/02; C07C67/055 


(72) Wang, Tao; Wade, Leslie E; Wong, Victor; Lowe, David M; Hagemeyer, 

Alfred; Han, Jun; Sokolovskii, Valery; 

(31) 03 531486 (32) 19 Dec 2003 (33) US 



(57) Disclosed is a method of producing a catalyst or pre-catalyst suitable 

for assisting in the production of alkenyl alkanoates (such as vinyl acetate), 

comprising: contacting palladium and gold precursors to a zirconia 

containing support material wherein the zirconia containing support material 

has a BET surface area of between about 10 m2/g to about 135 

m2/g; and reducing at least the palladium precursor by contacting a reducing 

environment to the zirconia containing support material. 

(21) 547073 (22) 19 Nov 2004 

(54) Layered support material for catalysts 

(86) PCT/US2004/038814 (87) WO2005/065821 

(51) IPC2010.01:B01J23/66; B01J35/08; B01J37/00,02,16 


(72) Wang, Tao; Wade, Leslie E; Wong, Victor; Sokolovskii, Valery; 

(31) 03 530936 (32) 19 Dec 2003 (33) US 



(57) Disclosed is a composition for catalyzing the production of an alkenyl 

alkanoates (such as vinyl acetate), comprising: a particulate, layered 

support material comprising at least an outer layer comprising a first support 

material layer (such as zirconia, silica, alumina or combinations 

thereof), a surfactant or bonding agent and an inner layer comprising a 

second support material (such as alumina, silicon carbide, zirconia, titania, 

steatite, niobia, silica, bentonite, clays, metals, glasses, quartz, silicon 

nitride, alumina-silica, pumice, non-zeolitic molecular sieves and combinations 

thereof) wherein the outer layer comprises at least palladium in 

combination with gold contacted thereon to form a catalyst or pre-catalyst, 

wherein the inner layer is free of palladium and gold. 

(21) 547074 (22) 19 Nov 2004 

(54) A catalyst comprising calcined palladium, calcined rhodium, gold and 

an alkali metal acetate on a support material 

(86) PCT/US2004/038825 (87) WO2005/065820 

(51) IPC2010.01:B01J23/52,58; B01J37/02,03,16; C07C67/055 


(72) Wang, Tao; Wade, Leslie E; Nicolau, Ioan; Kimmich, Barbara; Liu, 

Yumin; Han, Jun; 

(31) 03 531415 (32) 19 Dec 2003 (33) US 



(57) Disclosed is a method of producing alkenyl alkanoates (such as vinyl 

acetate), comprising: contacting a feed comprising an alkene, an alkanoic 

acid and an oxidizer to a catalyst or pre-catalyst comprising calcined 

palladium, calcined rhodium, gold and an alkali metal acetate on a support 

material. Also disclosed is a method of producing a catalyst or precatalyst 

suitable for assisting in the production of alkenyl alkanoates, 

comprising: a) contacting palladium, gold and rhodium precursors to a 

support material; b) calcining the contacted support material in a nonreducing 

atmosphere; c) reducing the palladium and rhodium precursors 

by contacting a reducing environment to the support material; and d) 

contacting an alkali metal acetate to the reduced support material to form 

an alkenyl alkanoate catalyst or pre-catalyst. 

(21) 547168 (22) 24 Nov 2004 

(54) Glycopegylated erythropoietin 

(86) PCT/US2004/039712 (87) WO2005/051327 

(51) IPC2010.01:A61K38/00; C07K7/00 

(71) BIOGENERIX AG 

(72) Defrees, Shawn; Bayer, Robert J; Zopf, David A; 

(31) 03 524989 (32) 24 Nov 2003 (33) US 

(31) 04 539387 (32) 26 Jan 2004 (33) US 

(31) 04 555504 (32) 22 Mar 2004 (33) US 

(31) 04 590573 (32) 23 Jul 2004 (33) US 

(31) 04 592744 (32) 29 Jul 2004 (33) US 

(31) 04 614518 (32) 29 Sep 2004 (33) US 

(31) 04 623387 (32) 29 Oct 2004 (33) US 





(57) Disclosed are conjugates between erythropoietin and PEG moieties. 

The conjugates are linked via an intact glycosyl linking group interposed 

between and covalently attached to the peptide and the modifying group. 

Also disclosed are methods for preparing the conjugates and methods for 

treating various disease conditions with the conjugates. 

(21) 547298 (22) 8 Nov 2004 

(54) Method for the production of capsules with a heat-shrinkable skirt 

and capsules obtained according to said method 

(86) PCT/FR2004/002862 (87) WO2005/046969 

(51) IPC2010.01:B29C47/00; B29C55/22; B29C61/08; B65D41/24,62 

(71) ALCAN PACKAGING CAPSULES 

(72) Granger, Jacques; Luciani, Andre; 

(31) 03 0313193 (32) 10 Nov 2003 (33) FR 



(57) Method for the production of capsules or caps with a heat shrinkable 

skirt is disclosed. The method comprises: 

(a) an extrusion step in which an extruded tube is formed made of a thermoplastic 

material by extrusion using a die supplied by an extruder operating 

at temperature T0 chosen as a function of the softening temperature 

or the melting temperature Tf of the thermoplastic material, the die 

having a diameter D0, a slit width or thickness E0O and a corresponding 

section with area S0; 

(b) an axial drawing step in which the extruded tube is drawn in the axial 

direction at the exit from the die of the extruder so as to obtain an axially 

drawn tube with diameter D1 less than D0 and a diameter D2, with thickness 

E1 less than EO and with a corresponding section with area S1, 

such that S0/S1 ranges between 2 and 10, 

(c) a radial expansion step of the extruded tube to form a radially expanded 

tube with diameter D2, thickness E2 and corresponding section 

with area S2, due to a radial expansion device, 

(d) a chopping step in which the expanded tube is chopped into tube portions 

with an appropriate length, the radially expanded tube pulled by an 

axial tension means; 

(e) a step to form tube portions in which each tube portion is placed on a 

conformation mandrel and is formed by heat shrinkage to form a heatshrunk 

capsule blank, one head also being assembled to the blank or 

formed from the blank, so as to obtain a heat shrinkable capsule or cap 

provided with head and a skirt. 

The extrusion, axial drawing, radial expansion and chopping steps are 

carried out continuously while moving so as to obtain capsules or caps 

that are both economic, easily heat shrinkable and with a stable axial 

dimension thereby avoiding any axial distortion. 

(21) 547415 (22) 13 Jan 2005 

(54) Arrangement and method for feeding animals 

(86) PCT/SE2005/000024 (87) WO2005/067704 

(51) IPC2010.01:A01K5/02; G01N21/35; A23K1/00 

(71) DELAVAL HOLDING AB 

(72) Mazeris, Fernando; 

(31) 04 0400047 (32) 13 Jan 2004 (33) SE 

(74) ELLIS TERRY, Level 12, 45 Johnston Street, Wellington 6011, New 

Zealand 

(57) A feeding device for feeding animals on a farm that includes an analyser, 

a feeder and a control device. The control device is configured to 

control the analyser to measure, at least once a day at least one constituent 

of the solid feed fed to the animals. The control device also controls 

the feeder such that the amount of feed the animals get depends on 

the earlier measured amounts. 

(21) 547458 (22) 3 Nov 2004 

(54) Cured in place liner with everted outer impermeable layer and method 

of manufacture 

(86) PCT/US2004/036633 (87) WO2005/047755 

(51) IPC2010.01:F16L55/16,165 

(71) INA ACQUISITION CORP. 

(72) Driver, Franklin Thomas; Wang, Weiping; 

(31) 03 704501 (32) 7 Nov 2003 (33) US 



(57) A cured in place liner 21 for a conduit or pipeline composed of a 

double tube 23 31, each of which has at least layer of resin impregnable 

material. The outer tube 31 which was formed with an edge seal 32 on 

the outside has been everted over the inner tube 23 so that the edge 

seal 32 is now on the inside and faces the inner tube 23. 

(21) 547755 (22) 3 Dec 2004 

(54) Packaging bag for nappies, for example, and production machine 

and method 

(86) PCT/FR2004/003113 (87) WO2005/056406 

(51) IPC2010.01:B65D33/00,24,25; B65D85/16 

(71) S2F Flexico 

(72) Doue, Philippe; 

(31) 03 0314276 (32) 4 Dec 2003 (33) FR 

(74) Freehills Patent & Trade Mark Attorneys, Level 43, 101 Collins Street, 

Melbourne, Victoria 3000, Australia 

(57) A bag 10 for packaging diapers includes gussets 26 folded against 

two diametrically opposite faces 25 of the body of the bag and held in 

position by detachable connecting elements 60 such as, for example, 

clips or hook and loop fasteners. 



(21) 547767 (22) 23 Dec 2004 

(54) Therapeutic agents and uses therefor 

(86) PCT/AU2004/001840 (87) WO2005/060992 

(51) IPC2010.01:A61K38/19,45; A61P35/00; A61P37/02 

(71) The Walter and Eliza Hall Institute of Medical Research 

(72) Shortman, Ken; O’Keeffe, Meredith; Fancke, Ben; Harrison, Len; 

Steptoe, Ray; Vremec, David; 

(31) 03 907195 (32) 24 Dec 2003 (33) AU 



(57) Provided is the use of Flt-3L (also known as fms-like tyrosine kinase- 

3 or foetal liver kinase-2) in the production of a medicament for preventing 

the onset of diabetes. 

(21) 547790 (22) 2 Nov 2004 

(54) A method of harvesting plants depending on the lunar phase 

(86) PCT/AU2004/001516 (87) WO2005/046311 

(51) IPC2010.01:A01D91/00; A01G1/00 

(71) Christopher Gary Parmenter 

(72) Parmenter, Christopher Gary; 

(31) 03 906309 (32) 17 Nov 2003 (33) AU 


Australia 

(57) A plant cultivation planning method for managing the life cycle of a 

plant in order to maximise the potency of extracts, fruit and usable portions 

of the plant is disclosed. The method includes: planting a plant; a 

computer calculating an optimum harvesting period of a mature plant; 

and a computer outputting a list of harvest dates and times for use in the 

harvesting. The optimum harvesting period occurs within a period of five 

days prior to a lunar apogee and five days after the lunar apogee in any 

given lunar cycle and it is adjusted according to the location of the plant 

geographically. 

(21) 547803 (22) 11 Nov 2004 

(54) Composition for topical use containing an extract of stryphnodendron, 

its preparation as well as its application 

(86) PCT/BR2004/000221 (87) WO2005/044288 

(51) IPC2010.01:A61K35/78; A61K36/48 

(71) AERP ASSOCIACAO DE ENSINO DE RIBEIRAO PRETO; APSEN 

FARMACEUTICA S.A. 

(72) Castro Franca, Suzelei de; Nunes de Oliveira, Joao Carlos; Pasqualin, 

Luiz; Bernades Couto, Lucelio; Comelli Lia, Raphael Carlos; 

(31) 03 05535 (32) 11 Nov 2003 (33) BR 



(57) Disclosed is a topical composition containing a Stryphnodendron genus 

plant extract wherein said composition contains an amount from 2% 

to 5% (w/w) of total phenols. Also disclosed is a process for said topical 

composition, a use of said composition in the manufacture of a topical 

composition for the treatment of cutaneous wounds and a method of 

treating cutaneous wounds in a non-human subject comprising administering 

said composition. 

(21) 547805 (22) 9 Nov 2004 

(54) Dual molecules containing peroxy derivative, the synthesis and therapeutic 

applications thereof 

(86) PCT/FR2004/002874 (87) WO2005/049619 

(51) IPC2010.01:C07D491/10; A61K31/47; A61P33/06 

(71) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; 

PALUMED S.A.; SANOFI-AVENTIS 

(72) Cazelles, Jerome; Cosledan, Frederic; Meunier, Bernard; Pellet, Alain; 

(31) 03 0313371 (32) 14 Nov 2003 (33) FR 



(57) The present disclosure relates to quinoline derivatives having dual 

peroxide molecules of formula (I), wherein the variables shown in formula 

(I) are as defined in the specification, containing a peroxide derivative, 

having in particular antimalarial activity. Also disclosed is the synthesis 

thereof, a medicinal compound of thereof, compositions containing 

thereof and to the therapeutic applications thereof. 

(21) 547835 (22) 27 Nov 2004 

(54) Synergistic insecticidal mixtures of thiodicarb and imidacloprid 

(86) PCT/EP2004/013470 (87) WO2005/058039 

(51) IPC2010.01:A01N47/24 

(71) Bayer CropScience AG 

(72) Andersch, Wolfram; Hungenberg, Heike; Thielert, Wolfgang; 

(31) 03 0358181 (32) 12 Dec 2003 (33) DE 

(31) 04 04028995 (32) 16 Jun 2004 (33) DE 

(74) HENRY HUGHES, 119-125 Willis Street, Wellington, New Zealand 

(57) The disclosure relates to an insecticidal composition comprising a 

synergistically effective mixture of thiodicarb having the formula shown 

herein and imidacloprid. The composition is suitable to combat animal 

pests. Also disclosed is a seed treated with this composition; and a process 

for the preparation of pesticides, wherein a synergistically effective 

mixture of thiodicarb having the formula shown herein and imidacloprid 

is mixed with extenders and/or surfactants. 


(21) 547861 (22) 25 Nov 2004 

(54) Nestable tray, blank, corresponding packaging and machine for forming 

one such tray 

(86) PCT/FR2004/003020 (87) WO2005/051772 

(51) IPC2010.01:B31B3/46; B65D21/02; B65D5/00,20,28,44,468 

(71) Otor 

(72) Durfort, Gilles; Le Lay, Nicolas; Mathieu, Gerard; Bacques, Jean- 

Yves; 

(31) 03 0313845 (32) 25 Nov 2003 (33) FR 

(31) 04 0407258 (32) 30 Jun 2004 (33) FR 

(74) P L BERRY & ASSOCIATES, AEQ Building, 61 Cambridge Terrace, 

Christchurch 8013, New Zealand 

(57) A tray (1) which is made from a sheet of cardboard comprising four 

lateral walls (2, 3, 4, 5) and a base (6). Two opposing lateral walls are 

each equipped with a panel (9) which is provided with a longitudinal flap 

(11) that is intended to form a fold which extends over part of the height 

of the wall, the cardboard basis weight being less than or equal to 350 g/ 

m2. Also disclosed is a blank, a packaging and a machine used to form 

one such tray. 




(21) 547936 (22) 24 Nov 2004 

(54) Cannulated fastener system with screwdriver shank passing through 

cannulation of bone screw and to rotate screw and having blade on end to 

commence cutting 

(86) PCT/US2004/039860 (87) WO2005/053753 

(51) IPC2010.01:A61B17/16,86,88 

(71) SYNTHES GMBH 

(72) Ciccone, Paul; Murray, Steven F; 

(31) 03 524880 (32) 26 Nov 2003 (33) US 


(57) A cannulated fastener system is provided for orthopedic applications 

that include attaching bone plates to bone. The bone fastener has a 

cannulation with an inner shape. One or more screwdrivers is provided 

with a shaft having a shape that matches the cannulation of the fastener 

to rotationally fix the fastener to the screwdriver. In addition, the screwdrivers 

have a cutting blade that begins the drilling of a hole for the bone 

fastener. The screwdrivers may either be for use with a single fastener or 

have multiple fasteners loaded within a retaining sleeve for automatic or 

controlled dispensing. 

(21) 547963 (22) 19 Nov 2004 

(54) Methods for producing copper ethanolamine solutions 

(86) PCT/US2004/039069 (87) WO2005/051961 

(51) IPC2010.01:C07F1/00 

(71) ARCH CHEMICALS, INC. 

(72) Patel, Jayesh P; Thomason, Susan M; Pasek, Eugene A; Lummus, 

Eric W; Cogan, Kenneth E; 

(31) 03 524112 (32) 19 Nov 2003 (33) US 

(31) 04 917598 (32) 13 Aug 2004 (33) US 



(57) A method for the production of an aqueous copper ethanolamine solution, 

comprising: 

a) providing in a vessel a mixture of: 

i) water; 

ii) an alkyl hydroxylamine, 

iii) an acid, 

an acid anhydride, or 

an alkyl hydroxylamine salt; and 

iv) a metallic copper bearing material; 

b) feeding oxygen into the mixture; 

c) maintaining the mixture at a temperature to dissolve metallic copper; 

and 

d) optionally removing excess metallic copper or other extraneous solids 

from the dissolved copper ethanolamine solution, thereby to form the 

copper ethanolamine solution; wherein oxygen is introduced into the vessel 

at a pressure of from about 5 to about 100 psig. 

(21) 548098 (22) 22 Dec 2004 

(54) Control of parasites in animals by the use of imidazo[1,2-b]pyridazine 

derivatives 

(86) PCT/US2004/043402 (87) WO2005/066177 

(51) IPC2010.01:A01N1/00; A61K31/50; C07D487/04; A61P33/00 

(71) SCHERING-PLOUGH, LTD 

(72) Winzenberg, Kevin N; Francis, Craig L; Sawutz, David G; Ganguly, 

Ashit; 

(31) 03 533729 (32) 31 Dec 2003 (33) US 



(57) Disclosed is a method of treating a parasite infestation or helminthiasis 

in non-human animals, comprising administering an imidazo[1,2b]pyridazine 

derivative of Formula (I), wherein R2 and R3 may be separate 

substituents or part of a fused ring as described in the specification, 

R4 is optionally substituted aryl or heteroaryl, and wherein the other 

substituents are as defined in the specification. Also disclosed are compounds 

of Formulas (V), (VI), and (VII), wherein the substituents are as 

defined in the specification, and compounds of Formula (I) selected from 

a list as described herein. 

(21) 548099 (22) 23 Dec 2004 

(54) Novel fused pyrrolocarbazoles 

(86) PCT/US2004/043160 (87) WO2005/063763 

(51) IPC2010.01:C07D487/04,14 

(71) CEPHALON, INC. 

(72) Becknell, Nadine C; Diebold, James L; Gingrich, Diane E; Hudkins, 

Robert L; Reddy, Dandu R; Tao, Ming; Underiner, Theodore L; Zulli, Allison 

L; 

(31) 03 532182 (32) 23 Dec 2003 (33) US 

(31) 04 017947 (32) 22 Dec 2004 (33) US 





(57) Disclosed is a compound of formula II wherein Q is CH2CH2 and the 

other substituents are disclosed within the specification or a stereoisomer 

or a salt thereof. Also disclosed is the use of the compound of formula II 

for treating prostate disorder, angiogenic disorder, pathological disorder, 

cancer of solid tumors and multiple myeloma or leukemia. 

(21) 548121 (22) 29 Dec 2004 

(54) Sleeved stop for a drill bit with coarse and fine adjustment and biased 

centering member 

(86) PCT/US2004/043944 (87) WO2005/065377 

(51) IPC2010.01:B23B39/00; B23B41/00; B23B45/14; B23B47/00; 

B23B51/00; A61B17/16; B23B49/00; B23Q17/22 

(71) Alex M. Greenberg 

(72) Greenberg, Alex M; 

(31) 03 748338 (32) 30 Dec 2003 (33) US 



(57) A stop for use with an electric drill bit, the stop having a combination 

of sleeves with differing thread pitch to provide for coarse and fine adjustment 

of the stop. The stop also has a centering member for use in a 

countersink (not shown) including a spring so that the centering member 

is biased to a fully extended position. Shoulder 106 limits depth of drilling 

when the spring is fully compressed. 

(21) 548123 (22) 10 Jan 2005 

(54) O-linked glycosylation of peptides 

(86) PCT/US2005/000799 (87) WO2005/070138 

(51) IPC2010.01:C07K1/00 

(71) NOVO NORDISK A/S 

(72) Defrees, Shawn; Zopf, David A; Wang, Zhi-Guang; Clausen, Henrik; 

(31) 04 535284 (32) 8 Jan 2004 (33) US 

(31) 04 544411 (32) 12 Feb 2004 (33) US 

(31) 04 546631 (32) 20 Feb 2004 (33) US 

(31) 04 555813 (32) 23 Mar 2004 (33) US 

(31) 04 570891 (32) 12 May 2004 (33) US 



(57) Provided is an isolated G-CSF polypeptide comprising an O-linked 

glycosylation site that does not exist in wildtype sequence, wherein said 

isolated G-CSF polypeptide comprises a peptide sequence having the 

formula of M1XnTPLGP or M1BoPZmXnTPLGP, wherein the superscript 

denotes the corresponding position of the amino acid in wildtype, and 

the subscripts n and m are integers selected from 0 to 3; at least one of 

X and B is Thr or Ser, and when more than one of X and B is Thr or Ser, 

the identity of these moieties is independently selected; and Z is selected 

from glutamate, or any uncharged amino acid. Further provided 

are corresponding nucleic acids and methods of making glycoconjugates 

of said peptides as well as using the peptides for G-CSF therapy. 

(21) 548128 (22) 28 Dec 2004 

(54) Novel 2-heteroaryl-substituted benzimidazole derivative 

(86) PCT/JP2004/019843 (87) WO2005/063738 

(51) IPC2010.01:A61K31/4196,4245,426,4192,427,433,4439,444, 

4709,496,497,506,5377; A61P13/12; A61P25/00; A61P3/04,10; A61P43/ 

00; C07D401/04,12,14; C07D413/04,14; C07D417/04 

(71) BANYU PHARMACEUTICAL CO., LTD. 

(72) Nonoshita, Katsumasa; Ogino, Yoshio; Ishikawa, Makoto; Sakai, 

Fumiko; Nakashima, Hiroshi; Nagae, Yoshikazu; Tsukahara, Daisuke; 

Arakawa, Keisuke; Nishimura, Teruyuki; Eiki, Jun-Ichi; 

(31) 03 436992 (32) 29 Dec 2003 (33) JP 

(31) 04 235696 (32) 13 Aug 2004 (33) JP 



(57) Disclosed is a compound of formula (I-0) or a pharmaceutically acceptable 

salt thereof, wherein X represents a carbon atom or a nitrogen 

atom; X1, X2, X3 and X4 each independently represent a carbon atom; 

and wherein the rest of the substituents are disclosed within the specification. 

Also disclosed is the use of a compound of formula (I-0) in the 

preparation for treating type 2 diabetes or for treating obesity. 

(21) 548213 (22) 28 Dec 2004 

(54) Benzo[d]isoxazol-3-ol DAAO inhibitors 

(86) PCT/US2004/043547 (87) WO2005/066143 

(51) IPC2010.01:C07D261/20; A61K31/423 

(71) Sepracor Inc. 

(72) Fang, Q. Kevin; Hopkins, Seth; Chytil, Milan; Heffernan, Michele; Wipf, 

Peter; 

(31) 03 532978 (32) 29 Dec 2003 (33) US 



(57) Disclosed are benzo[d]isoxazol-3-ol derivatives as represented by 

formula IA or a pharmaceutically acceptable salt or solvate thereof, 

wherein A is hydrogen, alkyl or M+; Z is O; R1, R2 , R3a and R4a are 

independently selected from hydrogen, alkyl, hydroxy, alkoxy, aryl, acyl, 

halo, cyano, haloalkyl, NHCOOR5 and SO2NH2; and wherein the other 

substituents are as described herein. Also disclosed is the use of a 

compound as defined above for the manufacture of a medicament for 

the treatment of schizophrenia, for treating or preventing loss of memory 

and / or cognition associated with Alzheimer's disease, for treating ataxia, 

for treating neuropathic pain or for preventing loss of neuronal function 

characteristic of neurodegenerative diseases. 

(21) 548232 (22) 12 Jan 2005 

(54) Device and method for cleaning the abdominal cavity in fish 

(86) PCT/NO2005/000015 (87) WO2005/067724 

(51) IPC2010.01:A22C25/08,14 

(71) RONNY SOLBERG; KNUT INGE SEIM 

(72) Solberg, Ronny; Seim, Knut Inge; 

(31) 04 040142 (32) 13 Jan 2004 (33) NO 



(31) 04 044625 (32) 27 Oct 2004 (33) NO 



(57) A method and device for cleaning the abdominal cavity in fish is disclosed. 

The device comprises transport mechanism(s) for introduction 

of the fish into the device, a fish detection device to determine when the 

fish has entered the device, and first and second cleaning tools. The first 

and second cleaning tools are configured, in use, to be inserted into the 

abdominal cavity of the fish, and move in opposing directions to each 

other, following the inside of the abdominal cavity. 

(21) 548235 (22) 12 Jan 2005 

(54) Sulfonamide derivatives as beta2 agonists for the treatment of diseases 

(86) PCT/IB2005/000112 (87) WO2005/080324 

(51) IPC2010.01:C07C311/08; C07C323/42; C07D295/03 

(71) PFIZER INC. 

(72) Brown, Alan Daniel; James, Kim; Lane, Charlotte Alice Louise; Moses, 

Ian Brian; Thomson, Nicholas Murray; 

(31) 04 04290168 (32) 22 Jan 2004 (33) EP 

(31) 04 0406388 (32) 22 Mar 2004 (33) GB 

(31) 04 600259 (32) 9 Aug 2004 (33) US 



(57) Disclosed is a compound of formula (1), or a pharmaceutically acceptable 

salt, stereoisomer, tautomer, solvate, or isotopic variant thereof, 

wherein the ketone group is attached in the meta or para position, R1 

and R2 are each H or C1-C4alkyl, n is 0, 1, or 2, and wherein Q1 is as 

defined in the specification. Also disclosed is the use of the compound 

to treat diseases in which the beta 2 receptor is involved. Also disclosed 

is a process for preparing the compound. 

(21) 548319 (22) 13 Jan 2005 

(54) Benzimidazole derivatives 

(86) PCT/EP2005/000291 (87) WO2005/068433 

(51) IPC2010.01:C07D235/28,18; C07D417/06; C07D235/26; C07D471/ 

04; C07D401/12; C07D403/06; C07D413/06; C07D401/04,06; A61K31/ 

4184,422,427,4402,4406 

(71) Novartis AG 

(72) Gerspacher, Marc; Weiler, Sven; 

(31) 04 0400781 (32) 14 Jan 2004 (33) GB 



(57) Disclosed is a compound of formula (I), wherein the substituents are 

as defined in the specification, and processes for its preparation. The 

compounds are benzimidazole derivatives that promote parathyroid hor- 

mone (PTH) release useful in the treatment of conditions of bone which 

are associated with increased calcium depletion or resorption, or in which 

stimulation of bone formation and calcium fixation in the bone is desirable. 

(21) 548374 (22) 10 Jan 2005 

(54) Azadecalin glucocorticoid receptor modulators 

(86) PCT/US2005/000607 (87) WO2005/070893 

(51) IPC2010.01:C07D217/04,06,08; C07D401/12; C07D405/06; 

C07D409/12,14; C07D413/12,14; C07D417/12; C07D513/06; A61K31/ 

4725,472; A61P5/44 

(71) Corcept Therapeutics, Inc 

(72) Clark, Robin D; Ray, Nicholas C; Blaney, Paul; Hurley, Christopher; 

Williams, Karen; Hunt, Hazel; Clark, David; 

(31) 04 535460 (32) 9 Jan 2004 (33) US 



(57) Disclosed is a piperidine derivative of the formula shown, with 

subtituents as disclosed in the specification. Also disclosed is the use of 

the compound for treating a disorder or condition by modulating a glucocorticoid 

receptor. 

(21) 548454 (22) 13 Jan 2005 

(54) Pharmaceutical compositions comprising midazolam in a high concentration 

(86) PCT/EP2005/050133 (87) WO2005/067893 

(51) IPC2010.01:A61K31/5517; A61K47/10; A61K9/00 

(71) Franciscus Wilhelmus Henricus Maria MERKUS 

(72) Merkus, Franciscus Wilhelmus Henricus Maria; 

(31) 04 0400804 (32) 14 Jan 2004 (33) GB 

(74) Allens Arthur Robinson Patent & Trade Marks Attorneys, 530 Collins 

Street, Melbourne, Victoria 3000, Australia 

(57) Disclosed is a pharmaceutical composition for intranasal administration, 

which composition is an aqueous solution comprising midazolam in 

a concentration of at least 35 mg/mL and a solubiliser selected from 

propylene glycol, glycerol, polyethylene glycol, povidone, ethanol and 

combination thereof, wherein the pH of the composition is at least 2.5 

and less than 4. 

(21) 548469 (22) 4 Feb 2005 

(54) Solid pharmaceutical formulation containing a salt of a 3-quinoline 

carboxamide derivative 

(86) PCT/EP2005/050485 (87) WO2005/074899 

(51) IPC2010.01:A61K31/47; A61K9/00 

(71) ACTIVE BIOTECH AB 

(72) Jansson, Karl; Fristedt, Tomas; Wannman, Hans; Bjork, Anders; 



(31) 04 0400235 (32) 6 Feb 2004 (33) SE 


(57) Disclosed is a pharmaceutical composition in the form of a hydrogel 

which contains 0.01-5.0% by weight of 7alpha-Methyl-11beta-fluor-19nortestosterone 

(eF-MENT), 0.1-1.5% by weight of acrylate/C10-30 alkyl 

acrylate crosspolymer, 0-1.0% by weight of polyacrylic acid, 0-2.0% by 

weight of a cellulose derivative, 5.0-20.0% by weight of propylene carbonate, 

0.01-5.0% by weight of glycerol, 0.01-5.0% by weight of 

cyclomethicone, 0.01-5.0% by weight of isopropyl myristate, 20.0-50.0% 

by weight of purified water, 30.0-60.0% by weight of ethanol and tris- 

(hydroxymethyl)-aminomethane at pH 5-7. 

The disclosure also relates to the use of a carbonic acid ester as a 

transdermal permeation agent for an active substance in a pharmaceutical 

composition in the form of a hydrogel, said composition comprising 

a polymer matrix and a C2-C4 alkyl alcohol. The disclosure also relates 

to a perspiration-resistant composition in the form of a hydrogel, comprising 

an acrylic polymer combined with a cellulose derivative. 

(21) 548513 (22) 14 Jan 2005 

(54) Methods of producing peptides/proteins in plants and peptides/proteins 

produced thereby 

(86) PCT/US2005/001160 (87) WO2005/069845 

(51) IPC2010.01:C07H21/00,02,04; C12N15/82; C07K19/00 

(71) OHIO UNIVERSITY 

(72) Kieliszewski, Marcia J; Xu, Jianfeng; Kopchick, John; Okada, Shigeru; 

(31) 04 536486 (32) 14 Jan 2004 (33) US 

(31) 04 582027 (32) 22 Jun 2004 (33) US 

(31) 04 602562 (32) 18 Aug 2004 (33) US 

(74) PHILLIPS ORMONDE FITZPATRICK, 367 Collins Street, Melbourne, 

Victoria 3000, Australia 

(57) Provided is a nucleic acid construct for expression of a biologically 

active fusion protein in plants comprising: a) at least one nucleic acid 

encoding at least one plant hydroxyproline O-glycomodule b) at least 

one nucleic acid encoding a biologically active mammalian protein and 

c) an operatively linked plant promoter; wherein the biologically active 

fusion protein, when expressed in plants, exhibits a pharmacokinetic 

plasma half-life that is increased as compared with the biologically active 

mammalian protein expressed in plants that lacks a plant hydroxyproline 

O-glycosylation glycomodule. Further provided are corresponding 

plant-derived bioactive mammalian fusion proteins and use of the 

proteins in the manufacture of medicaments. 


(21) 548525 (22) 22 Dec 2004 

(54) Microwave induced pyrolysis reactor and method using two chambers 

each with stirrers and microwave absorbing material 

(86) PCT/GB2004/050043 (87) WO2005/061098 

(51) IPC2010.01:B01J19/12; C22B7/00; C22B21/00 

(71) Cambridge University Technical Services Limited 

(72) Ludlow-Palafox, Carlos; Chase, Howard Allaker; 

(31) 03 0329556 (32) 22 Dec 2003 (33) GB 



(57) A continuous method and reactor for recycling a metal/organic laminate 

comprising metal such as aluminium, laminated with an organic 

material is disclosed. 

The method comprises the steps of: 

- Providing a reactor (1) comprising a first chamber (2) having a first rotary 

stirrer (4) and a second chamber (3) having a second rotary stirrer (5), 

each chamber (2, 3) containing a bed of particulate microwave absorbing 

material; 

- Introducing laminate and additional particulate microwave absorbing 

material into the first chamber (2) via an inlet (6); 

- Under a reducing or inert atmosphere stirring the mixture of particulate 

microwave absorbing material and laminate in the first chamber (2) using 

the first rotary stirrer (3) and applying microwave energy in the first 

chamber (2) to heat the particulate microwave absorbing material to a 

temperature sufficient to pyrolyse organic material in the laminate; 

- Transferring a portion of the mixture in the first chamber (2) to the second 

chamber (3); 

- Stirring the mixture in the second chamber (3) using the second rotary 

stirrer (5) and applying microwave energy in the second chamber (3) to 

heat the particulate microwave absorbing material to a temperature sufficient 

to pyrolyse organic material remaining in the laminate, whereby 

laminate or delaminated metal migrates towards and floats on the upper 

surface of the mixture in the second chamber (3), the second rotary stirrer 

(5) rotating in a horizontal plane and being so configured as to fluidise 

the mixture such that the upper surface of the fluidised mixture has a 

radial profile that biases laminate or delaminated metal floating on the 

fluidised mixture to migrate radially outwards; 

- Transferring a portion of the mixture in the second chamber (3) to an exit 

(7) from the reactor (1); and recovering metal from the exit (7). 

(21) 548583 (22) 10 Mar 2005 

(54) New quaternized quinuclidine esters 

(86) PCT/EP2005/002523 (87) WO2005/090342 

(51) IPC2010.01:C07D453/02; A61K31/439; A61P11/00; A61P13/00 

(71) ALMIRALL PRODESFARMA, SA 

(72) Fernandez Forner, Maria Dolors; Prat Quinones, Maria; Buil Albero, 

Maria Antonia; 

(31) 04 0400638 (32) 15 Mar 2004 (33) ES 



(57) Disclosed is a quaternized quinuclidine ester of formula (I): 

wherein the substituents are defined in the specification and X- represents 

a pharmaceutically acceptable anion of a mono or polyvalent acid; 

provided that the group B-(CH2)n-A-(CH2)m- is not a linear C1-4 alkyl 

group and further provided that the compound is not one of: 

1-Allyloxycarbonylmethyl-3-(2-hydroxy-2,2-di-thiophen-2-yl-acetoxy)-1azonia-bicyclo- 

[2.2.2]octane; and 

1-carboxymethyl-3-(2-hydroxy-2,2-di-thiophen-2-yl-acetoxy)-1-azoniabicyclo[2.2.2]octane. 

Also disclosed is a process for producing said esters, 

pharmaceutical compositions comprising said esters, the use of the 

ester in the manufacture of a medicament for the treatment of respiratory, 

urological or gastrointestinal disease or disorder and a combination 

product comprising said ester. 

(21) 548613 (22) 4 Feb 2005 

(54) Process for preparing 2-aminothiazole-5-aromatic carboxamides as 

kinase inhibitors 

(86) PCT/US2005/003728 (87) WO2005/077945 

(51) IPC2010.01:C07D417/14; A61P31/04; C07D417/12; C07D277/56; 

A61P31/12; A61K31/496,506; A61P35/00; C07D239/48 

(71) BRISTOL-MYERS SQUIBB COMPANY 



(72) Chen, Bang-Chi; Droghini, Roberto; Lajeunesse, Jean; Dimarco, John 

D; Galella, Michael; Chidambaram, Ramakrishnan; 

(31) 04 542490 (32) 6 Feb 2004 (33) US 

(31) 04 624937 (32) 4 Nov 2004 (33) US 



(57) Disclosed is a crystalline solvate of a 2-aminothiazole-5-aromatic 

carboxamides with formula (IV) which is characterized by its x-ray powder 

diffraction pattern, wherein the solvate is monohydrate, butanol or 

ethanol. Also disclosed is the pharmaceutical use of the compound for 

the treatment of cancer in particular chronic myelogenous leukemia (CML), 

gastrointestinal stromal tumor (GIST), small cell lung cancer (SCLC), 

non-small cell lung cancer (NSCLC), ovarian cancer, melanoma, mastocytosis, 

germ cell tumors, acute myelogenous leukemia (AML), pediatric 

sarcomas, breast cancer, colorectal cancer, pancreatic cancer, and prostate 

cancer. The process for preparing the crystalline solvate is also disclosed. 

(21) 548670 (22) 27 Jan 2005 

(54) Enhancement of anti-androgenic activity by a combination of inhibitors 

targeting different steps of a steroid-dependent gene activation pathway 

and uses thereof 

(86) PCT/US2005/003416 (87) WO2005/072462 

(51) IPC2010.01:A61K31/47,444,343 

(71) Androscience Corporation 

(72) Shih, Charles; Su, Ching-Yuan; 

(31) 04 539753 (32) 28 Jan 2004 (33) US 

(74) PIPERS, Level 1, 5A Pacific Rise, Mt Wellington, Auckland, New Zealand 

(57) Dislcosed is a method of inhibiting or reducing steroid-dependent 

gene activation comprising: 

a) providing a biological sample comprising a steroid receptor; 

b) administering a first compound to said biological sample, wherein said 

first compound induces degradation of said steroid receptor, and said 

first compound is selected from the group consisting of functional derivatives 

and functional analogues of curcumin; and 

c) administering a second compound to said biological sample, wherein 

said second compound inhibits said steroid receptor from activating a 

gene, and said second compound is selected from the group consisting 

of bicalutamide, hydroxyflutamide, docosahexaenoic acid (DHA), silibinin 

(SB), quercetin (QU), finesteride, dutasteride, vitamin E succinate (VES), 

and functional derivatives and functional analogues thereof; 

wherein said first compound and said second compound act at different 

steps within a gene activation pathway of said steroid receptor; further 

wherein steroid-dependent gene activation is reduced or inhibited greater 

than if said first compound or said second compound are administered 

alone. Further disclosed are pharmaceutical compositions and uses 

thereof. 

(21) 548687 (22) 9 Feb 2005 

(54) An endoluminal surgical staple delivery system 

(86) PCT/GB2005/000437 (87) WO2005/077280 

(51) IPC2010.01:A61B17/115,94 

(71) ANSON MEDICAL LIMITED 

(72) Jones, Anthony; Keeble, Duncan; 

(31) 04 0402796 (32) 9 Feb 2004 (33) GB 



(57) In order to be able to deliver staples 9 into the wall of an artery 2 at a 

particular spot in order to staple a stent to the artery wall for example, the 

distal end of the conduit 5 through which the staples 9 are delivered is 

bent away from the longitudinal axis of the artery and toward the artery 

wall. By fixing the conduit 5 at a position 8 near to the distal end to a 

stiffer elongate element such as balloon catheter 6 or catheter guide 

wire 3, axial translation of the conduit 5 relative to the stiffer elongate 

element will have the effect of deflecting the end of the conduit toward 

the artery wall. 

(21) 548693 (22) 17 Feb 2005 

(54) Polyheterocyclic compounds and their use as metabotropic glutamate 

receptor antagonists 

(86) PCT/US2005/005216 (87) WO2005/080386 

(51) IPC2010.01:C07D401/14; C07D413/14; A61K31/4545; A61P25/00; 

A61K31/5377,496 

(71) AstraZeneca AB 

(72) Arora, Jalaj; Edwards, Louise; Isaac, Methvin; Kers, Annika; Staaf, 

Karin; Slassi, Abdelmalik; Stefanac, Tomislav; Wensbo, David; Xin, Tao; 

Holm, Bjorn; 

(31) 04 545292 (32) 18 Feb 2004 (33) US 



(57) Disclosed is a compound of formula (I), wherein P is aryl or heteroaryl, 

X6 is N, X2 and X7 are each C or N, Q is heteroaryl, and wherein the rest 

of the substituents are as described in the specification. Also disclosed 

is the use of the compound to treat mGluR 5 mediated disorders. 

(21) 548771 (22) 29 Dec 2004 

(54) Phosphonates, monophosphonamidates, bisphosphonamidates for 

the treatment of viral diseases 

(86) PCT/US2004/043969 (87) WO2005/066189 

(51) IPC2010.01:A61K31/66; C07F9/44; C07D473/16; A61K31/52 

(71) GILEAD SCIENCES, INC. 

(72) Cheng, Xiaqin; Cook, Gary P; Desai, Manoj C; Doerffler, Edward; He, 

Gong-Xin; Kim, Choung U; Lee, William A; Rohloff, John C; Wang, Jianying; 

Yang, Zheng-Yu; 

(31) 03 533745 (32) 30 Dec 2003 (33) US 

(31) 04 590987 (32) 26 Jul 2004 (33) US 

(31) 04 606595 (32) 1 Sep 2004 (33) US 



(57) Disclosed are 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine derivatives 

as represented by the general formula IA or a pharmaceutically 

acceptable salt thereof, wherein: Y1A and Y1B are independently NH(Rx); 

where RX is as defined herein. Also disclosed is the use of a compound 

as defined above in the preparation of a medicament for the treatment of 

tumors, and wherein the medicament may further comprise an effective 

amount of at least one antiviral agent, and a pharmaceutically acceptable 

carrier. 



(21) 548819 (22) 17 Feb 2005 

(54) Hand-held electronically controlled injection device for injecting liquid 

medications 

(86) PCT/EP2005/050711 (87) WO2005/077441 

(51) IPC2010.01:A61M5/20,24,32,48 

(71) Ares Trading S.A. 

(72) Pongpairochana, Vincent; Maclean, Timothy John; Prasser, Robert; 

Lauchard, Gerhard; Wurmbauer, Werner; Kogler, Gerhard; 

(31) 04100647 (32) 18 Feb 2004 (33) EP 



(57) A hand-held, electronically controlled injection device for injecting preset 

doses of a liquid medication, is disclosed. The injection device comprises 

a housing for receiving a medication container containing the liquid 

medication, a contact surface for contacting a patient's skin, and a 

first actuator for moving the medication container within the housing to 

and from the contact surface. The contact surface of the housing comprises 

a through opening for receiving a needle assembly. The injection 

device also includes a releasable retaining means for locking the needle 

assembly in a predetermined position engaging the opening, during displacement 

of the medication container towards the contact surface, from 

a first operating position, withdrawn inside the housing, to a second operating 

position, connected to a needle of the needle assembly. 

(21) 548857 (22) 24 Feb 2005 

(54) Crystalline forms of a diazocine pharmaceutical compound for Parkinson’s 

and similar conditions 

(86) PCT/DK2005/000127 (87) WO2005/082920 

(51) IPC2010.01:C07H19/23; A61K31/7056; A61P25/16 

(71) H. LUNDBECK A/S 

(72) Rock, Michael Harold; Lopez De Diego, Heidi; Christensen, Kim Lasse; 

Nielsen, Ole; Buur, Anders; Howells, Mark; 

(31) 200400326 (32) 27 Feb 2004 (33) DK 

(31) 04 548351 (32) 27 Feb 2004 (33) US 



(57) Disclosed is a crystalline compound of formula I. Also disclosed are 

specific crystalline forms of the compound, with X-ray powder diffraction 

patterns as described in the specification. Also disclosed is a method for 

preparing crystalline compound I, and the use of the crystalline compound 

for treating a CNS disease, such as Parkinson’s disease Alzheimer’s 

disease, Huntington’s disease peripheral neuropathy, or AIDS dementia. 

(21) 548896 (22) 2 Feb 2005 

(54) 1H-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors 

(86) PCT/EP2005/001021 (87) WO2005/074922 

(51) IPC2010.01:A61K31/4162; A61P35/00; A61P31/12; A61P25/28; 

A61P17/06; A61P19/02; A61P9/10 

(71) PFIZER ITALIA S.R.L. 

(72) Fancelli, Daniele; Bindi, Simona; Varasi, Mario; Vianello, Paola; Vioglio, 

Sergio; Tesei, Dania; 

(31) 04 541452 (32) 3 Feb 2004 (33) US 



(57) Disclosed is a compound of formula (I), wherein the substituents are 

as defined in the specification, and processes for its preparation. The 

compounds are protein kinase inhibitors, particularly Aurora Kinases 

useful in the treatment of cell proliferative disorders. 

(21) 548991 (22) 16 Jan 2005 

(54) Perturbed membrane-binding compounds and methods of using the 

same 

(86) PCT/IL2005/000055 (87) WO2005/067388 

(51) IPC2010.01:A61K31/53; A61K49/00,04; A61K51/00; C07F5/00 

(71) Aposense Ltd 

(72) Ziv, Ilan; Shirvan, Anat; 

(31) 04 536493 (32) 15 Jan 2004 (33) US 

(31) 04 537289 (32) 20 Jan 2004 (33) US 

(31) 04 799586 (32) 15 Mar 2004 (33) US 


(57) The disclosure relates to compounds that selectively bind to cells 

undergoing perturbations and alterations of their normal plasma membrane 

organization, such as cells undergoing apoptosis or activated platelets. 

The disclosure further provides methods for utilizing said compounds 

in medical practice, for diagnostic and therapeutic purposes. 



(21) 548997 (22) 8 Feb 2005 

(54) Lever handle door furniture 

(86) PCT/AU2005/000152 (87) WO2005/080713 

(51) IPC2010.01:E05B1/00; E05B3/00,02,04 

(71) Assa Abloy Australia Pty Limited 

(72) Newman, Donald John; Watson, Robert John; 

(31) 2004900899 (32) 24 Feb 2004 (33) AU 


Australia 

(57) A handle assembly, in particular for a door lever handle, includes a 

handle 10, a spigot 11 to which the handle is attached, a return coil spring 

13 to bias the handle to the closed position, an operating plate 14 that is 

rotatable by the handle spigot, a mounting stock 15, and a housing 12 

engaged to one end of the spigot 11 and securable at the other end to 

the mounting stock 15. The spring 13, operating plate 14 and portions of 

the mounting stock 15 and spigot 11 are positioned within the housing 12 

once fitted to the mounting stock and the housing 12 is secured to the 

mounting stock 15 through engagement of the housing with the mounting 

stock. 

(21) 549099 (22) 25 Mar 2005 

(54) Medication dispensing apparatus with spring-driven locking feature 

enabled by administration of final dose 

(86) PCT/US2005/010206 (87) WO2005/097233 

(51) IPC2010.01:A61M5/00,315 

(71) ELI LILLY AND COMPANY 

(72) Jacobs, Alexander Thomas; Judson, Jared Alden; Row, Gordon 

Davidson; 

(31) 04 557545 (32) 30 Mar 2004 (33) US 

(31) 04 638027 (32) 21 Dec 2004 (33) US 



(57) A medication dispensing apparatus is disclosed. The medication dispensing 

apparatus has a drive member movable in a distal direction within 

a housing, and a fluid container with a piston advanceable by the drive 

member (60). The apparatus includes a latching element (180) having a 

skid (190) that is slidable along a surface of the drive member as the 

drive member passes distally during advancement. The drive member is 

arranged with the skid so as to maintain a latching lip of the latching 

element against a spring force in a first position free of the driving means 

during dose preparing and injecting prior to a final dose administration. 

The skid-engaging surface shifts distally of the skid such that the skid 

passes beyond a proximal end of that surface upon administration of a 

final dose, whereby the latching lip is urged by the spring force from the 

first position to a second position to physically lock the driving means to 

prevent further dose preparing and injecting. 

(21) 549109 (22) 3 Mar 2005 

(54) Novel hydroxy-6-heteroarylphenanthridines and their use as PDE4 

inhibitors 

(86) PCT/EP2005/050946 (87) WO2005/090311 

(51) IPC2010.01:C07D401/04,14; C07D405/04; C07D413/04; C07D417/ 

04,14; C07D471/04 

(71) Nycomed GmbH 

(72) Schmidt, Beate; Flockerzi, Dieter; Hatzelmann, Armin; Zitt, Christof; 

Barsig, Johannes; Marx, Degenhard; Kley, Hans-Peter; Kautz, Ulrich; 

(31) 04 04005005 (32) 3 Mar 2004 (33) EP 

(31) 04 04106372 (32) 7 Dec 2004 (33) EP 



(57) Disclosed is a compound of formula I wherein the substituents are 

disclosed within the specification or a salt thereof. 

Also disclosed is the use of a compound of formula I for the production of 

a pharmaceutical composition for treating bronchial asthma, COPD, psoriasis, 

atopic eczema or diabetes mellitus. 

(21) 549251 (22) 10 Mar 2005 

(54) Sulphonylpyrroles as HDAC inhibitors 

(86) PCT/EP2005/051086 (87) WO2005/087724 

(51) IPC2010.01:A61K31/40,4025; C07D207/48; C07D401/12; C07D403/ 

12; C07D409/12 

(71) 4SC AG 

(72) Maier, Thomas; Beckers, Thomas; Baer, Thomas; Gimmnich, Petra; 

Dullweber, Frank; Vennemann, Matthias; 

(31) 04 04101003 (32) 11 Mar 2004 (33) EP 



(57) Disclosed is a compound of formula I wherein the substituents are 

disclosed within the specification and a salt thereof. 

Also disclosed is the use of the compound of formula I for treating benign 

and/or malignant neoplasia. 

(21) 549381 (22) 21 Feb 2005 

(54) Process for the preparation of enantiomerically pure 1-substituted-3aminoalcohols 

(86) PCT/EP2005/001781 (87) WO2005/080370 

(51) IPC2010.01:C07B53/00; C07C213/00; C07D333/20,22 

(71) Lonza AG 

(72) Michel, Dominique; Mettler, Hanspeter; McGarrity, John; 



(31) 04 04003809 (32) 19 Feb 2004 (33) EP 

(31) 04 04010043 (32) 28 Apr 2004 (33) EP 



(57) A process for the preparation of salts of a carboxylic acid with an 

aminoalcohol of the formula of Ia and/or Ib wherein the substituents are 

disclosed in the specification. Comprising asymmetrically hydrogenating 

a salt of a carboxylic acid with an aminoketone of the formula wherein 

the substituents are defined in the specification, in the presence of a 

transition metal complex of a diphosphine ligand. 

Also disclosed are salts of a carboxylic acid said aminoketones and salts 

of a carboxylic acid of said aminoalcohols. 

(21) 549420 (22) 2 Mar 2005 

(54) Irrigation pipe with a plurality of connector elements integrally fitted to 

the wall of the pipe during manufacture 

(86) PCT/IL2005/000244 (87) WO2005/084418 

(51) IPC2010.01:A01G25/02; F16L11/12 

(71) NETAFIM LTD. 

(72) Masarwa, Abed; Schweitzer, Avi; 

(31) 04 548957 (32) 2 Mar 2004 (33) US 



(57) An irrigation pipe (10) and a method of production of an irrigation pipe 

(10) is disclosed. The irrigation pipe (10) has a plurality of connector 

elements (14) for attachment of lateral branches thereto. The connector 

elements (14) are integrally fitted to the pipe wall during manufacture, 

and may be fitted open and be adapted for closing after manufacture if 

not intended for use, or may be fitted closed and be adapted for opening 

after manufacture to enable the attachment of lateral branches. At least 

one of the connector elements is formed with an internal or external 

thread or is formed as a member of a bayonet lock. The connector elements 

have a low profile so that the irrigation pipe (10) is rollable on a 

reel. 

(21) 549430 (22) 30 Mar 2005 

(54) Process for preparing oxycodone hydrochloride having less than 25 

PPM 14-hydroxycodeinone 

(86) PCT/US2005/010666 (87) WO2005/097801 

(51) IPC2010.01:C07D489/00,08 

(71) EURO-CELTIQUE S.A. 

(72) Chapman, Robert; Rider, Lonn S; Hong, Qi; Kyle, Donald; Kupper, 

Robert; 

(31) 04 557492 (32) 30 Mar 2004 (33) US 

(31) 04 601534 (32) 13 Aug 2004 (33) US 

(31) 04 620072 (32) 18 Oct 2004 (33) US 

(31) 05 648625 (32) 31 Jan 2005 (33) US 

(31) 05 651778 (32) 10 Feb 2005 (33) US 

(74) F B RICE & CO, Level 23, 200 Queen Street, Melbourne, Victoria 

3000, Australia 

(57) A process for preparing an oxycodone hydrochloride composition 

having less than 25 ppm 14-hydroxycodeinone is disclosed, which process 

comprises the steps of: 

(a) providing an oxycodone base composition, said oxycodone base composition 

comprising an amount of 8a,14-dihydroxy-7,8-dihydrocodeinone, 

(b) reacting said oxycodone base composition with hydrochloric acid, 

whereby 8a,14-dihydroxy-7,8-dihydrocodeinone is converted to 14hydroxycodeinone; 

and 

(c) reducing an amount of 14-hydroxycodeinone in the oxycodone hydrochloride 

composition formed in step (b) to produce an oxycodone hydrochloride 

composition having less than 25 ppm 14-hydroxycodeinone. 

Also disclosed is a sustained release oral dosage form comprising particles, 

the particles comprising from about 10 mg to about 320 mg 

oxycodone hydrochloride composition having less than 25 ppm 

14·hydroxycodeinone, said particles being film-coated with a material that 

permits release of the oxycodone hydrochloride at a sustained rate in an 

aqueous medium. 


(21) 549590 (22) 3 Feb 2005 

(54) A blister pack for use with an inhalation device 

(86) PCT/US2005/003265 (87) WO2005/076872 

(51) IPC2010.01:A61M15/00; A61M16/00 

(71) MICRODOSE THERAPEUTX, INC. 

(72) Gumaste, Anand V; Bowers, John; 

(31) 04 542368 (32) 6 Feb 2004 (33) US 

(74) IP Gateway Patent and Trademark Attorneys, Suite 2, 18 Carol Avenue, 

Springwood, Brisbane, Queensland 4127, Australia 

(57) A medication pack for use with an inhalation device is made by folding 

a single elongate sheet of material 10 onto itself to form a plurality of 

single fold pleats 20 immediately adjacent and separated from one another 

along a length of the sheet. Each of the immediately adjacent pleats 

has facing inside walls that are affixed to each other to form pockets 26 

for the dry powder medicament 22. Sprocket slots 64 are provided to 

traction the sheet through the inhaler dispenser in which the pleated pockets 

are in turn opened up to expose the powder to a deaggregator and 

airflow passage. 




(21) 549787 (22) 11 Mar 2005 

(54) Antibodies binding to EphB4 for inhibiting angiogenesis and tumor 

growth 

(86) PCT/US2005/008280 (87) WO2005/090406 

(51) IPC2010.01:C07K16/28; A61K39/395; A61P35/00; C12N5/20 

(71) VasGene Therapeutics, Inc. 

(72) Krasnoperov, Valery; Zozulya, Sergey; Kertesz, Nathalie; Reddy, 

Ramachandra; Gill, Parkash; 

(31) 04 800350 (32) 12 Mar 2004 (33) US 

(31) 04 949720 (32) 23 Sep 2004 (33) US 

(31) 04 612908 (32) 23 Sep 2004 (33) US 

(74) Shelston IP, Level 21, 60 Margaret Street, Sydney, NSW 2000, Australia 

(57) Disclosed is an isolated monoclonal antibody or antigen binding portion 

thereof that binds to an epitope situated within specified amino acids 

of EphB4, inhibits binding of EphB4 to EphrinB2 and promotes apoptosis 

in a tumor cell. The antibody can be used in the treatment of cancer. 


(21) 549870 (22) 16 Mar 2005 

(54) Pharmaceutical formulations for dry powder inhalers comprising a 

low-dosage strength active ingredient 

(86) PCT/EP2005/002789 (87) WO2005/089717 

(51) IPC2010.01:A61K31/4704; A61K9/14 

(71) CHIESI FARMACEUTICI S.P.A. 

(72) Bilzi, Roberto; Armanni, Angela; Rastelli, Roberto; Cocconi, Daniela; 

Musa, Rossella; 

(31) 04 04006430 (32) 17 Mar 2004 (33) EP 



(57) Disclosed is a powder formulation for use in a dry powder inhaler, the 

powder comprising microparticles consisting of an active ingredient to 

be administered for the treatment of a respiratory disease having a therapeutical 

nominal dose equal to or lower than 20 ìg on each actuation of 

the powder inhaler and a non-therapeutically active physiologically acceptable 

excipient, wherein 

a) the MMD of the microparticles is comprised between 2 and 15 ìm; 

b) the d(0.1) is higher than 0.5 ìm; and 

c) the d(0.9) is lower than 60 ìm. 

Also disclosed is a process for the preparation of the powder formulation 

above. 

(21) 549893 (22) 24 Mar 2005 

(54) Use of anti-alpha5beta1 antibodiesin a stabilising solution to inhibit 

cancer cell proliferation 

(86) PCT/US2005/009939 (87) WO2005/092073 

(51) IPC2010.01:A61K38/00; A61K39/00,395; A61K49/00; C07K16/00 

(71) FACET BIOTECH CORPORATION 

(72) Ramakrishnan, Vanitha; Bhaskar, Vinay; Ho, Sun; Murray, Richard; 

Law, Debbie; 

(31) 05 657514 (32) 28 Feb 2005 (33) US 

(31) 04 556421 (32) 24 Mar 2004 (33) US 

(31) 04 556422 (32) 24 Mar 2004 (33) US 

(31) 04 625049 (32) 3 Nov 2004 (33) US 

(31) 05 651098 (32) 7 Feb 2005 (33) US 



(57) Disclosed is the use of: 

about 1.0 mg/mL to 15 mg/mL anti-alpha5beta1 antibody; 

about 22 mM to 27 mM citrate; 

about 145 mM to 165 mM sodium chloride; and 

about 0.04% to 0.06% polysorbate 80; 

in the manufacture of a medicament for inhibiting the proliferation of a 

cancer cell, wherein the cancer cell expresses alpha5beta1 integrin on 

its surface, and wherein the medicament is a liquid formulation and has 

a pH of about 5.5 to 7.5. 

(21) 549959 (22) 11 Apr 2005 

(54) Multiple-variable dose regimen for treating TNFalpha-related disorders 

using anti TNFalpha antibodies 

(86) PCT/US2005/012007 (87) WO2005/110452 

(51) IPC2010.01:A61K39/40,395; A61P37/06; C07K16/24 

(71) ABBOTT BIOTECHNOLOGY LTD 

(72) Granneman, George Richard; Hoffman, Rebeca S; Chartash, Elliot; 

Taylor, Lori K; Yan, Philip; 

(31) 04 561139 (32) 9 Apr 2004(33) US 

(31) 04 561710 (32) 12 Apr 2004 (33) US 

(31) 04 569100 (32) 7 May 2004 (33) US 



(57) Disclosed is the use of an isolated human anti-TNFalpha antibody, or 

an antigen-binding fragment thereof, in the manufacture of a medicament 

for treating an intestinal disorder in which TNFalpha activity is detrimental 

using a multiple-variable dose regimen, said regimen, when used, 

comprising administering to a subject in need thereof at least one induction 

dose ranging from about 20 mg to about 200 mg of the human anti- 

TNFalpha antibody, or antigen-binding fragment thereof, such that a 

threshold level of the human anti-TNFalpha antibody, or antigen-binding 

fragment thereof, is achieved within an induction phase; and subsequently 

administering to the subject at least one treatment dose of the human 

anti-TNFalpha antibody, or antigen-binding fragment thereof which is 40- 

60% of the induction dose, within a treatment phase, such that treatment 

of the intestinal disorder occurs. 


(21) 550269 (22) 30 Mar 2005 

(54) Skin conditioning agent containing sphingomyelin 

(86) PCT/JP2005/006030 (87) WO2005/094839 

(51) IPC2010.01:A23K1/16; A23L1/30; A23L2/38,52; A61K31/688 

(71) SNOW BRAND MILK PRODUCTS CO., LTD. 

(72) Kato, Ken; Ueda, Noriko; Miura, Susumu; Yoshioka, Toshimitsu; 

(31) 04 101142 (32) 30 Mar 2004 (33) JP 


(57) Disclosed is the use of sphingomyelin for manufacturing a skin beautifier 

for moisturising and/or decreasing the loss of water from the skin, 

preventing and/or improving skin roughness, and/or preventing wrinkles; 

wherein the skin beautifier is orally administered. 

Also disclosed is a cosmetic method by oral administration of a skin beautifier 

comprising sphingomylin. 

(21) 550507 (22) 12 Apr 2005 

(54) Seeded boehmite particulate material and methods for forming same 

(86) PCT/US2005/012038 (87) WO2005/100244 

(51) IPC2010.01:C01F7/44,02 

(71) SAINT-GOBAIN CERAMICS & PLASTICS, INC. 

(72) Bauer, Ralph; Yener, Doruk; Skowron, Margaret; Barnes, Martin; 

(31) 04 823400 (32) 13 Apr 2004 (33) US 

(31) 04 845764 (32) 14 May 2004 (33) US 



(57) Disclosed is a method for forming boehmite particulate material, comprising: 

providing a boehmite precursor and boehmite seeds in a suspension 

at a weight ratio not less than 60:40 of boehmite precursor to 

boehmite seeds, the suspension being a basic suspension or an acidic 

suspension containing formic acid; and heat treating the suspension at a 

temperature greater than about 120 deg C to convert the boehmite precursor 

into boehmite particulate material, the boehmite particulate material 

predominantly being comprised of platelet-shaped particles having 

an aspect ratio of not less than 3:1 and having a secondary aspect ratio 

of not less than 3: 1. 

(21) 550545 (22) 14 Mar 2005 

(54) A method of improving the efficiency of fat separation in the separation 

of a liquid food product 

(86) PCT/SE2005/000361 (87) WO2005/086994 



(51) IPC2010.01:A01J11/10; A01J25/11; A23C9/15 

(71) TETRA LAVAL HOLDINGS & FINANCE S.A. 

(72) Duchesne, Marius; Mansson, Rolf; 

(31) 04 0400634 (32) 15 Mar 2004 (33) SE 


(57) Provided is a method for improving the efficiency of fat separation in 

the separation of a liquid food product with a certain fat content into a 

lighter phase and heavier phase, comprising the steps a) said liquid food 

product is passed through a first separator where the product is separated 

into a first lighter phase and a first heavier phase, b) the first separator 

is regulated so that the first lighter phase will have a fat content 

which is less than 15%, c) the said first lighter phase is subsequently 

passed through a second separator where the product is further separated 

into a second lighter phase and a second heavier phase. 

(21) 550613 (22) 28 Sep 2005 

(54) Powered watercraft 

(86) PCT/US2005/034404 (87) WO2006/041662 

(51) IPC2010.01:B63B1/38 

(71) M SHIP CO., LLC. 

(72) Robinson, Charles W; Burns, William F; 

(31) 04 957914 (32) 4 Oct 2004 (33) US 



(57) A watercraft, comprising at least one hull having at least one planing 

surface, at least one vertical step in the planing surface, an onboard 

propulsion engine 106, and means 108 for venting exhaust from the 

onboard propulsion engine 106 at the vertical step in the planing surface 

while under way in order to introduce gas along the planing surface, the 

means for venting exhaust including means for venting a first proportion 

of the exhaust 108A at the vertical step in the planing surface, including 

a first exhaust conduit 108 that defines a first exhaust flow path 108A 

leading to the vertical step in the planing surface, and the means for 

venting exhaust including means for venting a second proportion of the 

exhaust to atmosphere, including a second exhaust conduit 109 that 

defines a second exhaust flow path 109A leading to atmosphere, wherein 

the onboard propulsion engine 106 is not an internal combustion engine 

with multiple cylinders exhausting through a corresponding number of 

exhaust ports at the underside. 

(21) 550665 (22) 8 Apr 2005 

(54) Novel water-soluble prodrugs of camptothecin derivatives 

(86) PCT/JP2005/006957 (87) WO2005/097803 

(51) IPC2010.01:A61K31/519; A61P1/00; A61P11/00; A61P13/10; A61P15/ 

00; A61P31/10; A61P35/00; C07D491/22 

(71) CHUGAI SEIYAKU KABUSHIKI KAISHA 

(72) Umeda, Isao; Ohwada, Jun; Ozawa, Sawako; 

(31) 2004 115713 (32) 9 Apr 2004(33) JP 



(57) Disclosed are water-soluble camptothecin prodrugs as represented 

by formula (2) or (3), or a pharmaceutically acceptable salt, or a hydrate 

or solvate thereof, wherein in Formula (2), R1 represents a hydrogen 

atom or an alkyl group; X represents a C=O or an alkylene group; R2 and 

R4 each independently represents a hydrogen atom, an alkyl group, or 

an amino acid side chain; and R3 represents an alkyl group; wherein in 

Formula (3), R1 is defined as in formula (2); n represents an integer from 

1 to 6; and R5 represents a hydrogen atom or COOR6 (wherein R6 represents 

a hydrogen atom or an alkyl group); wherein in Formula (2) and 

(3), Y is a group represented by formula (5): and the other substituents 

are as defined herein. Also disclosed is a therapeutic agent for a cell 

proliferation disorder (such as colorectal cancer, lung cancer, breast cancer, 

gastric cancer, uterine cervical cancer, bladder cancer or a solid 

tumor) which comprises the water-soluble prodrug as defined above as 

an effective ingredient. 

(21) 550792 (22) 31 Mar 2005 

(54) Antibacterial compositions 

(86) PCT/JP2005/006253 (87) WO2005/094850 

(51) IPC2010.01:A23L1/30,305; A61K35/20,74; A61P31/00 

(71) Meiji Dairies Corporation 

(72) Kume, Hisae; Sasaki, Hajime; 

(31) 04 107031 (32) 31 Mar 2004 (33) JP 



(57) Provided is the use of an antibacterial composition in the preparation 

of a medicament for inhibiting the proliferation of gram-positive bacteria, 

or both gram-positive and gram-negative bacteria, wherein the composition 

is (a) prepared using an acidic quark cheese, (b) comprises edible 

carbohydrates, proteins, and fats, and (c) has a pH of 4.6 or less, and 

wherein the energy ratio of carbohydrates, proteins, and fats is 50% to 

70%, 4% to 25% and 20% to 30%, respectively. 

(21) 550879 (22) 2 May 2005 

(54) Formulation of valproic acid (VPA) in fast and slow releasing components 

(86) PCT/EP2005/004739 (87) WO2005/105055 

(51) IPC2010.01:A61K31/19; A61K9/50; A61K45/08 

(71) TOPOTARGET GERMANY AG; DESITIN ARZNEIMITTEL GMBH 

(72) Franke, Hanshermann; Lennartz, Peter; Maurer, Alexander B; Hentsch, 

Bernd; Hovelmann, Sascha; Martin, Elke; 

(31) 04 04010333 (32) 30 Apr 2004 (33) EP 


(57) Disclosed is a pharmaceutical formulation comprising: 

(i) a fast releasing component which comprises compartments, and 

(ii) a slow releasing component which comprises compartments 

wherein the compartments contain valproic acid or a pharmaceutically 

acceptable salt thereof, and the slow and fast releasing components release 

the drug according to a release profile as described in the specification. 

Also described is a method of making the above formulation, and 

its use in treating diseases described in the specification, such as cancers. 



(21) 550934 (22) 19 May 2005 

(54) Chemical linkers and conjugates thereof 

(86) PCT/US2005/017804 (87) WO2005/112919 

(51) IPC2010.01:A61K31/403; A61K47/48; A61P35/00 

(71) Medarex, Inc 

(72) Horgan, Kilian; Gangwar, Sanjeev; Boyd, Sharon; Chen, Liang; 

Guerlavais, Vincent; Li, Zhi-Hong; Sufi, Bilal; 

(31) 04 572667 (32) 19 May 2004 (33) US 

(31) 05 661174 (32) 9 Mar 2005 (33) US 

(31) 05 669871 (32) 8 Apr 2005(33) US 



(57) Disclosed is a compound of formula (1), wherein the substituents are 

as listed in the specification and the cleavable linker contains a peptide 

or an amino acid, which provides drug-ligand conjugates that are potent 

cytotoxins. Also disclosed are cytotoxins represented by duocarmycins 

and derivatives thereof. 

(21) 551167 (22) 6 May 2005 

(54) Linear motion vacuum packaging system 

(86) PCT/US2005/015833 (87) WO2005/108210 

(51) IPC2010.01:B65B31/00,02 

(71) CP Packaging, Inc. 

(72) Buchko, Raymond G; 

(31) 04 568770 (32) 6 May 2004 (33) US 

(31) 04 568772 (32) 6 May 2004 (33) US 



(57) Articles A to be vacuum packed are placed within open sealable receptacles 

R on the platens 108 of a linear conveyor 102 and the vacuum 

chambers 116 of the vacuum unit 106 are placed over the receptacles as 

the conveyor and the vacuum unit are moved linearly from an upstream 

position to a downstream position whilst air from the receptacles on the 

covered platens is removed by the operation of the vacuum unit and the 

receptacles are sealed with gas tight seals. Once a batch of receptacles 

has been evacuated and sealed the vacuum chambers 116 are lifted off 

the platens 108 and the vacuum unit 106 is reciprocated back to the 

upstream position ready to be lowered onto a new set of receptacles 

placed on the conveyor at the upstream end. 

(21) 551169 (22) 29 Apr 2004 

(54) Method of detecting and predicting bronchodilatory response to beta 

agonist 

(86) PCT/IB2004/001286 (87) WO2005/106027 

(51) IPC2010.01:C12Q1/68 

(71) COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH; 

NICHOLAS PIRAMAL INDIA LIMITED 

(72) Kukreti, Ritushree; Bhatnagar, Paliav; Rao, Chandrika; Ghosh, Balram; 

Brahmachari, Samir Kumar; Guleria, Randeep; Das, Chinmoyee; 

(31) (32) 29 Apr 2004 (33) IN 


(57) Provided is a method of detecting single nucleotide polymorphism 

(SNP) in beta2AR gene associated with pharmacogenetic response in a 

human subject suffering from asthma, wherein said method is carried 

out on a blood sample of a subject who has been identified and categorized 

as a phenotypically good responder or poor responder to a 

pharmaco-logically active dose of a fast acting beta2 agonist, said method 

comprising the steps of: (a) isolating genomic DNA from the blood sample 

of the subject suffering from asthma; (b) amplifying the genomic DNA 

obtained in step (a) using specified PCR primers (c) sequencing the 

amplified PCR product obtained in step (b) and identifying the SNP of 

the sequenced PCR product to detect the specific beta2AR genotypes; 

(d) screening for polymorphism at position 46 to detect the specific SNP 

in beta2AR gene using specified snapshot primers, until the penultimate 

position of the SNP identified in step (c), and; (e) validating the subject 

for presence of SNP at nucleotide position 46 in beta2AR gene using 

specified allele specific oligonucleotides. Further provided are corresponding 

pharmaco-genetic marker polynucleotides comprising at least 20 base 

pairs encompassing the A/G polymorphism at position 46. 

(21) 551178 (22) 25 Aug 2005 

(54) Method of selecting a binder for a chipsealing process based on its 

adhesion index 

(86) PCT/US2005/030293 (87) WO2006/026374 

(51) IPC2010.01:E01C19/21; E01C7/35 

(71) Road Science, L.L.C. 

(72) Barnat, James; 

(31) 04 926174 (32) 25 Aug 2004 (33) US 



(57) Disclosed is a method of selecting a binder for a chip sealing process, 

comprising: 

providing at least one binder; 

determining the Adhesion Index of said at least one binder; 

selecting a binder for said chipsealing process after determining said Adhesion 

Index and based on said Adhesion Index of said at least one 

binder, wherein the selected binder has an Adhesion Index no greater 

than about 3.75, when calculated from 100 times the log10 of viscosity 

(centipoises) of said binder at said binder's highest temperature reached 

after contact with aggregate multiplied by the inverse of said binder's 

penetration value (decimillimeters) at 25°C. 

Also disclosed is a method of paving a surface comprising: 

applying an asphalt binder to said surface; and 

distributing aggregate on said asphalt binder in such a manner that the 

Adhesion Index of said binder substantially remains no greater than about 

3.75, when calculated as described above, while paving said surface, 

wherein said aggregate is in contact with said binder at a temperature of 

at least about 80 degrees C, said surface is at least about 6000 square 

meters, and said aggregate is distributed on said surface within about 5 

seconds of when said binder is applied, and where said binder's Adhesion 

Index is controlled by controlling the binder's temperature. 

(21) 551367 (22) 12 May 2005 

(54) Can end with tab for improved accessibility 

(86) PCT/US2005/016687 (87) WO2005/113352 

(51) IPC2010.01:B65D17/34 

(71) Rexam Beverage Can Company 

(72) Turner, Timothy; Forrest, Randall G; 

(31) 04 846416 (32) 14 May 2004 (33) US 



(57) The can end 10 for a container comprising a curled segment 14 which 

defines the outer perimeter of the can end, with a chuck wall 15 extending 

downwards from the curled segment to a central panel 12.. The central 

panel 12 which is centred about the longitudinal axis of the container, 

has an interior side, an exterior side, a non-detachable tab which is joined 

to the panel by a rivet 72, and a displaceable tear panel 20 which is 



defined by a frangible score 22 and a non-frangible hinge section 26. 

The tab has a nose end 78 which extends over a portion of the tear 

panel, and a lift end 70 opposite the nose end and two cut-outs 84 100, 

which are separated by a central section 76 which extends towards the 

rivet. The height of the lift end 70 of the tab is kept at a height greater 

than 1.27mm above the central panel, but below that of the outer curled 

segment 14. 

(21) 551397 (22) 12 May 2005 

(54) Growing system for aquatic animals 

(86) PCT/IE2005/000053 (87) WO2005/110075 

(51) IPC2010.01:A01K61/00,02 

(71) University College Cork 

(72) Mouzakitis, Gerasimos C; McCarron, Eimear Helen; Burnell, Gavin; 

(31) 2004 0336 (32) 14 May 2004 (33) IE 


(57) The invention provides for modular assembly which comprises interconnecting 

modular units. Each modular unit is adapted to be 

interconnectable with other modular units and at least one modular unit 

comprises an apparatus (1) for growing aquatic animals comprising at 

least two securing members (3, 6) adapted to be removably fixed together 

such that a feed substrate (7) can be reversibly sandwiched between 

the securing members. The modular assembly is constructed in 

the form of cage, container, box or tank. 

(21) 551468 (22) 24 Dec 2004 

(54) Polycyclic agents for the treatment of respiratory syncytial virus infections 

(86) PCT/AU2004/001830 (87) WO2005/061513 

(51) IPC2010.01:A61K31/4188,424,4353; C07D487/14; C07D471/14; 

C07D498/14; A61P31/14 

(71) Biota Scientific Management Pty Ltd 

(72) Bond, Silas; Sanford, Vanessa Anne; Lambert, John Nicholas; Lim, 

Chin Yu; Mitchell, Jeffrey Peter; Draffan, Alistair George; Nearn, Roland 

Henry; 

(31) 2003 907196 (32) 24 Dec 2003 (33) AU 



(57) Polycyclic indole derivative compounds of formula (I), and their use 

as in the treatment of infections involving viruses of the Pneumovirinae 

sub-family (RSV) are disclosed. In the formula ring (A) may be phenyl, 

pyridyl etc., (B-C) may be CH2-CH2 etc., (R1) may be phenyl and substituted 

forms thereof, and (R2) may be assorted substituents, or as defined 

in the specification. These compounds of formula (I) are particularly 

suitable for the treatment of respiratory syncytial virus infection. 

(21) 551585 (22) 28 Apr 2004 

(54) A housing for animal feedstuff 

(86) PCT/AU2004/000545 (87) WO2005/104828 

(51) IPC2010.01:A01K1/10; A01K5/02,01 

(71) Aisthorpe Holdings Pty Ltd 

(72) Aisthorpe, Stephen; Kay, David; 

(31) (32) 28 Apr 2004 (33) AU 


Australia 

(57) A housing (1) for animal feedstuff including a base (2), a roof (3) 

extending over the base (2), uprights (4) spaced apart from one another 

and extending between the base (2) and the roof (3), and a container (5) 

locatable between the uprights (4) for containing feedstuff. Livestock, 

such as cattle, access feedstuff within the container (5) by way of spaces 

between the uprights (4). In an embodiment, the uprights (4) are telescopic 

and the roof (3) can be pivoted between raised and lowered 

positions relative to the uprights (4). 

(21) 551594 (22) 7 Jul 2005 

(54) Novel carbamylated epo and method for its production 

(86) PCT/DK2005/000477 (87) WO2006/002646 

(51) IPC2010.01:A61K38/18; C07K14/505 

(71) H. LUNDBECK A/S 

(72) Christensen, Soren; Foldager, Lars; Valbjorn, Jesper; Thuesen, 

Marianne Hallberg; Pedersen, Anders Hjelholt; Munk, Morten; 

(31) 04 0401075 (32) 7 Jul 2004 (33) DK 

(31) 04 586370 (32) 7 Jul 2004 (33) US 

(31) 05 693870 (32) 23 Jun 2005 (33) US 





(57) Disclosed is a method for producing a carbamylated erythropoietin 

protein having less than about 40% aggregated protein and less than 

about 40% by weight of over- and under-carbamylated protein as measured 

by ESI-mass spectrometry, which method comprises contacting an 

amount of erythropoietin with an amount of cyanate at a temperature, 

pH, and for a time period sufficient for the amine groups on the lysines 

and the N-terminal amino acids of the erythropoietin to become at least 

about 90% carbamylated. 

(21) 551637 (22) 2 Jun 2005 

(54) Antitumor effect fortifier, antitumor agent and method of therapy for 

cancer 

(86) PCT/JP2005/010182 (87) WO2005/120480 

(51) IPC2010.01:A61K31/132,44,506,53; A61K33/24; A61P35/00 

(71) TAIHO PHARMACEUTICAL CO., LTD. 

(72) Koizumi, Katsuhisa; Uchida, Junji; Takechi, Teiji; Nukatsuka, Mamoru; 

(31) 04 171520 (32) 9 Jun 2004 (33) JP 



(57) The disclosure relates to the use of cis-oxalate (lR,2Rdiaminocyclohexane) 

platinum(II) for the manufacture of a medicament 

effective for treating a disease or disorder that would benefit from 

potentiating the antitumor activity of a composition comprising a therapeutically 

effective amount of tegafur, an antitumor effect potentiating 

amount of gimeracil and a side effect inhibiting effective amount of oteracil 

potassium. Also disclosed is an antitumour preparation comprising these 

for ingredients and a kit comprising a combination of these ingredients. 

(21) 551640 (22) 20 May 2005 

(54) Process for the production of an influenza vaccine 

(86) PCT/US2005/017606 (87) WO2005/113758 

(51) IPC2010.01:A61K39/12,145; C12N5/00,06; C12N7/00 

(71) ID BIOMEDICAL CORPORATION 

(72) Trepainier, Pierre; Dugre, Robert; Hassel, Tom; 

(31) 04 572612 (32) 20 May 2004 (33) US 



(57) A serially passaged and cloned Madin-Oarby Canine Kidney (MOCK)derived 

cell line characterized in that it has a higher susceptibility to viral 

infection than its parental MOCK cell line, wherein said higher susceptibility 

is the capability to produce at least 1.2 fold greater titer of virus than 

produced in said parental cell line. 

(21) 551780 (22) 18 May 2005 

(54) Alkyl substituted indoloquinoxalines 

(86) PCT/SE2005/000718 (87) WO2005/123741 

(51) IPC2010.01:A61K31/4985; A61P25/00; A61P37/00; C07D487/04 

(71) OXYPHARMA AB 

(72) Bergman, Jan; Engqvist, Robert; Gerdin, Bengt; Kihlstrom, Ingemar; 

Bjorklund, Ulf; 

(31) 04 0401555 (32) 17 Jun 2004 (33) SE 


(57) Disclosed is a substituted indoloquinoxaline of formula (I) wherein X 

is CO or CH2 and wherein the rest of the substituents are disclosed 

within the specification and pharmacologically acceptable salts thereof. 

Also disclosed is the use of a compound of formula (I) in the manufacture 

of a medicament for preventing and/or treating autoimmune diseases. 

(21) 551859 (22) 20 Jun 2005 

(54) Pyrimidine derivatives as 11beta-HSD1 inhibitors 

(86) PCT/EP2005/006649 (87) WO2006/000371 

(51) IPC2010.01:A61K31/505; A61P3/00; C07D239/42,69; C07D401/12; 

C07D409/12,14; C07D413/12 

(71) F. Hoffmann-La Roche AG 

(72) Amrein, Kurt; Hunziker, Daniel; Kuhn, Bernd; Mayweg, Alexander; 

Neidhart, Werner; 

(31) 04 102999 (32) 28 Jun 2004 (33) EP 



(57) Pyrimidine derivative compounds of formula (I), as well as 

pharmaceutically acceptable salts and esters thereof are disclosed, 

wherein R1 to R5 are as defined in the specification. These compounds 

can be used in the form of pharmaceutical compositions for the treatment 

and prophylaxis of diabetes, obesity, eating disorders, dyslipidemiae 

and hypertension. 

(21) 551910 (22) 1 Jun 2005 

(54) Compositions comprising nebivolol and an angiotensin II receptor 

antagonist (ARB) 

(86) PCT/US2005/019111 (87) WO2005/117858 

(51) IPC2010.01:A61K31/155,352,40,403,41,427; A61P9/00 

(71) Mylan Laboratories, Inc. 

(72) Davis, Eric; O’Donnell, John; Bottini, Peter Bruce; 

(31) 04 577423 (32) 4 Jun 2004 (33) US 

(31) 05 141235 (32) 31 May 2005 (33) US 



(57) Disclosed is a composition comprising nebivolol and an angiotensin 

II receptor antagonist (ARB) as the only pharmaceutically active agents. 

Further disclosed is the use of such for the preparation of a medicament 

for the treatment of cardiovascular disorders. 


(21) 551994 (22) 30 Jun 2006 

(54) Vapour-phase hydrogenation of glycerol 

(86) PCT/GB2006/050181 (87) WO2007/010299 

(51) IPC2010.01:C07C29/132; C07C31/10,20 

(71) DAVY PROCESS TECHNOLOGY LIMITED 

(72) Tuck, Michael William; Tilley, Simon Nicholas; Tuck, Michael William 

Marshall; 

(31) 05 14593 (32) 15 Jul 2005 (33) GB 



(57) Disclosed is a process for hydrogenation of glycerol in which a feed 

comprising glycerol is contacted with a stream of a hydrogen-containing 

gas and subjected to hydrogenation in the vapour phase in the presence 

of a catalyst at a temperature of from about 160 degrees C to about 260 

degrees C a pressure of from about 10 to about 30 bar, a hydrogen to 

glycerol ratio of from 400:1 to about 600:1 and a residence time of from 

about 0.01 to about 2.5 seconds, to be selectively converted into a 1,2propanediol 

or propanol as the major product. 



(21) 552046 (22) 1 Jun 2005 

(54) Index and method of use of adapted food compositions for dysphagic 

persons 

(86) PCT/CA2005/000849 (87) WO2005/117617 

(51) IPC2010.01:A23L1/00; A23P1/00; G01N33/02 

(71) Prophagia Inc. 

(72) Dufresne, Therese; Joujaij, Nada; Lachance, Nicole; 

(31) 04 575373 (32) 1 Jun 2004 (33) US 



(57) Disclosed is a method for preparing a solid food that has improved 

transit from lips to stomach in a dysphagic person comprising modulating 

Swallowing Texture (ST) index of a solid food composition by adjusting 

at least one parameter selected from the group consisting of firmness, 

adhesiveness, springiness and cohesiveness in order to obtain a 

ST index below 80, said ST index being calculated according to the formula: 

ST index = (F + IAI) x S x C 

wherein F is firmness, IAI is absolute value of adhesiveness, S is springiness 

and C is cohesiveness, whereby a ST index below 80 is considered 

safe to swallow for a dysphagic person. 

The disclosure also relates a method in which a quantitative and descriptive 

approach is used to adapt the food texture in the clinical management 

of dysphagia. The disclosure further relates to a method of use for 

determining and modulating the physical characteristics of foods in a 

manner to allow the food composition at serving temperature to have a 

desired combination of firmness, adhesiveness, springiness and cohesiveness 

to overcome dysphagia-related problems. 

(21) 552166 (22) 22 Jun 2004 

(54) Nutritional composition for stimulating and improving the intestinal 

barrier integrity 

(86) PCT/NL2004/000444 (87) WO2005/122790 

(51) IPC2010.01:A23L1/29,30 

(71) N.V. Nutricia 

(72) Van Tol, Eric Alexander Franciscus; Willemsen, Linette Eustachia 

Maria; Koetsier, Marleen Antoinette; Beermann, Christopher; Stahl, Bernd; 

(31) (32) 22 Jun 2004 (33) NL 


(57) Use of polyunsaturated fatty acids for the manufacture of a nutritional 

composition for use in a method for stimulating intestinal barrier integrity, 

said method comprising administering to a mammal a nutritional composition 

comprising: 

(a) eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and arachidonic 

acid (ARA), wherein the content of long chain polyunsaturated 

fatty acid with 20 and 22 carbon atoms does not exceed 15 wt.% of the 

total fat content; and 

(b) at least one oligosaccharide with a DP between 2 and 60 which comprises 

at least 66% galactose as a monose unit and at least one oligosaccharide 

with a DP between 2 and 60 which comprises at least 66% 

fructose as a monose unit. 

(21) 552245 (22) 8 Jun 2005 

(54) Methods of controlling molluscs with a material containing at least 

49% corn cob 

(86) PCT/US2005/020352 (87) WO2006/007353 

(51) IPC2010.01:A01N25/12,34; A01N65/44 

(71) Sci Protek, Inc 

(72) Grech, Nigel; 

(31) 04 871195 (32) 18 Jun 2004 (33) US 


Australia 

(57) Disclosed is a material for controlling molluscs, wherein said material 

does not include a conventional molluscicide but comprises a mixture of: 

(a) at least about 49% crushed corn cob; and (b) a structural carbohydrate 

selected from hay, straw, seed husks, seed chaff, coconut coir 

fiber, sisal fiber, coconut shells, nut shells, cotton fibers, cereal seed 

chaff, legume seed pods, sugar cane bagasse, or combinations thereof. 

It is also disclosed that the above material may further contain other 

materials such as attractants (selected from molasses, maple sugar, 

cottonseed meal, anise, garlic, nutmeg, liquorice, vanilla, synthetic and 

natural flavouring agents, cane syrup, corn syrup, oils, gypsum, lime, 

fats, proteins, carbohydrates, alginates, gums, malt sugar, beet molasses, 

cane molasses, honey, bone meal, beer, ales, chocolate, peanut 

butter, nuts, shrimp, fish, blood plasma, blood meal, milk, or combinations 

thereof), simple mineral salts, simple organic salts, or combinations 

thereof, and simple naturally occurring substances (such as kaolinite, 

gypsum, borates, silicates, diamataceous earth, plant extracts, or combinations 

thereof). Also disclosed is a method of inducing death and / or 

disrupting natural metabolic processes in a mollusc, the method comprising 

exposing the mollusc to a material as defined above. 

(21) 552449 (22) 21 Jun 2005 

(54) Dimensional analysis of saccharide conjugates with GPC & SEC- 

MALS 

(86) PCT/IB2005/02532 (87) WO2005/000920 

(51) IPC2010.01:A61K39/08,095; A61K47/48; B01D15/00 

(71) Novartis Vaccines and Diagnostics S.r.l. 

(72) Capannoli, Giorgio; Carinci, Valeria; D’Ascenzi, Sandro; Magagnoli, 

Claudia; 

(31) 04 0413868 (32) 21 Jun 2004 (33) GB 

(74) F B RICE & CO, Level 23, 44 Market Street, Sydney, New South 

Wales 2000, Australia 

(57) Provided is a composition comprising a conjugate of a capsular saccharide 

from serogroup A, C, W135, or Y of Neisseria meningitidis, 

wherein the conjugate has a specified molecular mass or size. Further 

provided are mixtures of the said compositions, plurality of batches of 

mixtures and batches of corresponding vaccines, as well as methods of 

producing them. 

(21) 552459 (22) 7 Jul 2005 

(54) Non-maltogenic exoamylase variants 

(86) PCT/GB2005/002675 (87) WO2006/003461 

(51) IPC2010.01:A21D8/04; A23K1/165; A23L1/09; C12N9/28; C12P19/ 

14 

(71) DANISCO A/S; GENENCOR INTERNATIONAL, INC. 

(72) Berg, Casper Tune; Derkx, Patrick M.F.; Fioresi, Carol; Gerritse, 

Gijsbert; Kellet-Smith, Anja Hemmingen; Kragh, Karsten Matthias; Liu, Wei; 

Shaw, Andrew; Sorensen, Bo Spange; Thoudahl, Charlotte Refdahl; 

(31) 04 608919 (32) 7 Jul 2004 (33) US 

(31) 04 886504 (32) 7 Jul 2004 (33) US 

(31) 04 886505 (32) 7 Jul 2004 (33) US 

(31) 04 886527 (32) 7 Jul 2004 (33) US 

(31) 04 612407 (32) 22 Sep 2004 (33) US 

(31) 04 947612 (32) 22 Sep 2004 (33) US 



(57) Provided is a PS4 variant polypeptide having an amino acid sequence 

which is at least 70% identical to specified sequences and which comprises 

an amino acid mutation at position 146, with reference to the position 

numbering of a specified Pseudomonas saccharophilia exoamylase 

sequence. Further provided are polypeptides with additional specified 

mutations and DNAs corresponding to the mutant polypeptides. The 

polypeptides are useful in food products requiring maltogenic alpha-amylase 

activity, e.g. in baking. 

(21) 552649 (22) 27 Jul 2005 

(54) Benzyloxy derivatives as monoamine oxidase-B (MAOB) inhibitors 

(86) PCT/EP2005/008143 (87) WO2006/013049 

(51) IPC2010.01:C07D207/27,277; C07D403/04; C07D413/04; C07D417/ 

04; A61K31/4015,4025; A61P25/00 

(71) F.Hoffmann-La Roche AG 

(72) Rodriquez-Sarmiento, Rosa Maria; Wostl, Wolfgang; Wyler, Rene; 

(31) 16.1.2007 (32) 2 Aug 2004 (33) EP 





(57) Disclosed are benzyloxy derivatives of formula (I); wherein the variables 

are as defined in the specification; as well as their pharmaceutically 

acceptable salts for the treatment of diseases, which are mediated by 

monoamine oxidase B inhibitors (MAOB inhibitors), for example Alzheimer's 

disease and senile dementia. 

(21) 552836 (22) 13 Jul 2005 

(54) Microbial mixture for treating plants to control or suppress a plant 

pathogen, particularly blight 

(86) PCT/US2005/025012 (87) WO2006/017361 

(51) IPC2010.01:C12N1/20,00; A01N63/00; A01P3/00; A01P1/00 

(71) WILLIAM BROWER 

(72) Brower, William; 

(31) 04 587563 (32) 13 Jul 2004 (33) US 



(57) Disclosed is a plant pathogen control formulation comprising: 

a) a microbe mixture comprising a mixture of beneficial bacteria including 

the group consisting of: Bacillus subtilis, Baccillus licheniformis, Bacillus 

axotoformans, Bacillus megaterium, Bacillus coagulans, Bacillus pumulis, 

Bacillus thurengiensis, Bacillus stearotermophilis, Paenbacillius polymyxa, 

Paenibaccillus durum, Azotobactor chroococcum, Pseudomonas 

aureofaceans, and Pseudomonas fluorescence; 

b) Kaolin clay; 

c) a yeast; 

d) a Yucca plant extract; and 

e) a calcium-source material. 

(21) 552842 (22) 3 Aug 2005 

(54) Rage fusion proteins and methods of use 

(86) PCT/US2005/027694 (87) WO2006/017643 

(51) IPC2010.01:A61K38/17; C07K14/705; C12N15/62 

(71) THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF 

NEW YORK; TRANSTECH PHARMA, INC 

(72) Mjalli, Adnan, MM; Stern, David M; Tian, Ye E; Webster, Jeffrey C; 

Rothlein, Robert; Schmidt, Ann Marie; Yan, Shi Du; 

(31) 04 598362 (32) 3 Aug 2004 (33) US 



(57) Provided is a fusion protein comprising a RAGE polypeptide linked at 

its carboxyl terminus to the amino terminus of a non-RAGE polypeptide, 

wherein the RAGE polypeptide is a fragment of a specified sequence of 

human sRAGE and wherein the non-RAGE polypeptide comprises a CH2 

domain or a portion of a CH2 domain, and a CH3 domain of an immunoglobulin. 

Further provided are corresponding polynucleotides, methods 

of making the protein and use of the protein in the manufacture of 

medicaments. 

(21) 552892 (22) 24 Jun 2005 

(54) A transaction processing method, apparatus and system 

(86) PCT/AU2005/000902 (87) WO2006/000021 

(51) IPC2010.01:G06Q20/00; G06Q30/00; H04M11/08 

(71) Ian Charles Ogilvy 

(72) Ogilvy, Ian Charles; 

(31) 04 903470 (32) 25 Jun 2004 (33) AU 

(31) 04 903997 (32) 19 Jul 2004 (33) AU 

(31) 04 904941 (32) 30 Aug 2004 (33) AU 

(31) 05 901230 (32) 14 Mar 2005 (33) AU 

(74) JAMES & WELLS, Level 12, KPMG Centre, 85 Alexandra Street, 

Hamilton, New Zealand 

(57) This invention relates to a method of making a payment and the method 

includes the following steps: 

a. Providing information associated with a payer, the information being 

provided in a manner so that a payee can access the information; 

b. Receiving information about the payment by a payer electronic device 

associated with the payer; and 

c. Giving instructions for making the payment using the electronic device 

associated with the payer. 

This invention also relates to a device for facilitating a payment transaction 

from a payer to a payee. The device comprises of a payer electronics 

device associated with a payer, the payer electronic device including 

payment information receiving means for receiving information about the 

payment, and payment instructing means for giving instructions for making 

the payment. 

Also, the invention relates to a transaction processing system for processing 

a payment transaction that includes payment instruction receiving means 

arranged to receive instructions for making a payment to a payee, from a 

payer electronic device associated with the payer. A payment processing 

means authorises the transfer of funds from a payer account to a payee 

account. 


(21) 552927 (22) 21 Jul 2005 

(54) Preparation of alkyl-substituted 2-deoxy-2-fluoro-D-ribofuranosyl 

pyrimidines and purines and their derivatives 

(86) PCT/US2005/025916 (87) WO2006/012440 

(51) IPC2010.01:C07H19/00; C07H21/00; C07H5/04,06; C08B37/00; 

C07H1/00 

(71) PHARMASSET, INC. 

(72) Wang, Peiyuan; Chun, Byoung-Kwon; Shi, Junxing; Du, Jinfa; Stec, 

Wojciech; 

(31) 04 589866 (32) 21 Jul 2004 (33) US 

(31) 04 608320 (32) 9 Sep 2004 (33) US 



(57) Disclosed is a compound according to Formula (I) wherein, the 

substituents are disclosed within the specification. The process for preparing 

the compound and intermediates used in the process are also 

disclosed. The compounds are alkyl-substituted 2-deoxy-2-fluro-Dribofuranosyl 

pyrimidine and purine derivatives. 

The compound of Formula (I) is an anti-HCV inhibitor. 




(21) 553098 (22) 23 Jun 2005 

(54) Methods for identifying factors for differentiating definitive endoderm 

(86) PCT/US2005/022604 (87) WO2006/016999 

(51) IPC2010.01:C12Q1/68; C12N5/07,071 

(71) CyThera, Inc 

(72) D’Amore, Kevin Allen; Agulnick, Alaln D; Eliazer, Susan; Baetge, 

Emmanuel E; 

(31) 04586566 (32) 9 Jul 2004 (33) US 

(31) 04 587942 (32) 14 Jul 2004 (33) US 

(31) 04 021618 (32) 23 Dec 2004 (33) US 

(31) 05 115868 (32) 26 Apr 2005 (33) US 



(57) Disclosed is a method of identifying a differentiation factor capable of 

promoting the differentiation of human definitive endoderm cells in a cell 

population comprising human cells, said method comprising the steps 

of: providing a cell population comprising human definitive endoderm 

cells, wherein said human definitive endoderm cells comprise at least 

10% of the human cells in said cell population; providing a candidate 

differentiation factor to said cell population; determining expression of a 

marker in said cell population at a first time point; determining expression 

of the same marker in said cell population at a second time point, 

wherein said second time point is subsequent to said first time point and 

wherein said second time point is subsequent to providing said cell population 

with said candidate differentiation factor; and determining if expression 

of the marker in said cell population at said second time point is 

increased or decreased as compared to the expression of the marker in 

said cell population at said first time point, wherein an increase or decrease 

in expression of said marker in said cell population indicates that 

said candidate differentiation factor is capable of promoting the differentiation 

of said human definitive endoderm cells. 


(21) 553159 (22) 26 Aug 2005 

(54) N-Adamantan-2-yl-2-phenoxy-acetamide derivatives as 11-beta 

hydroxysteroid dehydrogenase inhibitors 

(86) PCT/EP2005/054197 (87) WO2006/024627 

(51) IPC2010.01:A61K31/165; A61P19/10; A61P25/28; A61P27/06; A61P3/ 

04,10; A61P9/00; C07C235/22; C07D307/85; C07D311/66; C07D319/20; 

A61K31/343,353 

(71) Janssen Pharmaceutica N.V. 

(72) Jaroskova, Libuse; Linders, Joannes Theodorus Maria; Van Der 

Veken, Louis Jozef Elisabeth; Willemsens, Gustaaf Henri Maria; Bischoff, 

Francois Paul; 

(31) 04 04104152 (32) 30 Aug 2004 (33) EP 



(57) Disclosed is the use of a 11Beta-HSD1 inhibitor as represented by 

the N-adamantan-2-yl-acetamide derivatives of formula (I) for the manufacture 

of a medicament for treating pathologies associated with excess 

cortisol formation (such as obesity, diabetes, obesity related cardiovascular 

diseases, dementia, cognition, osteoporosis, stress and glaucoma), 

wherein Z represents O, S, NR6, SO or SO2; and wherein the other 

substituents are as described herein. 

(21) 553335 (22) 23 Aug 2005 

(54) Pyrimidine sulphonamide (sulfonamide) derivatives as chemokine 

receptor modulators 

(86) PCT/GB2005/003257 (87) WO2006/024823 

(51) IPC2010.01:A61K31/5377; C07D401/12; C07D403/12; C07D417/12 

(71) ASTRAZENECA AB 

(72) Cheshire, David Ranulf; Cox, Rhona Jane; Meghani, Premji; Preston, 

Cherylin Francis; Smith, Neal Michael; Stonehouse, Jeffrey Paul; 

(31) 04 0419235 (32) 28 Aug 2004 (33) GB 

(31) 05 0502544 (32) 8 Feb 2005 (33) GB 


(57) Disclosed is a compound of formula (1), or a pharmaceutically acceptable 

salt, solvate, or in vivo hydrolysable ester thereof, wherein X is 

a bond, CH2, O, S, SO, or SO2, and wherein the other substituents are 

as described in the specification. Also disclosed is the use of the compounds 

to treat asthma, allergic rhinitis, COPD, inflammatory bowel disease, 

osteoarthritis, osteoporosis, rheumatoid arthritis, psoriasis, or cancer. 

Also disclosed is a process for preparing the compound and intermediates 

useful in the process. 

(21) 553386 (22) 25 Jul 2005 

(54) Methods and devices for diagnosis of appendicitis 

(86) PCT/US2005/026218 (87) WO2006/012588 

(51) IPC2010.01:C12Q1/68; G01N33/53,558 

(71) ASPENBIO PHARMA, INC. 

(72) Colgin, Mark A; Bealer, John F; Donnelly, Richard; Newman, Diane; 

(31) 04 590631 (32) 23 Jul 2004 (33) US 



(57) Provided is the use of an immunoassay for detecting the presence of 

MRP8/14 for diagnosing appendicitis from a patient fluid sample selected 

from the group consisting of blood, plasma, or serum, by detecting the 

presence of MRP8/14 at a level higher than 10lJg/ml in the fluid sample. 

Further provided are corresponding analysis devices and kits. 


(21) 553446 (22) 7 Sep 2005 

(54) Testosterone gels comprising propylene glycol as penetration enhancer 

(86) PCT/EP2005/010293 (87) WO2006/027278 

(51) IPC2010.01:A61K31/568; A61K47/10; A61K9/06; A61P5/24 

(71) Laboratoires Besins International 

(72) Salin-Drouin, Dominique; 

(31) 04 04292170 (32) 9 Sep 2004 (33) EP 

(31) 04 638360 (32) 23 Dec 2004 (33) US 



(57) Disclosed is a pharmaceutical composition comprising: 

-0.5 to 5.0 % (w/w) of testosterone, 

-40.0 to 75.0% (w/w) of at least one C2-C6 alcohol, 

-0.1 to 5.0% (w/w) of at least one gelling agent, 

-0.1 to 5.0 % (w/w) of propylene glycol, 

- 0.05 to 5.0 % (w/w) of isopropyl myristate, 

- optionally, water. 

(21) 553461 (22) 16 Sep 2005 

(54) Flexible hydraulic compositions 

(86) PCT/US2005/033394 (87) WO2006/034145 

(51) IPC2010.01:C08K3/00 

(71) UNITED STATES GYPSUM COMPANY 

(72) Dubey, Ashish; 

(31) 05 224403 (32) 12 Sep 2005 (33) US 

(31) 04 610389 (32) 16 Sep 2004 (33) US 





(57) Disclosed is a composition for the manufacture of articles comprising: 

a hydraulic component comprising at least 55% Class C fly ash; 

about 10% to about 25% of a water-soluble, film-forming polymer on a 

dry, weight basis; and water. 

(21) 553463 (22) 23 Jan 2006 

(54) Cement-based hydraulic flexible composites and package therefor 

(86) PCT/US2006/002192 (87) WO2006/08115 

(51) IPC2010.01:B32B13/14; B65D85/00 


(72) Dubey, Ashish; Reicherts, James E; Fernette, Mark E; 

(31) 05 224398 (32) 12 Sep 2005 (33) US 

(31) 05 224403 (32) 12 Sep 2005 (33) US 

(31) 05 646968 (32) 24 Jan 2005 (33) US 

(31) 06 334166 (32) 18 Jan 2006 (33) US 



(57) A membrane or flexible mat 10 comprising a base mat 14 to which a 

flexible coating 12 has been applied. The flexing coating 12 is a hydrated 

hydraulic component like fly ash or cements. The membrane can be rolled 

into a tubular package for transport, storage or sale. 

(21) 553565 (22) 7 Sep 2005 

(54) Compositions and methods for the diagnosis and treatment of tumor 

using TAT188 antibodies 

(86) PCT/US2005/031798 (87) WO2006/029183 

(51) IPC2010.01:A61K39/395; A61K47/48; A61P35/00; C07K16/30 

(71) GENENTECH, INC. 

(72) Cairns, Belinda; Chen, Ruihuan; Chuntharapai, Anan; Frantz, 

Gretchen; Hillan, Kenneth; Koeppen, Kartmut; Phillips, Heidi; Polakis, Paul; 

Reed, Chae Janeka; Sakanaka, Chie; Smith, Victoria; Spencer, Susan; 

Williams, P Mickey; Wu, Thomas; Zhang, Zemin; 

(31) 04 936626 (32) 8 Sep 2004 (33) US 



(57) Disclosed are antibodies (3B5.1, 12B9.1 and 12G12.1) which bind to 

TAT188 and are effectively internalized and capable of causing cell death 

in TAT188 expressing cells. The antibodies are useful for the treatment 

of cancer. 

(21) 553616 (22) 21 Sep 2005 

(54) Strain of lactobacillus acidophilus having analgesic properties in the 

gastrointestinal system 

(86) PCT/EP2005/010880 (87) WO2006/032542 

(51) IPC2010.01:A23C9/123; A23L1/30; A61K35/74; C12Q1/02 

(71) Danisco A/S 

(72) Desreumaux, Pierre; Carcano, Didier; 

(31) 04 0409966 (32) 21 Sep 2004 (33) FR 

(74) WRAYS, Ground Floor, 56 Ord Street, West Perth, WA 6005, Australia 

(57) Provided is the use of at least one strain of Lactobacillus acidophilus 

to prepare a pharmaceutically acceptable support or food product administered 

to humans or animals for an analgesic purpose in the 

gastrointestinal system. Further provided is a process for selecting a 

microorganism for said use. 

(21) 553775 (22) 20 Sep 2005 

(54) Immunogenic composition for use in vaccination against 

staphylococcei 

(86) PCT/EP2005/010184 (87) WO2006/032472 

(51) IPC2010.01:A61K39/085,116; A61P31/04; C07K16/12 

(71) GLAXOSMITHKLINE BIOLOGICALS S.A. 

(72) Castado, Cindy; Lecrenier, Nicolas Pierre Fernand; Neyt, Cecile Anne; 

Poolman, Jan; 

(31) 0421082 (32) 22 Sep 2004 (33) GB 

(31) 0421078 (32) 22 Sep 2004 (33) GB 

(31) 0421081 (32) 22 Sep 2004 (33) GB 

(31) 0421079 (32) 22 Sep 2004 (33) GB 

(31) 0503143 (32) 15 Feb 2005 (33) GB 


(57) An immunogenic composition comprising at least two different proteins 

or immunogenic fragments selected from at least two groups of 

proteins or immunogenic fragments selected from the following groups: 

Group a) at least one staphylococcal extracellular component binding protein 

orimmunogenic fragment 

Group b) at least one staphylococcal transporter protein or immunogenic 

fragment 

Group c) at least one staphylococcal regulator of virulence, toxin or 

immunogenic fragment 

wherein said immunogenic fragments are capable of eliciting a protective 

immune response against Staphylococcal infection and wherein at least 

one protein or immunogenic fragment is selected from group a) and at 

least one protein or immunogenic fragment is selected from group b). 


(21) 553776 (22) 20 Sep 2005 

(54) Immunogenic composition comprising staphylococcal PNAG and Type 

5 and/or 8 Capsular polysaccharide or oligosaccharide. 

(86) PCT/EP2005/010260 (87) WO2006/032500 

(51) IPC2010.01:A61K39/085,116,385; A61P31/04 


(72) Castado, Cindy; Lecrenier, Nicolas Pierre Fernand; Neyt, Cecile Anne; 

Poolman, Jan; 

(31) 0421079 (32) 22 Sep 2004 (33) GB 

(31) 0421082 (32) 22 Sep 2004 (33) GB 

(31) 0421081 (32) 22 Sep 2004 (33) GB 

(31) 0421078 (32) 22 Sep 2004 (33) GB 

(31) 0503143 (32) 15 Feb 2005 (33) GB 


(57) The disclosed is an immunogenic composition comprising staphylococcal 

PNAG having less than 50% N-acetylation and Type 8 capsular 

polysaccharide or oligosaccharide from S. aureus. 

(21) 554236 (22) 8 Sep 2005 

(54) Host-vector system for antibiotic-free cole1 plasmid propagation 

(86) PCT/EP2005/054450 (87) WO2006/029985 

(51) IPC2010.01:C12N15/70 

(71) Boehringer Ingelheim RCV GmbH & Co KG 

(72) Grabherr, Reingard; Pfaffenzeller, Irene; 

(31) 04 04022201 (32) 17 Sep 2004 (33) EP 



(57) Provided is a non-naturally occurring bacterial cell containing i) a DNA 

sequence encoding a protein the expression of which is to be regulated, 

and, operably associated thereto, ii) a DNA sequence encoding an RNA 

sequence that mimics an RNA II sequence, or parts thereof, and that is 

complementary to an RNA I sequence that is transcribable from a plasmid 

with a ColE1 origin of replication. Further provided is the host-vector 

system and the plasmid to be used in the host-vector system. 

(21) 554260 (22) 30 Sep 2007 (23) 31 Mar 2008 

(54) Selenomethionine andor selenocysteine administration to non-human 

animals to increase selenium content in protein sources 

(51) IPC2010.01:A23K1/175,16,18; A61K33/04; C07C391/00; A61P3/02; 

A61K9/20 



(71) AgResearch Limited 

(72) Knowles, Scott Oliver; Grace, Neville Donovan; Munday, Rex; 



(57) Disclosed is a method of increasing selenium content in protein sources 

from an animal, such as milk or meat, by orally administering a tablet 

containing selenocysteine, selenomethionine, or combinations thereof. 

Also disclosed is a tablet containing selenomethionine, for oral administration, 

to increase selenium content of protein sources such as milk and 

meat from that animal, wherein the tablet releases selenomethionine 

over at least one month. 

(21) 554410 (22) 7 Sep 2005 

(54) Plant-specific genetic elements and transfer cassettes for plant transformation 

(86) PCT/US2005/031537 (87) WO2006/029076 

(51) IPC2010.01:A01H1/00; C12N15/82 

(71) J.R. SIMPLOT COMPANY 

(72) Rommens, Caius M T; Bougri, Oleg V; Yan, Hua; 

(31) 04 607586 (32) 8 Sep 2004 (33) US 

(31) 05 684525 (32) 26 May 2005 (33) US 

(31) 05 698938 (32) 14 Jul 2005 (33) US 

(74) KNIGHTSBRIDGE PATENT ATTORNEYS, Level 14, 200 Queen 

Street, Melbourne, Victoria 3000, Australia 

(57) Provided is a vector for transferring and integrating a desired polynucleotide 

into the genome of at least one cell of a plant via bacterialmediated 

transformation means, comprising: (1) a first polynucleotide, 

comprising the consensus sequence [A/C/G] - [A/C/T] - [A/C/T] - [G/T] - 

A- [C/G] - NNNNNN - A [G/T] - A - [A/C/T] - [A/G] - TCCTG - [C/G/T] - [A/ 

C/G] – N, which is (i) nicked when exposed to an enzyme involved in 

bacterial-mediated plant transformation and (ii) not identical to a bacterial 

border sequence; (2) a second polynucleotide, which is a bacterial T- 

DNA border; and (3) a desired polynucleotide positioned between the 

first and second polynucleotides. Further provided is the method of transforming 

plants with the vector. 

(21) 554426 (22) 27 Sep 2005 

(54) Conveniently implantable sustained release drug compositions comprising 

at least one non-polymeric excipient 

(86) PCT/US2005/034822 (87) WO2006/039336 

(51) IPC2010.01:A61K9/00,10 

(71) RAMSCOR, INC 

(72) Wong, Vernon; Wood, Louis; 

(31) 04 614484 (32) 1 Oct 2004 (33) US 

(31) 05 709665 (32) 19 Aug 2005 (33) US 



(57) Discloses a pharmaceutical formulation for the sustained release of 

at least one active agent comprising at least one non-polymeric, 

biocompatible, biodegradable excipient wherein the excipient in said formulation 

is at least 20% of said formulation and provides for the sustained 

release of said active agent for at least four days. 

(21) 554464 (22) 28 Oct 2005 

(54) Containment pens for finfish aquaculture 

(86) PCT/US2005/039536 (87) WO2006/050386 

(51) IPC2010.01:A01K61/00 

(71) OCEAN FARM TECHNOLOGIES INC. 

(72) Page, Stephen H; 

(31) 04 976641 (32) 29 Oct 2004 (33) US 

(31) 05 671861 (32) 14 Apr 2005 (33) US 



(57) A containment pen for finfish aquaculture, comprising a supporting 

structure, a net attached to the supporting structure and defining a containment 

volume of sufficient size for swimming finfish, wherein the net 

comprises a plurality of removable net panels, wherein each of the removable 

net panels comprises a discrete piece of flexible netting attached 

along its perimeter to one or more substantially rigid beams, and 

wherein the removable net panels are configured to be removable from 

the containment pen with the piece of flexible netting remaining attached 

to the substantially rigid beams. The plurality of removable net panels 

provides the supporting structure for a majority of the containment pen 

and adjoining net panels are attached by attaching together adjoining 

beams, and the panels are shaped so that a beam of one panel extends 

generally parallel to and adjacent a beam of an adjoining panel. 

(21) 554559 (22) 27 Oct 2005 

(54) Adrenocorticotropic hormone (ACTH) analogs and related methods 

(86) PCT/US2005/038789 (87) WO2006/052468 

(51) IPC2010.01:A61K38/16,35 

(71) UNIVERSITY OF DENVER; UNIVERSITY OF FLORIDA; OKLAHOMA 

MEDICAL RESEARCH FOUNDATION 

(72) Dores, Robert M; Haskell-Luevano, Carrie; Hochgeschwender, Ute 

H; Costa, Jessica I; Brennan, Miles B; 

(31) 04 622436 (32) 27 Oct 2004 (33) US 



(57) Disclosed is an adrenocoticotropic hormone (ACTH) analog peptide 

capable of reducing ACTH-induced corticosteroid secretion. The peptide 

is useful for lowering the corticosteroid levels in a subject suffering 

from Cushing’s syndrome or premature labour in which maternal plasma 

corticotrophin-releasing hormone levels are elevated. 


(21) 554584 (22) 11 Oct 2005 

(54) Releasable toilet seat assembly removable via horizontally deflecting 

mounts attached to seat held in place with caps closed over mounts 

(86) PCT/US2005/036462 (87) WO2006/044343 

(51) IPC2010.01:A47K13/12,26 

(71) KOHLER CO. 

(72) Vierkant, Erich C; Halloran, Daniel N; Cowell, Brian D; 

(31) 04 966271 (32) 15 Oct 2004 (33) US 



(57) A mounting assembly is disclosed for mounting a toilet seat and/or 

cover in a releasable fashion to the rear of a toilet bowl base. The assembly 

includes a fastener permanently affixed to the toilet base on which 

is mounted a cross shaped mount. The mount is engaged by deflectable 

arms extending from a hinge base. The arms flex outward slightly during 

mounting and dismounting, where mounting and dismounting can be 

achieved by a horizontal sliding motion. A hinged cap snaps onto the pair 

of arms to cover the fastener and prevent deflection of the arms and thus 

separation of the base member from the fastener. 



(21) 554681 (22) 5 Oct 2005 

(54) Mouldable biodegradable polymer 

(86) PCT/AU2005/001507 (87) WO2006/037157 

(51) IPC2010.01:C08L3/02; A61F13/15,26; A61L15/62; C08L3/04,12,14 

(71) Plantic Technologies Ltd 

(72) Henderson, Rulande; Partridge, Ian John; Rose, Elizabeth Emily; 

Oakley, Nicholas Roy; 

(31) 04 905695 (32) 5 Oct 2004 (33) AU 

(74) WATERMARK PATENT & TRADE MARK ATTORNEYS, Level 2, 302 

Burwood Road, Hawthorn, Victoria 3122, Australia 

(57) Disclosed is a biodegradable injection mouldable polymer composed, 

on a dry weight basis, of: 

a) from 50 to 85% by weight of a starch and/or a modified high amylose 

starch; 

b) from 4 to 13% by weight of a water soluble polymer selected from 

polyvinylacetate, polyvinyl alcohol and copolymers of ethylene and 

vinylalcohol which have a melting point compatible with the molten state 

of the starch components; 

c) from 10 to 35% by weight of a polyol plasticiser; 

d) from 0.5 to 10% of a polyethylene oxide or polyethylene glycol; 

e) from 0.25 to 3% of a food grade emulsifier; and 

f) from 0.1 to 1.5% by weight of a C12-22 fatty acid or salt. 

Also disclosed is a medical device formed from the above composition 

with a final moisture content of 2-3% by weight. Also disclosed is a tampon 

applicator made by injection moulding with a composition as above. 

(21) 554706 (22) 23 Apr 2007 (23) 26 Jun 2008 

(54) Plant propagation method comprising a Trichoderma species and 

charcoal obtained from flash carbonization of plant matter 

(51) IPC2010.01:A01C1/06,00; A01H4/00; A01N61/00; A01N63/04 

(71) BioDiscovery New Zealand Limited 

(72) Hill, Robert Anthony; 

(74) IPPC, Level 20, ASB House, 135 Albert Street, Auckland 1010, New 

Zealand 

(57) Disclosed is a method of vegetative propagation including the step of 

transferring a cutting of a tree species used in plantation forestry to a 

growth medium amended with a combination of charcoal and at least 

one selected isolate of a Trichoderma species, wherein the charcoal is 

prepared from biomass that is primarily plant matter by the method of 

flash carbonization. Further disclosed is a growth medium amendment, 

a method of growing seedlings and a seed coating containing the same. 

(21) 554827 (22) 8 Nov 2005 

(54) Medical triage system 

(86) PCT/US2005/040353 (87) WO2006/052920 

(51) IPC2010.01:G06K1/00 

(71) MEDCOR, INC. 

(72) Glimp, Thomas, H.; Biggerstaff, Wendy, K.; Huffine, Thomas, S.; 

Kantenwein, Scott, A.; Kinch, Diane, M.; Kleeburg, Peter, B.; Sahouri, Tim, 

I.; Seeger, Philip, C.; Smith, Curtis, H.; Victorson, Troyt, M.; Zoiss, Joyce, 

H.; 

(31) 04 985732 (32) 9 Nov 2004 (33) US 

(31) 04 985850 (32) 9 Nov 2004 (33) US 

(31) 04 985724 (32) 9 Nov 2004 (33) US 



(57) A computer-implemented method of adaptively operating a medical 

triage system is disclosed. The method comprises: presenting by a client 

computer to a triage operator a set of triage questions to ask of persons 

to be triaged; presenting by the client computer to the triage operator a 

number of triage dispositions from which to select based on responses 

to the set of triage questions; acquiring by the client computer triagerelated 

data as a result of the triage of the persons, wherein the triagerelated 

data is stored in a database coupled with the client computer and 

represents an aggregate of triage-related data from the triage of the persons; 

and analyzing the triage-related data with a server coupled with 

the database. 

The method then may comprise: setting with the server a threshold level 

of undesirable aggregate triage outcomes affiliated with previously-assigned 

triage dispositions; modifying with the server at least one ques- 

tion within the set of triage questions based on the analysis of the triagerelated 

data to reduce a level of undesirable aggregate triage outcomes 

associated with exceeding the threshold level; and presenting by the 

client computer to the triage operator the at least one modified question 

to ask a next person to be triaged. 

Alternatively, the method may comprise: modifying with the server at least 

one of the triage dispositions based on the analysis of the triage-related 

data; and presenting by the client computer to the triage operator the at 

least one modified disposition from which to select when performing triage 

on a next person. 


(21) 555163 (22) 14 May 2007 (23) 14 May 2008 

(54) Methods of immune or hematological enhancement, inhibiting tumour 

formation or growth, and treating or preventing cancer, cancer symptoms, 

or the symptoms of cancer treatments 

(51) IPC2010.01:A61K38/40; A23L1/00; A61P31/00; A61P35/00 

(71) FONTERRA CO-OPERATIVE GROUP LIMITED 

(72) Kanwar, Jagat Rakesh; Krissansen, Geoffrey Wayne; Sun, Xueying; 

Palmano, Kay Patricia; MacGibbon, Alastair Kenneth Hugh; 



(57) Disclosed is the use of milk fat or a milk fat analogue in the preparation 

of a medicament for administration to a subject at risk of developing, 

suffering from, or being treated for mucositis. 

Also disclosed is a composition comprising about 2 grams to about 210 

grams of milk fat or a milk fat analogue and from about 0.7 grams to 

about 210 grams of one or more anti-tumour agents. 

(21) 555166 (22) 19 Oct 2005 

(54) System and method for resolving transactions 

(86) PCT/US2005/037949 (87) WO2006/045060 

(51) IPC2010.01:G06Q40/00 

(71) APOLLO ENTERPRISE SOLUTIONS, LLC 

(72) Imrey, Christopher, G.; House, William, J., III; 

(31) 04 620131 (32) 19 Oct 2004 (33) US 



(57) A method for settling a transaction is disclosed. The method comprises: 

receiving information, at a server, regarding the transaction; 

seeking available information pertinent to the transaction from at least one 

source external to the server; 

processing data from the available information using a rules based engine 

including rules established on behalf of a party to the transaction located 

at the server; and 

presenting a transaction settlement offer set to a user based on at least 

one decision made by the rules based engine. 

The transaction settlement offer comprises at least one individually 

selectable offer including at least one decisioned settlement term based 

on the rules established on behalf of the party to the transaction and 

available information. Each individually selectable offer is selectable by 

the user to facilitate settlement of the transaction. 

(21) 555216 (22) 10 Nov 2005 

(54) Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition 

of notch pathway activation 



(86) PCT/NL2005/000788 (87) WO2006/052128 

(51) IPC2010.01:A61K38/17,55; A61P35/00; A61K39/395 

(71) Hubrecht Laboratorium 

(72) Clevers, Johannes, Carolus; Van Gijn, Maria, Elisabeth; Van Es, 

Johannes, Hendrikus; 

(31) 04 04078090 (32) 10 Nov 2004 (33) EP 

(31) 05 05075806 (32) 6 Apr 2005(33) US 



(57) Disclosed is a use of a Notch pathway inhibitor in the preparation of a 

medicament for inducing the differentiation of an intestinal adenoma and/ 

or adenocarcinoma cells into a goblet cell thereby treating an intestinal 

adenoma and/or adenocarcinoma. 

(21) 555239 (22) 18 Oct 2005 

(54) High yield method of producing pure rebaudioside A 

(86) PCT/US2005/037766 (87) WO2006/045023 

(51) IPC2010.01:A23L1/236 

(71) SWEET GREEN FIELDS, LLC 

(72) Jackson, Mel, Clinton; Francis, Gordon, James; Chase, Robert, 

Gordon; 

(31) 04 620280 (32) 18 Oct 2004 (33) US 

(31) 05 678653 (32) 6 May 2005 (33) US 

(31) 05 252430 (32) 17 Oct 2005 (33) US 



(57) Provided is a method of purifying rebaudioside A from Stevia starting 

material, comprising using a selected EtOH solvent, with successive 

refluxes of increasing water content. Further provided is 99% pure 

rebaudioside A and various composition comprising the purified 

rebaudioside A. 


(21) 555334 (22) 23 Dec 2005 

(54) Method of treatment or prophylaxis of a neuropathic condition using 

AT2 receptor antagonist 

(86) PCT/AU2005/001975 (87) WO2006/066361 

(51) IPC2010.01:A61K38/08; A61K31/517; A61P25/02,06 

(71) Spinifex Pharmaceuticals Pty Ltd 

(72) Smith, Maree Therese; Wyse, Bruce, Douglas; 

(31) 04 907332 (32) 24 Dec 2004 (33) AU 



(57) Disclosed is an AT2 receptor antagonist compound of formula I wherein 

the substituents are disclosed within the specification, or a 

pharmaceutically compatible salt thereof. Also disclosed is the use of 

the compound of formula I for treating neuropathic pain. 


(21) 555463 (22) 30 Nov 2005 

(54) Unidirectional translation system for bone fixation with interengaging 

teeth for resilient engagement 

(86) PCT/US2005/043359 (87) WO2006/060506 

(51) IPC2010.01:A61B17/70,80 

(71) SYNTHES GMBH 

(72) Barrall, Benjamin, S.; Davis, Barclay, Ross; Chien, Dennis; 

(31) 04 001902 (32) 1 Dec 2004 (33) US 


(57) A fixation assembly (100) is described comprising at least two plates 

(10, 60), one of which may be a contoured plate (10) and one of which 

may be a securing plate (60). The contoured plate may have a plurality of 

teeth (50b, 52b), and the securing plate may have a resilient securing 

element (74). The teeth may be arranged so that the resilient securing 

element encounters progressive resistance as the plates are compressed 

by having the teeth in plural rows of increasing distance in a transverse 

extent. 

(21) 555488 (22) 4 Nov 2005 

(54) Cryopreservation of cells 

(86) PCT/US2005/040183 (87) WO2006/052835 

(51) IPC2010.01:C12N5/02,04,14 

(71) DOW AGROSCIENCES LLC 

(72) Ainley, William, Michael; Beringer, Jeffrey, R.; Larsen, Cory, Michelle, 

Leatherman; Lu, Min; Shen, Liu, Yin; Jayakumar, Pon, Samuel; Garrison, 

Robbi, Janette; Pareddy, Dayakar, Reddy; 

(31) 04 625401 (32) 5 Nov 2004 (33) US 



(57) Provided is a method for making a cryopreserved plant cell comprising: 

(a) passaging plant cells to about mid-log growth phase for at least 1 

passage, wherein said plant cells are not pre-treated with stabilizers; (b) 

concentrating said passaged plant cells; and (c) adding a cryopreservation 

media to said concentrated passaged cells to form a cryopreservation 

composition. 

(21) 555573 (22) 14 Dec 2005 

(54) Coating compositions for making substrates 

(86) PCT/EP2005/056763 (87) WO2006/067073 

(51) IPC2010.01:C08K5/09; B41M5/145,26,30,32; C08K5/098; C09D11/ 

02 

(71) Ciba Holding Inc. 

(72) O’Donoghue, Karen; Campbell, Jonathan; 

(31) 04 0428299 (32) 24 Dec 2004 (33) GB 



(57) The disclosure relates to coating compositions for marking substrates, 

which comprise a colour former in an amount of from 0.01 to 30%, a 

metal salt of a carboxylic acid in an amount of from 0.01 to 30%, a binder 

in an amount of from 3 to 60% and an organic solvent in an amount of 

from 20 to 95%, wherein each amount is by weight based on the weight 

of the composition, wherein the organic solvent is a polar organic solvent 

or a mixture of polar organic solvents, wherein the carboxylic acid is a 

carboxylic acid of formula (I) or a mixture of carboxylic acids of formula 

(I). The disclosure relates also relates to a process for the preparation of 

the coating compositions, substrates coated with these compositions and 

a process for preparing a marked substrate using these compositions. 

(21) 555622 (22) 9 Sep 2005 

(54) A printed object and a print monitoring system for inspection of same 

(86) PCT/US2005/032440 (87) WO2006/052316 

(51) IPC2010.01:B41F17/00; B41F33/00; B24D15/00 

(71) Scientific Games International, Inc. 

(72) Duke, Dana Kipland; 

(31) 04 983960 (32) 8 Nov 2004 (33) US 





(57) A printed object having a longitudinal print axis is disclosed. The object 

comprises a printed area located on a substrate. Print indicia are 

printed on the substrate within the printed area in a two-dimensional matrix 

that has a longitudinal indicia axis that extends substantially parallel to 

the longitudinal print axis and a transverse indicia axis that extends substantially 

transverse to the longitudinal print axis. The print indicia within 

the printed area have a maximum width substantially parallel to the transverse 

indicia axis. At least one print validation symbol is printed on the 

substrate in a predetermined first validation print area. The at least one 

print validation symbol extends at least about the maximum width of the 

print indicia. 

(21) 555635 (22) 12 Dec 2005 

(54) Water current powered generating apparatus 

(86) PCT/GB2005/004775 (87) WO2006/061652 

(51) IPC2010.01:F03B17/06; F03B13/26 

(71) Scotrenewables (Marine Power) Ltd 

(72) Johnston, Barry; 

(31) 04 0427197 (32) 11 Dec 2004 (33) GB 

(74) P L BERRY & ASSOCIATES, AEQ Building, 61 Cambridge Terrace, 

Christchurch 8013, New Zealand 

(57) A power generating apparatus, suitable for use in extracting energy 

from the tidal movement of water, is disclosed. The power generating 

apparatus includes an elongate buoyancy vessel that has a generally 

circular cross section. Depending from the underside of the buoyancy 

vessel is at least one rotor assembly. The rotor assembly includes at 

least one rotor having rotor blades. The or each rotor assembly is connected 

to the vessel through a hinged joint mounting so as to be movable 

from a first, stowed position close to the vessel, such that the mounting 

means is immediately by and extends along the vessel, to a second 

deployed condition facing the direction of tidal currents. The or each rotor 

is connected to a power generator so that movement of water across 

the rotor blades of the or each rotor drives that rotor so as to generate 

power in the power generator. 

(21) 555996 (22) 22 Dec 2005 

(54) PERFORMANCE BASED RANK PREDICTION FOR MIMO DESIGN 

(86) PCT/US2005/046742 (87) WO2006/069300 

(51) IPC2010.01:H04L27/26; H04L1/06 

(71) Qualcomm Incorporated 

(72) Sampath, Hemanth; Kadous, Tamer; 

(31) 04 021791 (32) 22 Dec 2004 (33) US 



(57) A method of rank prediction for a multiple-input multiple-output (MIMO) 

communication system having a number of tones is disclosed. The method 

includes the steps of: for each tone, calculating MIMO channel matrices 

corresponding to layer transmissions; calculating signal-to-noise ratios 

(SNRs) for each tone based on the MIMO channel matrices; mapping 

the SNRs for each tone to generate effective SNRs for each layer transmission; 

selecting a highest packet format (PF) with an SNR threshold 

less than the effective SNRs for each layer transmission; selecting an 

absolute highest PF of the selected highest PFs for each layer transmission; 

selecting a rank based on the selected absolute highest PF; and 

transmitting a ranking to a transmitting side which indicates the layer 

transmissions to select for transmission so as to maximize spectral efficiency. 

(21) 556004 (22) 21 Dec 2005 

(54) Compositions of influenza viral proteins comprising at least one flagellin 

and at least one influenza M2 protein 

(86) PCT/US2005/046662 (87) WO2006/069262 

(51) IPC2010.01:C07K19/00; A61K39/12,39; C07K14/11; A61K39/145 

(71) VaxInnate Corporation 

(72) Powell, Thomas J; Nakaar, Valerian; Song, Langzhou; McDonald, 

William F; Hewitt, Duane D; 

(31) 04 638254 (32) 21 Dec 2004 (33) US 

(31) 04 638350 (32) 21 Dec 2004 (33) US 

(31) 05 645067 (32) 19 Jan 2005 (33) US 

(31) 05 653207 (32) 15 Feb 2005 (33) US 

(31) 05 666878 (32) 31 Mar 2005 (33) US 

(31) 05 682077 (32) 18 May 2005 (33) US 

(31) 05 741202 (32) 30 Nov 2005 (33) US 



(57) Disclosed is a fusion protein comprising at least one flagellin or a 

portion thereof and at least one influenza M2 protein or a functional portion 

thereof. Further disclosed is a composition comprising at least one 

flagellin or at least a portion thereof and at least one M2 protein or a 

functional portion thereof. 


(21) 556143 (22) 19 Dec 2005 

(54) Regulation of metalloprotease cleavage of cell surface proteins 

(86) PCT/AU2005/001917 (87) WO2006/063415 

(51) IPC2010.01:C12N9/50; A61K35/00; A61K38/57; A61K39/395; 

A61P37/02; C07K16/40 

(71) Monash University; Memorial Sloan Kettering Cancer Centre 

(72) Lackmann, Martin; Janes, Peter W; Nikolov, Dimitar B; Saha, 

Nayanendu; 

(31) 04 637425 (32) 17 Dec 2004 (33) US 

(74) FISHER ADAMS KELLY, Level 29, 12 Creek Street, Brisbane, Queensland 


(57) Provided is a modified mammalian ADAM10 or ADAMl7 protease, or 

functional fragment thereof, having one or more non-conservative substitutions 

of amino acids of a substrate recognition site, thereby having a 

modified ability to recognize, bind and/or proteolytically cleave a substrate 

protein compared to a wild-type ADAM 10 or ADAM 17 protease, wherein 

the substrate recognition site comprises residues 573 - 579 ofADAM10 

or residues 583 - 590 of ADAMI7. Further provided are corresponding 

nucleic acid sequences, antibodies binding the substrate recognition sites, 

and use of the modulators of the substrate recognition sited in the manufacture 

of medicaments. 

(21) 556242 (22) 21 Dec 2005 

(54) An encapsulated edible fibre product having controlled water absorbtion 

(86) PCT/US2005/046866 (87) WO2006/071797 

(51) IPC2010.01:A23L1/308; A21D2/18; A23L1/00,16,10 



(71) Kraft Foods Holdings, Inc. 

(72) Chew, Wen-Sherng; Finley, John Westcott; Campbell, Bruce; Cudia, 

Ariel; 

(31) 04 25462 (32) 29 Dec 2004 (33) US 



(57) Disclosed is an encapsulated edible fiber product having controlled 

water absorption, said encapsulated edible fiber product comprising substantially 

unswollen edible fiber particles (such as celluloses, raw starches, 

modified starches, glucans, brans, hydrocolloids, xanthans, algins, alginate 

salts, pectins, guars, chitosan and mixtures thereof) having an outer 

surface, wherein at least about 80% of the outer surface of the edible 

fiber particles is covered with an inner layer comprising an edible fat or 

lipid (such as a low- or reduced-calorie triglyceride or blends thereof 

having one or two short chain fatty acids and one or two long chain 

saturated fatty acids, and which have a melting point of about 30 to about 

40°C); at least about 90% of the inner layer is covered with an outer layer 

comprising a edible protein (such as casein, zein, soy isolate, milk protein 

concentrate, whey protein concentrate and mixtures thereof); the 

inner and outer layers provide an effective moisture barrier to prevent 

significant swelling of the edible fiber particles due to moisture absorption 

during processing, storage, and initial stages of digestion by a human; 

and the moisture barrier is breached during later stages of digestion 

so that the edible fiber particles swell due to moisture absorption. 

(21) 556251 (22) 12 Jan 2006 

(54) Reinforcing member for a patient interface 

(86) PCT/AU2006/000033 (87) WO2006/074514 

(51) IPC2010.01:A61M16/06; A62B18/08 

(71) ResMed Ltd 

(72) Lynch, Susan Robyn; Hitchcock, Robin Garth; Davidson, Aaron 

Samuel; Veliss, Lee James; 

(31) 05 643121 (32) 12 Jan 2005 (33) US 



(57) A cushion for a CPAP mask has a non-face contacting portion 422 

adapted to be connected to the mask frame, a face contacting portion 

424 adapted to engage on a users face, and a gusset portion 426 interconnecting 

the frame contacting portion and the face contacting portion. 

The face contacting portion includes a side wall 428 and a flexible membrane 

432 extending from the side wall and a reinforcing member including 

multiple thickened reinforcing ribs 420 provided on a portion of the 

interior surface 416 of the side wall (shown on the exterior surface in the 

drawing but limited to the interior surface as claimed). The reinforcing 

member provides reinforcement to the side wall of the cushion to limit 

the lateral expansion of the cushion when the interior of the cushion is 

pressurized. 

(21) 556274 (22) 8 Dec 2005 

(54) Respiratory devices and methods of use 

(86) PCT/US2005/044888 (87) WO2006/063339 

(51) IPC2010.01:A61M16/00; A62B7/10 

(71) Ventus Medical, Inc 

(72) Doshi, Rajiv; Howard, Robert A; Hatanaka, Motohide; 

(31) 04 634715 (32) 8 Dec 2004 (33) US 



(57) A nasal respiratory device for modifying a subject’s respiration. The 

device includes an adhesive or compressible holdfast 28 that secures 

the device in communication with the nasal cavity without covering the 

subject’s mouth and a passageway 6 for the inhaled and exhaled air. The 

passageway 6 includes an airflow resistor 24 that is configured to offer 

more resistance to the exhaled than to the inhaled air that passes through 

the passageway. 


(21) 556360 (22) 10 Dec 2004 

(54) Ink fountain liner 

(86) PCT/DK2004/000872 (87) WO2006/061016 

(51) IPC2010.01:B41F31/02 

(71) Lars Jepsen 

(72) Jepsen, Lars; 

(74) Hodgkinson McInnes Patents, Level 21, 201 Elizabeth Street, Sydney, 

New South Wales 2000, Australia 

(57) A sheet material liner 19 that covers the areas below a radial type ink 

fountain in a printing machine that would otherwise be wetted by spilt ink. 

This liner has a bottom panel 20 and integral side panels 21. When installed 

in a printer, the edge 24 of the bottom panel 20 closest to the nip 

between the ink roller and the fountain bottom does not protrude beyond 

the bottom edge of the fountain. The edge 24 carries a continuous strip 

of adhesive to sealingly join it to the bottom of the ink fountain. 



(21) 556392 (22) 11 Jan 2007 

(54) Axle lifting device for a vehicle 

(86) PCT/EP2007/000217 (87) WO2006/082679 

(51) IPC2010.01:B62D61/12; B60G11/27; B60G9/00 

(71) SAF-HOLLAND GmbH 

(72) Hock, Helmut; Panke, Harald; 

(31) 06 06001839 (32) 13 Jan 2006 (33) DE 

(74) AHEARN FOX, Level 4, T&G Building, 141 Queen Street, Brisbane, 

Queensland 4000, Australia 

(57) Disclosed is an axle raising device for a vehicle, in particular for pneumatic-suspension 

vehicle axes, which comprises of a support element 

(2), a lifting element (4), and a lever element (6). The support element 

and the lever element can be coupled to one another by means of the 

lifting element in such a way that, when the lifting element is actuated, 

the support element is supported on a frame element (16) of the vehicle, 

and the lever element exerts a preferably vertical force on an axle link of 

the vehicle in order to raise the vehicle. The lever element is positionally 

fixed in relation to a distal end of the axle link and/or the frame element. 

The support element is rotatably or pivotably mounted on the lever element. 

(21) 556434 (22) 30 Jan 2006 

(54) Heterocyclic substituted phenyl methanones as inhibitors of the glycine 

transporter 1 

(86) PCT/EP2006/000761 (87) WO2006/082001 

(51) IPC2010.01:C07D209/44; C07D403/04; C07D471/04; C07D209/08; 

C07D231/56; C07D417/04; C07D401/04; C07D409/04; C07D487/04; 

C07D209/88; C07D405/04; C07D491/08; C07D498/08; C07D413/04; 

C07D235/06 


(72) Jolidon, Synese; Narquizian, Robert; Norcross, Roger David; Pinard, 

Emmanuel; 

(31) 05 05100813 (32) 7 Feb 2005 (33) EP 



(57) Disclosed is a compound of formula I, or a pharmaceutically acceptable 

salt thereof, wherein ‘het’ is a bicyclic amine selected from the 

groups a) to h), and where the other substituents are as defined in the 

specification. 

Also disclosed is a method of making compounds of formula I, and their 

use in treating psychoses, pain, neurodegenerative dysfunction in memory 

and learning, schizophrenia, dementia and other diseases in which cognitive 

processes are impaired, such as attention deficit disorders or Alzheimer's 

disease. 

(21) 556517 (22) 14 Feb 2006 

(54) Process for making trans-1-((1R, 3S)-6-chloro-3-phenylindan-1-YL)- 

3, 3-dimethylpiperazine 

(86) PCT/DK2006/000086 (87) WO2006/086984 

(51) IPC2010.01:C07D295/073; C07C49/697 

(71) H Lundbeck A/S 

(72) Dahl, Allan Carsten; Wohlk Nielsen, Christina; Suteu, Christina; Robin, 

David; Brosen, Peter; 

(31) 05 00237 (32) 16 Feb 2005 (33) DK 



(57) Disclosed is a method for manufacturing a compound of formula I 

(compound I ) or a salt thereof, the method comprising: 

resolving the racemic compound of formula IV (Compound IV) using chiral 

chromatography; and 

converting the enantiomer of formula IVa (Compound IVa) obtained thereby 

to the compound of formula I. 

Also disclosed are the compounds of formula (IVa) and (IVb). 

(21) 556555 (22) 16 Jul 2007 (23) 30 Sep 2008 

(54) Improvements in a solar heat collection system 

(51) IPC2010.01:F24J2/51,04,24,46; E04H17/14 

(71) BRUCE JAMES KING 

(72) King, Bruce James; 



(57) A solar water heating system comprising a plurality of lengths of water 

conduit pipe 3, a plurality of lengths of water conduit jacket pipe 4, at 

least one of the plurality of lengths of water conduit pipe 3 being positioned 

inside each length of water conduit jacket pipe 4, one or more 

spacing elements for positioning the plurality of lengths of water conduit 

pipe inside the plurality of lengths of water conduit jacket pipe such that 

an insulating space is provided between the lengths of water conduit 

pipe and lengths of water conduit jacket pipe, and a plurality of solar 

collector pipes containing a heat transfer medium, the solar collector 

pipes being thermally connected to at least one of the plurality of lengths 

of water conduit pipe, wherein the lengths of water conduit pipe are fluidly 

connected to form a circulation system. 



(21) 556593 (22) 28 Feb 2006 

(54) Method and device for the assessment of bowel function 

(86) PCT/EP2006/060336 (87) WO2006/089970 

(51) IPC2010.01:A61B5/00; B42D15/00 

(71) EURO-CELTIQUE S.A. 

(72) Leyendecker, Petra; Hopp, Michael; Drews, Axel; 

(31) 05 05004378 (32) 28 Feb 2005 (33) EP 

(74) F B RICE & CO, Level 23, 200 Queen Street, Melbourne, Victoria 


(57) Method for assessing bowel function in a person is disclosed. The 

method includes: 

providing the person with a numeric analog scale for at least three parameters 

which are associated with bowel function; 

causing the person to indicate on the numeric analog scale the amount 

and/or intensity of the parameters being experienced; 

processing the input values of the amounts and/or intensities of the parameters 

indicated on the scale by calculating the average value using a 

processing unit; and assessing bowel function based on the output of 

the average value. 

(21) 556602 (22) 18 Jul 2007 (23) 17 Jul 2008 

(54) A panel antenna and method of forming a panel antenna 

(51) IPC2010.01:H01Q1/36; H01Q21/00; H01Q5/00; H01Q21/06; H01Q1/ 

38 

(60) 556602 

(71) TIMES-7 HOLDINGS LIMITED 

(72) Ehlen, Mathias Martin Ernest; 

(74) ELLIS TERRY, Level 12, 45 Johnston Street, Wellington 6011, New 

Zealand 

(57) A panel antenna comprises a panel formed of dielectric material; a 

plurality of radiating elements formed on a surface of the dielectric material 

by forming grooves in a first conductive sheet secured to the dielectric 

material; and a feed network for the radiating elements formed by 

forming grooves in the first conductive sheet. A method of forming the 

antenna is also disclosed. 

(21) 556651 (22) 20 Jan 2006 

(54) Yersinia spp. polypeptides and methods of use 

(86) PCT/US2006/002474 (87) WO2006/079076 

(51) IPC2010.01:A61K39/02; C07K14/24 

(71) Epitopix, LLC 

(72) Emery, Daryll A; Straub, Darren E; Wonderling, Laura; 

(31) 05 646106 (32) 21 Jan 2005 (33) US 



(57) Provided is a composition comprising a mixture of at least two 

polypeptides isolated from Yersinia species incubated in media with an 

iron chelator. The compositions of sarcosine insoluble polypeptides are 

useful as medicaments and vaccines for animals and fish. 

(21) 556707 (22) 23 Jan 2006 

(54) Medicament that is intended for oral administration, comprising a 

cyclooxygenase-2 inhibitor, and preparation method thereof 

(86) PCT/FR2006/000144 (87) WO2006/077334 

(51) IPC2010.01:A61K9/50; A61K31/4164; A61K9/16; A61K47/00 

(71) Vetoquinol 

(72) Moreau, Marinette; Osty, Nicolas; 

(31) 05 0500708 (32) 24 Jan 2005 (33) FR 



(57) Disclosed is a medicament that is intended for oral administration 

and that has an improved bio-availability, said medicament comprising 

an agglomerate based on inert solid particles that are based on at least 

one excipient, said agglomerate comprising a cyclooxygenase-2 inhibitor 

and at least one hydrophilic polymer, characterized in that said agglomerate 

comprises the product of spraying said particles with a solution 

or suspension of micronized grains of said inhibitor in said polymer 

(s) in order to agglomerate said particles, and in that said inhibitor is 

composed of at least one compound of formula (I) and a salt or solvate 

of this compound, wherein the variables are as defined in the specification. 

Preferred compounds of formula (I) include imidazoles such as 

cimicoxib. The process of preparing said medicament is also disclosed. 

(21) 560328 (22) 8 Feb 2006 

(54) Neutralizing monoclonal antibodies against severe acute respiratory 

syndrome-associated coronavirus 

(86) PCT/US2006/004599 (87) WO2006/086561 

(51) IPC2010.01:A61K39/215; C12Q1/70 

(71) New York Blood Centre 

(72) Jiang, Shibo; He, Yuxian; 

(31) 05 141925 (32) 31 May 2005 (33) US 

(31) 05 651046 (32) 8 Feb 2005 (33) US 



(57) Provided is an isolated neutralizing monoclonal antibody capable of 

binding to the receptor binding domain of the spike protein of the severe 

acute respiratory syndrome-associated coronavirus (SARS-CoV) wherein 

the antibody is produced by Hybridoma 30F9 with ATCC Accession No. 

PTA6523. 

(21) 560415 (22) 16 Feb 2006 

(54) Systems and method for identifying replikin scaffolds and uses of 

said replikin scaffolds 

(86) PCT/US2006/005343 (87) WO2006/088962 

(51) IPC2010.01:C12Q1/70; C07H21/04; C12N15/86; G01N33/48,50; 

G06F19/00 

(71) Samuel Bogoch; Elenore S. Bogoch; Samuel Winston Bogoch; Anne- 

Elenore Bogoch Borsanyi 

(72) Bogoch, Samuel; Bogoch, Elenore S; Bogoch, Samuel Winston; 

Borsanyi, Anne-Elenore Bogoch; 

(31) 05 653083 (32) 16 Feb 2005 (33) US 

(31) 05 014443 (32) 28 Apr 2005 (33) US 



(57) Provided is a method of identifying a Replikin Scaffold in a virus or 

organism comprising identifying a series of Replikin Scaffold peptides 

comprising about 16 to about 30 amino acids comprising (l) a terminal 

lysine and a lysine immediately adjacent to said terminal lysine; (2) a 

terminal histidine and a histidine immediately adjacent to said terminal 

histidine, (3) a lysine within about 6 to about 10 amino acids from another 

lysine; and (4) at least 6% lysines, wherein identification of said Replikin 

Scaffold provides for identification of a virulent virus or organism and/or 

wherein identification of said Replikin Scaffold provides for identification 

of a target for control of the replication of a virus or organism. Further 

provided are Replikin peptides and variants of them and their use in the 

manufacture of vaccines for influenza. 




(21) 560468 (22) 5 Jan 2006 

(54) Compositions for immunizing against mycobacterium using Ag85A 

(86) PCT/GB2006/000023 (87) WO2006/072787 

(51) IPC2010.01:C07K14/35; A61K39/04 

(71) ISIS INNOVATION LIMITED 

(72) McShane, Helen; Pathan, Ansar A; Hill, Adrian; Gilbert, Sarah C; 

(31) 05 0500102 (32) 5 Jan 2005 (33) GB 

(31) 05 649804 (32) 3 Feb 2005 (33) US 


(57) Disclosed is an immunogenic composition comprising a non-replicating 

or replication impaired poxvirus vector expressing the translation product 

of a mycobacterial Ag8Sa gene for use in treating or preventing mycobacterial 

infection or disease by inducing a central memory T cell immune 

response in a patient, wherein the viral vector expresses Ag8SA 

with a PK C-terminus tag, a TPA leader sequence, and a truncated Cterminus. 

(21) 560731 (22) 17 Aug 2007 (23) 11 Nov 2008 

(54) Bollard apparatus 

(51) IPC2010.01:E01F13/04; E01F9/019 

(71) MULTICRAFT PROJECT SERVICES LIMITED 

(72) Broadhurst, Robert Charles; 



(57) A retractable bollard apparatus 1 comprising a cylinder 3 which is 

closed at one end 4 and open at the other end 5 and a post 2. The 

cylinder 3 has an internal chamber 7 between the open 5 and closed 4 

ends. The cylinder 3 is placed vertically in the ground and its open end 5 

is at the surface. The post 2 which slides into the cylinder 3 has a head 

11 which caps the open end 5 of the cylinder and a base 15 which rests 

inside the cylinder when the post 2 is in a retracted position. The cylinder 

3 has multiple fluid tight seals 8a 8b 8c between the inner edge of the 

cylinder 3 and the outer edge of the post 2. This allows the raising of the 

post 2 to form an obstruction when required, by pumping a pressurised 

fluid into the internal chamber 7 of the cylinder through an inlet 28. Even 

when fully raised a portion of the outer surface of the post 2 will remain in 

contact with the seals 8a 8b 8c and thus within the chamber 7. To lower 

the post 2 the pressurised fluid is released. 

(21) 560928 (22) 1 Feb 2006 

(54) Purification of streptococcal agalactiae capsular polysaccharide 

(86) PCT/IB2006/000626 (87) WO2006/082527 

(51) IPC2010.01:C08B37/00; C12P19/04 

(71) Novartis Vaccines and Diagnostics SRL 

(72) Costantino, Paolo; 

(31) 05 0502096 (32) 1 Feb 2005 (33) GB 

(74) F B RICE & CO, Level 23, 44 Market Street, Sydney, New South 

Wales 2000, Australia 

(57) Disclosed is a process for purifying a Streptococcus agalactiae 

capsular polysaccharide, comprising the steps of: (a) removing contaminating 

nucleic acids and/or proteins from capsular polysaccharide in aqueous 

form by the use of alcoholic precipitation, wherein an alcohol and an 

aqueous metal cation are used to precipitate the nucleic acids and/or 

proteins leaving the polysaccharide in solution; (b) separating the precipitated 

material from the polysaccharide; and (c) diafiltration to remove 

fragments of group-specific saccharide from the polysaccharide. 

(21) 561292 (22) 27 Feb 2006 

(54) Clip for attaching ceiling panels to T-grid 

(86) PCT/US2006/006861 (87) WO2006/107460 

(51) IPC2010.01:E04B2/00; E04B5/00; E04B9/00 

(71) USG INTERIORS, INC. 

(72) Wendt, Alan C; Likozar, Martin E; Lehane, James J; 

(31) 05 98626 (32) 4 Apr 2005(33) US 



(57) An adaptor 17 for mounting rectangular ceiling panels 15 on a suspended 

ceiling grid 12. The suspended ceiling grid 12 is made up of 

inverted T shaped grid members with horizontal flanges and vertical webs. 

The adaptor 17, which is placed below the grid 12, at intersections of the 

inverted T shaped members, has four cantilever shaped gripping elements 

arranged in a cruciform pattern on top. These four cantilever shaped 

gripping sections on the adaptor are arranged so as to easily slip over 

and engage the four inverted T shaped members at the intersection 

during installation. The adaptor also has four panel support elements on 

the bottom. Each panel support element is directly below one of the gripping 

elements. These panel support elements on the adaptor engage 

upward flanges on the ceiling panels. The weight of the ceiling panels is 

thus transferred through the adaptors to the ceiling grid. 

(21) 561293 (22) 3 Mar 2006 

(54) Crystallisation and purification of glycopyrronium bromide 

(86) PCT/GB2006/000770 (87) WO2006/092617 

(51) IPC2010.01:C07D207/12; A61K31/40; A61P1/06; A61P13/06 

(71) SOSEI R&D LTD 

(72) Baxter, Andrew Douglas; Sinden, Kenneth Walter; Kleinebekel, Stefan; 

(31) 05 0504463 (32) 3 Mar 2005 (33) GB 



(57) Disclosed is a method for the production of crystalline glycopyrronium 

bromide in the form of predominantly the R,S and S,R diastereoisomers 

with respect to the R,R, and S,S diastereoisomers, which comprises 

separating the desired diastereoisomers by one or more controlled crys- 



tallisation steps conducted in a solvent comprising the same or different 

compounds of the formula R1COR2 or R1COOR2 (such as methyl ethyl 

ketone or methyl, isobutyl ketone) wherein R1 and R2 are independently 

alkyl. 

(21) 561573 (22) 24 Mar 2006 

(54) Isoflavonoid dimers 

(86) PCT/AU2006/000395 (87) WO2006/099681 

(51) IPC2010.01:C07D471/04; C07D491/052; C07D493/04; C07D495/04; 

A61K31/35,382,436,4365,4375; A61P29/00; A61P35/00; A61P37/00; 

A61P9/00 

(71) Novogen Research Pty Ltd 

(72) Heaton, Andrew; Kumar, Naresh; 

(31) 2005 901475 (32) 24 Mar 2005 (33) AU 

(31) 05 668609 (32) 6 Apr 2005(33) US 

(31) 2005 905985 (32) 28 Oct 2005 (33) AU 

(74) DAVIES COLLISON CAVE - SYDNEY, 255 Elizabeth Street, Sydney, 

New South Wales 2000, Australia 

(57) Disclosed is a compound of formula (I), or a pharmaceutically acceptable 

salt thereof, wherein X is O, NR12, or S, and wherein the other 

substituents are as defined in the specification. Also disclosed is a method 

for preparing the above compound, and its use in treating cancer, unwanted 

proliferation or upregulation of cellular growth, inflammation or 

inflammatory disorders, autoimmune disorders, cardiovascular disorders 

and disorders associated with estrogen receptor activation. Also disclosed 

is a drink or foodstuff containing the compound. 

(21) 561576 (22) 16 Mar 2006 

(54) Channel structures for a quasi-orthogonal multiple-access communication 

system 

(86) PCT/US2006/009757 (87) WO2006/099577 

(51) IPC2010.01:H04J11/00 


(72) Ji, Tingfang; Naguib, Ayman; Sutivong, Arak; Gore, Dhananjay Ashok; 

Gorokhov, Alexei; 

(31) 05 662634 (32) 16 Mar 2005 (33) US 

(31) 05 129140 (32) 13 May 2005 (33) US 



(57) A method of assigning system resources in a communication system 

is disclosed. The method includes: scheduling several terminals for data 

transmission; and assigning the terminals with channels in at least two 

channel sets. Each channel set comprises several channels and is associated 

with a specific mapping of the channels to system resources 

available for data transmission. The mapping for each channel set is 

pseudorandom with respect to the mapping for each remaining one of 

the at least two channel sets for at least a subset of the channels. 

(21) 561666 (22) 17 Mar 2006 

(54) Nanoparticulate biphosphonate compositions 

(86) PCT/US2006/009791 (87) WO2006/102117 

(51) IPC2010.01:A61K9/51; A61K31/663; A61K47/02; A61K9/14; A61P19/ 

08; A61P9/10 

(71) Elan Pharma International Limited 

(72) Liversidge, Gary; Jenkins, Scott; 

(31) 05 662693 (32) 17 Mar 2005 (33) US 



(57) Disclosed is a bisphosphonate dispersion consisting of: 

(a) an aqueous dispersion medium; 

(b) particles of at least one bisphosphonate complexed with a multivalent 

cation and having an effective average particle size of less than about 

2000 nm, the bisphosphonate-cation complex particles dispersed in the 

aqueous dispersion medium; and 

(c) at least one surface stabilizer adsorbed on the surface of the particles. 

Also disclosed is an oral dosage form of a bisphosphonate composition 

comprising: 

(a) particles consisting of at least one bisphosphonate complexed with a 

multivalent cation and having an effective average particle size of less 

than about 2000 nm, the bisphosphonate-cation complex particles having 

at least one surface stabilizer adsorbed on the surface of the particles; 

(b) a permeation enhancer; and 

(c) a chelating agent. 

Also disclosed is a method of making the nanoparticulate bisphosphonate 

dispersion, and its use in inhibiting bone resorption 

(21) 561783 (22) 21 Feb 2006 

(54) Glove with an adhesive portion on the inner side of the cuff formed by 

an unfinshed region of the glove material where in use the adhesive portion 

of the glove is in contact with the cuff of a garment worn by the user 

(86) PCT/GB2006/000611 (87) WO2006/100422 

(51) IPC2010.01:A41D19/00; A61B19/04 

(71) REGENT MEDICAL LIMITED 

(72) Day, Jonathan; Leeming, Christine; Rogers, Jan; Williams, Haydn; 

(31) 05 0505862 (32) 22 Mar 2005 (33) GB 



(31) 05 0511993 (32) 13 Jun 2005 (33) GB 



(57) A glove having a hand portion and a wrist portion, extending from the 

hand portion and terminating in a hand insertion opening, is disclosed. 

The wrist portion includes a region of adhesive material provided on a 

surface which, in use, will form the inside of the glove. The adhesive 

material is formed by an unfinished region of glove material, where, in 

use, the region of the adhesive material is in contact with the cuff of a 

garment worn by the user so as to prevent roll-down of the glove. 


(21) 561999 (22) 26 Sep 2007 (23) 26 Sep 2008 

(54) Marker assisted selection of bovine for milk fat colour 

(51) IPC2010.01:C12Q1/68 

(71) VIALACTIA BIOSCIENCES (NZ) LIMITED 

(72) Thomas, Natalie Louise; Ward, Hamish Evan; Davis, Stephen Richard; 

Lehnert, Klaus; Barnett, Julia Leigh; Berry, Sarah Dianne; Snell, Russell 

Grant; Macgibbon, Alastair Kenneth Hugh; Spelman, Richard; Pearson, 

John Frederick; Oxley, Penny Elizabeth; Beattie, Elizabeth Marie; 



(57) Provided is a method of determining genetic merit of a bovine with 

respect to milk or tissue colour or beta-carotene content or with respect 

to capability of producing progeny that will have increased or decreased 

milk or tissue colour or beta-carotene content, which comprises the step 

of determining the scavenger receptor class 1, member 1 (SCARB1) 

allelic profile of said bovine, and determining the genetic merit of the 

bovine on the basis of the SCARB1 allelic profile. Further provided are 

bovines selected by the method and milk obtained from such selected 

bovines. 

(21) 562002 (22) 2 Mar 2006 

(54) Novel adhesive compositions comprising phloroglucinol (1,3,5trihydroxybenzene), 

manufacturing thereof, and applications thereof 

(86) PCT/IL2006/000289 (87) WO2006/092798 

(51) IPC2010.01:C08L101/00; A61L24/00,08; C08L5/04 

(71) TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. 

(72) Bianco-Peled, Havazelet; Biton, Ronit; Shecter-Harkavyk, Inna; 

(31) 05 657413 (32) 2 Mar 2005 (33) US 


(57) Disclosed is a composition-of-matter comprising a cross-linked form 

of a water miscible 

polymer, at least one cross-linking agent comprised of divalent ions for 

effecting said 

cross-linked form of said water miscible polymer, and at least one phloroglucinol 

type compound selected from the group consisting of: phloroglucinol, 

a derivative of phloroglucinol, and a polymer synthetically prepared 

from phloroglucinol or a derivative of phloroglucinol. Also disclosed 

is a method of manufacturing the composition-of-matter and its use as 

an adhesive. 

(21) 562092 (22) 28 Sep 2007 (23) 26 Sep 2008 

(54) Antimicrobial effect of copolymers of aniline with 3-amino benzoic 

acid, anthranilic acid and ethyl 3-amino benzoate 

(51) IPC2010.01:A61K31/785; A61P31/04; C08G73/00,02 

(60) 562092\562092 

(71) Auckland UniServices Limited 

(72) Gizdavic-Nikolaidis, Marija; Easteal, Allan James; Stepanovic, Srdjan; 


(57) Disclosed are aniline random copolymers and the synthesis thereof 

for use as antimicrobial (antibacterial, antifungal or antiviral material) 

material of for the manufacture of antimicrobial objects, suitable for use 

in the health, food, packaging, water, paint, wood, textile, poultry, glass, 

paper, rubber, ceramic, seafood, sports, plastic and agricultural industries. 

The aniline random copolymer is represented by the structure shown 

herein: wherein, R3 = H, -CO2H, -CO2Me, or -CO2Et or as defined in 

the specification. R is typically H or a C1-C6 alkyl, x is an integer between 

1 and 0 and m indicates the degree of polymerisation, and wherein 

said copolymer is not polyaniline. Preferred copolymers are copolymers 

of aniline with 3-aminobenzoic acid, 2-aminobenzoic acid and ethyl 3aminobenzoate. 

(21) 562188 (22) 3 Apr 2006 

(54) Methods and apparatus for encoding and decoding an highband portion 

of a speech signal 

(86) PCT/US2006/012231 (87) WO2006/107837 

(51) IPC2010.01:G10L21/04; G10L19/14 


(72) Vos, Koen Bernard; Kandhadai, Ananthapadmanabhan A; 

(31) 05 667901 (32) 1 Apr 2005(33) US 

(31) 05 673965 (32) 22 Apr 2005 (33) US 



(57) A wideband speech encoding apparatus and a method for encoding/ 

decoding speech is disclosed. The wideband speech encoder apparatus 

includes a lowband encoder and a highband encoder. The highband encoder 

is configured to calculate values for coding parameters that specify 

a spectral envelope, an extended signal, and a gain envelope. The gain 

envelope is based on the relation between the highband and lowband 

portions. 

(21) 562309 (22) 10 Mar 2006 

(54) Process for the manufacture of sodium cellulose sulfate which can 

be used for micro-encapsulation 

(86) PCT/EP2006/060626 (87) WO2006/095021 

(51) IPC2010.01:C08B7/00; C08B5/14 

(71) Fraunhofer-Gesellschaft zur Forderung der angewandten Forschung 

e.V.; Ziel Biopharma Ltd. 

(72) Hauser, Oliver; Fischer, Steffen; Hettrich, Kay; Wagenknecht, 

Wolfgang; 

(31) 05 05011367 (32) 11 Mar 2005 (33) DE 



(57) Method for the production of regio-selective substituted cellulose 

sulfate (CS) characterized by a combination of the following steps: 

a) swelling of native cellulose in a polar aprotic solvent; 

b) addition of a sulfating reagent and an acetylating reagent, for the simultaneous 

esterification and distribution of acetate groups and suIfate groups 

along and between the polymer chains; 

c) directly followed by a complete neutralization with a base, preferably 

sodium hydroxide, whereby the sulfate without cleaving the acetyl group 

is transferred into a sodium salt of the cellulose sulfate (SCS), whereby 

the directly following neutralization also avoids cleavage of acetate groups 

and consequently the degradation of the cellulose chains; and 

d) subsequent precipitation, deacetylation, washing and drying of the SCS, 

whereby the SCS is characterized by a solution viscosity, which is greater 

than 10 mPas at a concentration of 1% in water. 

Cellulose sulfate formed by this method is water-soluble and has an adjustable 

solution viscosity in aqueous solution, which makes it useful as 



an auxiliary material with ideal biological compatibility for biological and 

medical applications, in particular it is suitable for the encapsulation and 

immobilization of biological objects, e.g. tissue, cells, microorganisms, 

enzymes or viruses in microcapsules. 

(21) 562374 (22) 21 Apr 2006 

(54) Heated food storage and display cabinet with heated air curtain 

(86) PCT/GB2006/001469 (87) WO2006/111767 

(51) IPC2010.01:A47F3/00 

(71) Alan Nuttall Limited 

(72) Nuttall, Alan David; Steele, Michael James; Richardson, Gareth; 

(31) 05 50508204 (32) 22 Apr 2005 (33) GB 



(57) A heated food storage and display cabinet (10) is disclosed. The cabinet 

comprises an open fronted enclosed chamber (30) within which packs 

of food can be stored, flow inducing means (52), and heater means (54) 

arranged in an upper region thereof. The flow inducing means is operable 

to draw air from an upper portion of the enclosed chamber, direct 

the air over the heater means to heat the air and subsequently urge the 

heated air down the rear wall (18) of the chamber and across the floor 

(22) towards the open front of the chamber. The heated air is subsequently 

directed upwardly and rearwardly across the open front of the 

chamber by an airflow direction member (78) to provide a heated air 

curtain (70) across the open front of the chamber. A portion of the heated 

air (64, 68) passes into the chamber as the heated air moves down the 

rear wall and across the floor so as to pass over and around packs of 

food stored therein. 

(21) 562455 (22) 14 Apr 2006 

(54) Method for determining pre-remission phase of ulcerative colitis using 

PGE-MUM and reagent kit for the same 

(86) PCT/JP2006/307939 (87) WO2006/118004 

(51) IPC2010.01:G01N33/493,53,577 

(71) Fujirebio Inc.; Mutsunori Fujiwara; Isao Okayasu; Yuzo Hayashi 

(72) Fujiwara, Mutsunori; Okayasu, Isao; Hayashi, Yuzo; 

(31) 05 117521 (32) 14 Apr 2005 (33) JP 



(57) Disclosed is a method for judging stages between a pre-remission 

phase and a remission phase of ulcerative colitis comprising the steps 

of: 

setting as a base value a value of a main metabolite of prostaglandin 

(PGE-MUM) concentration in urine obtained by measuring PGE-MUM 

contained in the urine of patients diagnosed as being in the remission 

phase of ulcerative colitis, said remission having been induced by the 

administration of anti-inflammatory drugs; and 

judging that ulcerative colitis is in the pre-remission phase when the value 

of PGE-MUM concentration in urine of the patients is in a range exceeding 

the base value and being not more than 3 times the base value, and 

that ulcerative colitis is in the remission phase when the value of PGE- 

MUM concentration in urine of the patients is in a range of not more than 

the base value. 


(21) 562602 (22) 17 Oct 2007 (23) 9 Oct 2008 

(54) Method for calculating a strategy to service a loan 

(51) IPC2010.01:G06Q40/00 

(71) ENABLEME LIMITED 

(72) Mcqueen, Hannah Lee; 



(57) A computer controlled process for calculating a strategy to service a 

loan, is disclosed. The computer is programmed to carry out the steps 

of: (a) receiving a total repayment amount available to service the loan 

over a first period and at least one further period, (b) receiving a total 

loan amount, (c) receiving an estimated variable interest rate for the first 

period, (d) receiving a fixed interest rate for the first period and at least 

one further period, and (e) calculating a variable interest rate loan amount 

and a fixed interest rate loan amount for each period and associated 

repayment amounts. The sum of all loan amounts is equal to the total 

loan amount and the sum of all repayment amounts is equal to the total 

repayment value, where the associated repayment amounts are such 

that the variable interest rate loan amount is substantially paid in full by 

the end of the first period. 


(21) 562675 (22) 28 Jul 2005 

(54) Credential interface 

(86) PCT/US2005/026853 (87) WO2006/115518 

(51) IPC2010.01:H04L9/32; G06F21/00 

(71) MICROSOFT CORPORATION 

(72) Ruzyski, David M; Hong, James H; McNeil, Brian K; Guzak, Chris J; 

Wentz, Brian D; Schutz, Klaus U; Richards, Stefan; Perlin, Eric C; Ilac, 

Cristian; Reasor, Sterling M; Flo, Eric R; Stephens, John; Hutz, Benjamin 

A; 

(31) 05 112844 (32) 22 Apr 2005 (33) US 



(57) A method of authenticating a user is disclosed. Multiple sets of credential 

information for multiple credentials and from multiple credential 

providers are received. Each set of credential information to enable tailoring 

of a portion of a graphical user interface to present one of the 

multiple credentials and to specify an acceptable credential type for the 

one of the multiple credentials. A request to authenticate the user is 

received. The multiple credentials are presented on the graphical user 

interface. The graphical user interface includes a corresponding portion 

for each of the multiple credentials that is tailored based on its set of 

credential information. An authenticator for one of the multiple credentials 

that is of the acceptable credential type is received. The authenticator 

is capable of authenticating the user. 

Alternatively a method of authenticating a user comprises gathering sets 

of information associated with two or more credentials. Each of the credentials 

capable of authenticating users and the sets of information are 

associated with the each of the credentials including instructions for submitting 

an authenticator for the each of the credentials to an authenticating 

entity. A graphical user interface to display the sets of information 

associated with the two or more credentials is tailored and the graphical 

user interface is presented. The graphical user interface enables selection 

of at least one of the two credentials. 



(21) 562694 (22) 13 Apr 2006 

(54) Isothiazole and isoxazole derivatives in the form of lipase and phospholipase 

inhibitors 

(86) PCT/EP2006/003411 (87) WO2006/111321 

(51) IPC2010.01:C07D261/20; A61K31/423,428,437,454; A61P3/10; 

C07D275/04; C07D413/12; C07D498/04; C07D513/04 

(71) Sanofi-Aventis 

(72) Zoller, Gerhard; Petry, Stefan; Muller, Gunter; Heuer, Hubert; 

Tennagels, Norbert; 

(31) 05 05018389 (32) 20 Apr 2005 (33) DE 



(57) Disclosed is a compound of Formula (I), wherein A is defined as S or 

O, each X is CR or N and the remaining substituents are as defined in 

the specification, the tautomeric forms of the compound and the physiologically 

tolerated salts thereof, and the use thereof as medicaments, 

for example to treat fatty acid metabolism and glucose utilisation disorders. 

(21) 562725 (22) 13 Apr 2006 

(54) A pressure relieving mattress 

(86) PCT/GB2006/001353 (87) WO2006/114571 

(51) IPC2010.01:A61G7/057; A47C27/00,18,20 

(71) Invacare UK Operations Limited 

(72) Lewis, Jan Anthony; Mahoney, Ian Robert; 

(31) 05 0508403 (32) 26 Apr 2005 (33) GB 



(57) This disclosure relates to mattresses such as a pressure relieving 

mattress and in particular ones for profiling beds. The mattress comprises 

a base portion (11) , a carriage portion (12), an upper portion (13) 

and an inflatable pressure relieving underlay (14) disposed between the 

carriage (12) and the upper portion (13). The facing surfaces (15) and 

(16) of the base portion (11) and the carriage portion (12), respectively, 

are coated with a low friction material so that the two slide easily relative 

to one another. This sliding movement is restricted to longitudinal relative 

movement by the engagement of co-operating formations (17, 18). 

The combination provides particularly flexible mattress arrangement which 

also avoids the problem of the leg section of the mattress kicking upwardly 

when a profiling bed is articulated. 

(21) 562743 (22) 11 May 2006 

(54) Fast drying gypsum products 

(86) PCT/US2006/018123 (87) WO2006/137997 

(51) IPC2010.01:C04B28/14 


(72) Liu, Quingxia; Lettkeman, Dennis M; Wilson, John W; Randall, Brian 

S; Blackburn, David R; 

(31) 05 152661 (32) 14 Jun 2005 (33) US 



(57) A gypsum slurry includes water, a hydraulic material including at least 

50% calcium sulfate hemihydrate, and a polycarboxylate dispersant. The 

dispersant includes vinyl ether, acrylic acid, and maleic acid repeating 

units and has a molecular weight range of from 20,000 to 80,000 Daltons. 

A wallboard panel can be made with a facing sheet and a core of the set 

slurry. 

(21) 562783 (22) 24 Oct 2007 (23) 24 Oct 2008 

(54) Method of reducing greenhouse gas production 

(51) IPC2010.01:A23K1/16; A61K35/78; A61K36/19,45 

(71) Methane Reduction Technologies Limited 

(72) Duncan, Kelvin; 



(57) Disclosed is a method of suppressing methanogen archaea activity 

in a non-human animal by the step of introducing an extract derived from 

the plant species Impatiens balsamina into an environment in which 

methanogen archaea are present in the non-human animal. 

(21) 563032 (22) 31 Oct 2007 (23) 21 Nov 2008 

(54) Plant resistance gene for powdery mildew and uses thereof 

(51) IPC2010.01:A01N65/00; C07K14/415; C12N15/82; A01H1/00; 

C12N15/29; A01H5/08 

(60) 563032 

(71) THE NEW ZEALAND INSTITUTE FOR PLANT AND FOOD RE- 

SEARCH LIMITED 

(72) Bus, Vincent Gerardus Maria; Rikkerink, Hendrikus Antonius; Hilario- 

Andrade, Elena Maria; Dare, Andrew Patrick; Gardiner, Susan Elizabeth; 

Yoon, Minsoo; 



(57) Disclosed are methods for producing a plant with altered resistance 

to powdery mildew, the methods comprising transformation of a plant 

with a genetic construct including a polynucleotide encoding of a polypeptide 

with an amino acid sequence as defined in the specification, or a 

variant or fragment thereof. Also disclosed are isolated polypeptides, 

polynucleotides, constructs and vectors useful for producing a plant cell 

and plants transformed to contain and express the polypeptides, 

polynucleotides and constructs. 

(21) 563065 (22) 15 May 2006 

(54) Thermosetting powder compositions 

(86) PCT/EP2006/004556 (87) WO2006/125545 



(51) IPC2010.01:C08L67/00 

(71) Cytec Surface Specialties, S.A. 

(72) Moens, Luc; Knoops, Nele; Maetens, Daniel; 

(31) 05 05011415 (32) 26 May 2005 (33) EP 



(57) A thermosetting powder composition comprising a binder composition 

is disclosed, which comprises: from 99 to 55 parts by weight, calculated 

on the total weight of polyesters, of at least one amorphous polyester 

(A) which comprises, with respect to the total amount of acids, from 

50 to 100 mol % of isophthalic acid and optionally from 0 to 50 mol % of 

at least one other aliphatic, cycloaliphatic and/or aromatic polycarboxylic 

acid and, with respect to the total amount of alcohols, from 70 to 100 mol 

% of neopentyl glycol and optionally from 0 to 30 mol % of at least one 

other aliphatic and/or cycloaliphatic polyol, said amorphous polyester (A) 

having a number average molecular weight of from 1100 to 11500; and 

from 1 to 45 parts by weight, calculated on the total weight of polyesters, 

of at least one amorphous polyester (B) which comprises, with respect 

to the total amount 15 of acids, from 75 to 100 mol % of at least one 

straight-chain saturated di-carboxylic aliphatic acid having from 4 to 14 

carbon atoms and optionally from 0 to 25 mol % of at least one other 

aliphatic, cycloaliphatic and/or aromatic polycarboxylic acid and, with 

respect to the total amount of alcohols, from 75 to 100 mol % of at least 

one branched chain aliphatic diol and optionally from 0 to 25 mol % of at 

least one 20 other aliphatic or cycloaliphatic polyol, said amorphous polyester 

(B) having a number average molecular weight of from 1100 to 

17000. These thermosetting powder compositions give coatings having 

remarkable weatherability, excellent mechanical properties and an outstanding 

flow. 


(21) 563187 (22) 18 Apr 2006 

(54) Peptides and peptide mimetics to treat pathologies characterized by 

an inflammatory response 

(86) PCT/US2006/014839 (87) WO2006/118805 

(51) IPC2010.01:A61K38/00 

(71) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA; THE UAB 

RESEARCH FOUNDATION 

(72) Anantharamalah, Gattadahalli M; Fogelman, Alan M; Navab, 

Mohamad; 

(31) 05 676431 (32) 29 Apr 2005 (33) US 

(31) 05 697495 (32) 7 Jul 2005 (33) US 

(74) PIPERS, Level 1, 5A Pacific Rise, Mt Wellington, Auckland, New 

Zealand 

(57) Provided is the use of a "D" or "L" peptide that comprises the amino 

acid sequence DWFKAFYDKVAEKFKEAF or 

FAEKFKEAVKDYFAKFWD, in the manufacture of a medicament suitable 

for administration to a mammalian subject for the treatment or prevention 

of one or more symptoms of a condition selected from the group 

consisting of restenosis, emphysema, Paget's disease, Wegener's granulomatosis, 

central nervous system vasculitis (CNSV), Sjögren's syndrome, 

corneal ulcer, ulcerative colitis, reperfusion injury, ischemic 

reperfusion injury a cancer, osteoarthritis, inflammatory bowel disease, 

allergic rhinitis, cachexia, Crohns’ disease, dermatitis, asthma, erectile 

dysfunction, and macular degeneration. 


(21) 563193 (22) 2 May 2006 

(54) Human monoclonal antibodies to programmed death 1(PD-1) and 

methods for treating cancer using anti-PD-1 antibodies alone or in combination 

with other immunotherapeutics 

(86) PCT/JP2006/309606 (87) WO2006/121168 

(51) IPC2010.01:C12N15/09; C07K16/28; C12N5/00; C12P21/08; C12Q1/ 

02 

(71) Ono Pharmaceutical Co., Ltd; Medarex, Inc. 

(72) Korman, Alan J; Srinivasan, Mohan; Wang, Changyu; Selby, Mark J; 

Chen, Bing; Cardarelli, Josephine M; 

(31) 05 679466 (32) 9 May 2005 (33) US 

(31) 05 738434 (32) 21 Nov 2005 (33) US 

(31) 05 748919 (32) 8 Dec 2005 (33) US 



(57) Disclosed is an isolated human monoclonal antibody, or an antigenbinding 

portion thereof, wherein the antibody cross-competes for binding 

to PD-1 with a reference antibody. Methods for detecting PD-1, as well 

as methods for treating various diseases, including cancer and infectious 

diseases, using anti-PD-1 antibodies are also disclosed. 

(21) 563311 (22) 9 Nov 2007 (23) 5 Nov 2008 

(54) Docking iron 

(51) IPC2010.01:A61D1/04 

(71) TE PARI PRODUCTS LIMITED 

(72) Blampied, Nicholas Mark; 



(57) A tail docking iron 10 is provided with a heated blade 18 and an opposed 

anvil 20. Pulling the handles 12 and 22 together will cause the 

blade to close on a tail caught between the blade and the anvil to dock 

the tail. At the same time as the blade and anvil are brought together the 

anvil is rotated on it’s axis so that the wool on the tail near the anvil is 

caught in the protrusions on the anvil and pulled away from the docking 

site to provide a cleaner dock. 

(21) 563350 (22) 12 Nov 2007 (23) 28 Oct 2008 

(54) Improvements in and relating to attachments, brackets and support 

assemblies 

(51) IPC2010.01:B62J7/02,04,06,08 

(71) Kiwijoe New Zealand Limited 

(72) Maguire, Patrick David; 



(57) An attachment device, a bracket assembly and a support assembly, 

for use on bicycles, are disclosed. 

The attachment device includes a ratchet or gripping mechanism, a strap 

fixed to a body portion of the attachment with the free end being passed 

around part of the frame into the gripping mechanism. 

The bracket assembly includes two attachment devices that are connected 

to each other via at least one support member. 

The support assembly includes a support frame having at least two support 

members and attachment devices. 



(21) 563386 (22) 13 Nov 2007 (23) 9 Oct 2008 

(54) Hinges 

(51) IPC2010.01:E05D3/02; E05D5/04; E05D15/00 

(71) JOHN DAWSON AND ROCHELLE LEIGH CLARK 

(72) Dawson, John; 



(57) Disclosed is a hinge assembly including a first leaf and a second leaf 

each with at least one sleeve, the second leaf being complementary to 

the first leaf. The hinge assembly further includes a hinge pin for insertion 

through the sleeves when aligned. At least one leaf is substantially 

plate-like with a general plate plane and at least one passageway through 

the plate plane. The passageway is coincident with and parallel to the 

plate plane and is suitable for receiving a fixing screw. The axis of the at 

least one passageway is offset from, but is substantially normal to the 

leafs sleeve axis. The general plate plane is substantially parallel to its 

leafs sleeve axis. 


(21) 563423 (22) 7 Jun 2006 

(54) Inhibitors of AKT activity 

(86) PCT/US2006/022079 (87) WO2006/135627 

(51) IPC2010.01:A61K31/397; C07D249/16 

(71) MERCK SHARP & DOHME CORP. 

(72) Armstrong, Donna J; Hu, Essa H; Kelly, Michael J III; Layton, Mark E; 

Li, Yiwei; Liang, Jun; Rodzinak, Kevin J; Rossi, Michael A; Sanderson, 

Philip E; Wang, Jiabing; 

(31) 05 689726 (32) 10 Jun 2005 (33) US 

(31) 05 734188 (32) 7 Nov 2005 (33) US 



(57) Disclosed is a naphthyridine compound according to Formula E 

wherein the substituents are disclosed within the specification or a 

pharmaceutically acceptable salt tautomer or a stereoisomer thereof. 

Also disclosed is the use of the compound of Formula E as inhibitors of 

the serine/threonine kinase Akt (also known as PKB) and hence for the 

treatment of cancer. 

(21) 563430 (22) 14 Apr 2006 

(54) The use of alkenyl succinic anhydride compounds derived from symmetrical 

olefins in internal sizing for paper production 

(86) PCT/US2006/014225 (87) WO2006/113519 

(51) IPC2010.01:D21C3/22; D21H11/00; D21H13/00; D21H15/00; 

D21H17/00; D21H19/00; D21H21/00; D21H23/00; D21H25/00; D21H27/ 

00; D21H17/14,16 

(71) NALCO COMPANY 

(72) Ward, William J; Andruszkiewicz, Krzysztof; Gray, Ross T; McGinnis, 

Timothy Patrick; Novak, Robert W; 

(31) 05 107045 (32) 15 Apr 2005 (33) US 

(74) PIPERS, Level 1, 5A Pacific Rise, Mt Wellington, Auckland, New 

Zealand 

(57) Disclosed is a method of imparting resistance of paper to penetration 

by liquids comprising incorporating in the paper a size composition comprising 

one or more alkenyl succinic anhydride sizing agents prepared 

from the reaction of maleic anhydride and one or more substantially symmetrical 

C20-C28 internal olefins (such as 10-eicosene, 11-docosene, 

12-tetracosene, 13-hexacosene, 14-octacosene, 9-eicosene, 10heneicosene, 

10-docosene, 11-tetracosene, 11-tricosene, 12hexacosene, 

12-pentacosene, 13-octacosene, 13-heptacosene), or a 

mixture thereof. 

(21) 563505 (22) 17 May 2006 

(54) A vehicle locating unit with improved power management method 

(86) PCT/US2006/018963 (87) WO2006/124925 

(51) IPC2010.01:H04B1/16,38; H04M1/00 

(71) LoJack Operating Company LP 

(72) Romano, Frank; Krishna, Sampath; Nguyen, Son; Rhodes, Jesse; 

Crewe, Philip Grahame; Cletheroe, Daniel Jonathan Finchley; Marsden, 

Mark; Greendale, Steven Walter; Watson, Nigel James; Stroud, Ian 

Christopher; Howe, Timoth David; Smith, Gerard Edward; 

(31) 05 131847 (32) 18 May 2005 (33) US 



(57) A vehicle locating unit with improved power management is disclosed. 

A receiver receives a signal from a network of communication sources. 

A signal strength monitoring subsystem determines which of the communication 

sources are transmitting the strongest signals. A power management 

subsystem is responsive to the signal strength monitoring subsystem 

and is configured to alternatively enter sleep and wake-up modes, 

synchronize the wake-up mode to the communication source transmitting 

the strongest signal, and test the signal strength of at least one additional 

communication source according to a predefined sequence. 

(21) 563573 (22) 23 May 2006 

(54) Pelvic clamp with straight guide and two displaceable arms 

(86) PCT/IB2006/051650 (87) WO2006/126167 

(51) IPC2010.01:A61B17/64 

(71) Synthes GmbH 

(72) Lanz, Andreas; 

(31) 05 684475 (32) 24 May 2005 (33) US 



(57) Disclosed is a pelvic clamp with a rail-like straight guide (7’) for two 

arms (6') which are displaceable relative to one another along this straight 

guide and project from the straight guide. On each of the free ends of the 

arms a tubular carrier (4') for a tip intended for bone contact is provided. 



A locking device releasable by means of at least one handle (12) is provided 

between the two parts displaceable relative to one another, namely 

between at least one of the arms and the straight guide. The locking 

device comprises a catch having an oblique surface directed towards 

the arms, and can be disengaged by a force acting on the arm along the 

straight guide against the force of a restoring spring. The catch is blocked 

in the other direction by a steeper blocking surface of the catch, and can 

only be released with the aid of the handle. 

(21) 563794 (22) 27 Nov 2007 (23) 24 Oct 2008 

(54) Method and apparatus for stacking loads in vehicles 

(51) IPC2010.01:B65G1/00; B65G7/00; B65G65/00; B65G67/00; B65G69/ 

00; B66F9/00; E01B25/00 

(71) NZee Loda Limited 

(72) Holmes, Mark John; Rabarts, Graham Bruce; 



(57) A bearer system for supporting a removable load including a bearer, 

and two or more movable bearer supports characterised in that the bearer 

system includes an enclosed track configured to retain each of the movable 

bearer supports and to allow the movable bearer supports to be 

moved in a substantially horizontal plane. At least part of the track is 

attached to a substantially vertical supporting structure. Preferably, the 

bearer storage track is configured to enable the bearer to be moved 

along an enclosed track from an in-use position to an out-of-use position. 

(21) 563817 (22) 28 Apr 2006 

(54) Method for preparing a ginkgo extract having a reduced content of 4'- 

O-methyl pyridoxine and biflavones 

(86) PCT/EP2006/004039 (87) WO2006/117171 

(51) IPC2010.01:A61K36/00 

(71) Dr. Willmar Schwabe GmbH & Co. KG 

(72) Erdelmeier, Clemens; Hauer, Hermann; Koch, Egon; Lang, Friedrich; 

Stumpf, Karl-Heinz; 

(31) 05 05020642 (32) 3 May 2005 (33) DE 



(57) Disclosed is a method for preparing an extract from Ginkgo biloba 

having a reduced content of 4’-O-methyl pyridoxine and biflavones compared 

to the original extract, comprising: 

(a) preparing a Ginkgo extract solution in a solvent, 

(b) applying the solution to an adsorber resin and eluting the purified extract 

from the adsorber resin using a solvent, wherein the biflavones to 

be removed remain on the adsorber resin, 

(c) applying the solution to an acidic ion exchanger and eluting the purified 

extract from the ion exchanger using a solvent, wherein the 4'-O-methyl 

pyridoxine to be removed remains on the ion exchanger, 

wherein steps (b) and (c) can also be carried out in reverse order, and 

(d) concentrating and drying the extract solution to the dry extract, wherein 

the content of 4'-O-methyl pyridoxine in the dry extract is 20 ppm at the 

most, and wherein the content of biflavones in the dry extract is 25% of 

the original value of the original extract at the most. 

Also disclosed is Ginkgo biloba extract obtained by the above method, 

and its use in treating dementia and symptoms thereof or cerebral and 

peripheral blood circulation disorders. 

(21) 563877 (22) 31 May 2006 

(54) Assignment acknowledgement for a wireless communication system 

(86) PCT/US2006/021211 (87) WO2006/130742 

(51) IPC2010.01:H04W16/02 


(72) Agrawal, Avneesh; Khandekar, Aamod; Gorokhov, Alexei; 

(31) 05 142121 (32) 31 May 2005 (33) US 

(31) 05 260931 (32) 27 Oct 2005 (33) US 

(31) 06 370638 (32) 7 Mar 2006 (33) US 



(57) A method for acknowledging a message in a wireless communication 

system is disclosed. The method includes: 

determining a type of message being acknowledged; 

assigning a channel identification based upon the type; 

generating the acknowledgment for transmission via a communication 

channel; and mapping the acknowledgment to resources for a signaling 

channel that punctures traffic channels based upon the channel identification. 

(21) 564090 (22) 13 Jun 2006 

(54) Antifungal compositions comprising azoxystrobin and thiabendazole 

and their use in treating wallboards and building materials 

(86) PCT/GB2006/002167 (87) WO2006/134347 

(51) IPC2010.01:B27K3/38; A01N43/36,54,653,78; B27K3/50; A01P3/00 

(71) Syngenta Participations AG 

(72) Cornish, Alexander; Greiner, Anja; James, John; Knauf-Beiter, 

Gertrude; Steiner, Johann; 

(31) 05 690403 (32) 14 Jun 2005 (33) US 



(57) Disclosed is a composition comprising azoxystrobin and thiabendazole, 

and optionally fludioxonil. Also disclosed is a paper product comprising 

the composition, a wallboard having a gypsum core and a paper 

coating comprising the composition, and a building material comprising 

the composition. 

(21) 564092 (22) 25 May 2006 

(54) TWEAK binding antibodies 

(86) PCT/US2006/019706 (87) WO2006/130374 

(51) IPC2010.01:A61K39/395; C12P21/08; A61P35/00 

(71) Biogen Idec MA Inc. 

(72) Burkly, Linda C; Garber, Ellen; Lugovskoy, Alexey; 

(31) 05 685149 (32) 27 May 2005 (33) US 


Australia 

(57) Disclosed is an isolated protein comprising an immunoglobulin heavy 

chain variable domain sequence and an immunoglobulin light chain variable 

domain sequence that can form an antigen binding site that binds to 

human TNF-like weak inducer of apoptosis ('TWEAK'), wherein the protein 

has one or more of the following properties: 

(a) the protein competes for binding to human TWEAK with one or more of 

the group consisting of: 

(i) an antibody comprising a heavy chain variable domain of SEQ ID NO:50 

and a light chain variable domain of SEQ ID NO:51; 

(ii) an antibody having a heavy chain of SEQ ID NO:64 and a light chain of 

SEQ ID NO:66; and 



(iii) an antibody having a heavy chain of SEQ ID NO:64 and a light chain of 

SEQ ID NO:68; 

(b) the protein binds to an epitope on human TWEAK that overlaps with 

the epitope bound by the antibody according to anyone of (a)(i) to (iii); 

(c) the heavy and/or light chain variable domain sequence is encoded by 

a nucleic acid that hybridizes under high stringency conditions to the 

complement of a nucleic acid encoding the antibody according to anyone 

of (a)(i) to (iii); 

(d) the heavy and/or light chain variable domain sequence is at least 80% 

identical to the amino acid sequence of the corresponding variable domain 

of the antibody according to anyone of (a)(i) to (iii); 

(e) the heavy and light chain variable domain sequences are collectively 

at least 95% identical in the complementarity determining regions ('CDRs') 

to the CDRs of the heavy and light chain variable domains of the antibody 

according to anyone of (a)(i) to (iii); or 

(f) the heavy and light chain variable domain sequences are collectively at 

least 95% identical in the framework regions to the framework regions of 

the heavy and light chain variable domains of the antibody according to 

anyone of (a)(i) to (iii). 


(21) 564125 (22) 30 Jun 2006 

(54) Adhesive composition and method 

(86) PCT/SE2006/050231 (87) WO2007/004978 

(51) IPC2010.01:C09J103/02; C09J139/02 

(71) Akzo Nobel Coatings International B.V. 

(72) Khabbaz, Farideh; Eriksson, Per Anders; Fare, Joanna; Furberg, Anna 

Kristina; 

(31) 05 05106006 (32) 1 Jul 2005 (33) EP 



(57) An adhesive composition for wood based products containing gelatinised 

starch and one or more polymer groups which contain a primary 

amine group. Also described is a method of manufacture of the adhesive 

composition whereby the starch and polymer(s) containing a primary 

amine group in an aqueous phase are heated between 50 and 

99°C to gelatinise the starch. 

(21) 564218 (22) 1 Jun 2006 

(54) Method of detoxication of yperite by using haloalkane dehalogenases 

(86) PCT/CZ2006/000036 (87) WO2006/128390 

(51) IPC2010.01:A62D3/00; B09C1/10; C02F11/00,02; C02F3/34 

(71) Masarykova univerzita 

(72) Prokop, Zbynek; Damborsky, Jiri; Oplustil, Frantisek; Jesenska, 

Andrea; Nagata, Yuji; 

(31) 05 352 (32) 3 Jun 2005 (33) CZ 



(57) Provided is a method of detoxication of yperite by the use of haloalkane 

dehalogenases wherein said yperite is treated with at least one haloalkane 

dehalogenase selected from the group of enzymes EC 3.8.1.5, at the 

concentration of enzyme 1x10-6 to 1x100 moll-1 , at temperature from 

+10 degrees C to +70 degrees C and pH from 4 to 12 in liquid medium. 

(21) 564295 (22) 16 Jun 2006 

(54) Serving base station selection in a wireless communication system 

(86) PCT/US2006/023502 (87) WO2006/138570 

(51) IPC2010.01:H04B7/00; H04W48/20; H04W52/14,40,02,22; H04W74/ 

08 


(72) Julian, David Jonathan; Agrawal, Avneesh; Teague, Edward Harrison; 

(31) 05 691435 (32) 16 Jun 2005 (33) US 

(31) 06 793115 (32) 18 Apr 2006 (33) US 



(57) An apparatus for selecting a serving base station in a wireless communication 

system is disclosed. The apparatus includes: means for sending 

a transmission on reverse link to multiple base stations in a wireless 

communication system; means for receiving feedback from the multiple 

base stations; and means for selecting a serving base station for a terminal 

for the reverse link based on one or more of the received feedback. 

The feedback metrics include erasure indications. Erasure indications 

are used to determine if decoding of one or more codewords in the transmission 

on the reverse link meet a predetermined level of confidence. 


(21) 564341 (22) 12 Jul 2006 

(54) Novel enzymes for use in enzymatic bleaching of food products 

(86) PCT/EP2006/064132 (87) WO2007/006792 

(51) IPC2010.01:A23L1/27; C12N9/00; C12N1/21; C12N15/52,63,79; 

C12N5/00 

(71) DSM IP Assets B.V. 

(72) Zorn, Holger; Scheibner, Manuela; Hulsdau, Barbel; Berger, Ralf 

Gunter; Boer De, Lex; Meima, Roelf Bernhard; 

(31) 05 05053329 (32) 12 Jul 2005 (33) EP 

(31) 05 05056825 (32) 15 Dec 2005 (33) EP 



(57) Disclosed is an isolated polypeptide having bleaching activity, the 

polypeptide is selected from the group consisting of: 

a. an isolated polypeptide according to any one of SEQ ID NO: 8-12 or a 

functional equivalent; or 

b. an isolated polypeptide obtainable by expressing a polynucleotide according 

to any one of SEQ ID NO: 1-7; or 

c. A polypeptide comprising at least one of SEQ ID NO: 13-17. 

Further disclosed in uses of the polypeptide as described in vectors, host 

cells and in manufacturing processes of food products. 

(21) 564371 (22) 23 Jun 2006 

(54) Immunogenic composition comprising Hib saccharide conjugate and 

at least two further bacterial saccharide conjugates 

(86) PCT/EP2006/006210 (87) WO2007/000322 

(51) IPC2010.01:A61K39/095,102,116 


(72) Biemans, Ralph Leon; Boutriau, Dominique; Capiau, Carine; Denoel, 

Philippe; Duvivier, Pierre; Poolman, Jan; 

(31) 05 0513069 (32) 27 Jun 2005 (33) GB 

(31) 05 0513071 (32) 27 Jun 2005 (33) GB 

(31) 05 0515556 (32) 28 Jul 2005 (33) GB 

(31) 05 0524204 (32) 28 Nov 2005 (33) GB 

(31) 05 0526040 (32) 21 Dec 2005 (33) GB 

(31) 05 0526041 (32) 21 Dec 2005 (33) GB 


(57) Disclosed is an immunogenic composition comprising a Hib saccharide 

conjugate and at least two further bacterial saccharide conjugates 

wherein the Hib conjugate is present in a lower saccharide dose than the 

mean saccharide dose of all the at least two further bacterial saccharide 

conjugates. 

(21) 564642 (22) 20 Jul 2006 

(54) Grating-based sensor combining label-free binding detection and fluorescence 

amplification and readout system for sensor 

(86) PCT/US2006/028473 (87) WO2007/019024 

(51) IPC2010.01:G01N21/55,64 

(71) SRU Biosystems, Inc. 



(72) Cunningham, Brian T; Laing, Lance G; Li, Peter Y; Binder, Brant; 

Jogikalmath, Gangadhar; Borsody, Alex; Shulz, Stephen C; 

(31) 05 707579 (32) 11 Aug 2005 (33) US 

(31) 05 713694 (32) 2 Sep 2005 (33) US 

(31) 06 778160 (32) 28 Feb 2006 (33) US 

(31) 06 790207 (32) 7 Apr 2006(33) US 



(57) Disclosed is an optical sensor for testing samples. The sensor comprises 

a substrate with a periodic surface grating structure. The structure 

is constructed in a way that makes optical interrogation with light 

possible in both in an evanescent resonance (ER) mode and a label-free 

detection mode. 

(21) 564847 (22) 17 Feb 2006 

(54) Method for detection of microorganism and kit for detection of microorganism 

(86) PCT/JP2006/302893 (87) WO2007/094077 

(51) IPC2010.01:C12N15/09; C12Q1/04,25,68 

(71) MORINAGA MILK INDUSTRY CO., LTD. 

(72) Yoshida, Shinichi; Soejima, Takashi; 



(57) Provided is a method for detecting live cells by distinguishing live 

uninjured cells from dead cells and injured cells of a microorganism in a 

test sample, which comprises the following steps: a) the step of treating 

the test sample with a topoisomerase poison and/or a DNA gyrase poison, 

b) the step of extracting DNA from the test sample, and amplifying a 

target region of the extracted DNA by PCR wherein the length of the 

target region is 100 to 3000 nucleotides, and c) the step of analyzing an 

amplification product. 

(21) 564883 (22) 23 May 2006 

(54) Reciprocating mechanism for a reel assembly 

(86) PCT/US2006/019726 (87) WO2006/130377 

(51) IPC2010.01:B65H75/44; B65H54/28 

(71) Great Stuff, Inc. 

(72) Caamano, Ray; Okonsky, Christian; Francis, Daniel; 

(31) 05 685637 (32) 27 May 2005 (33) US 

(31) 06 772455 (32) 10 Feb 2006 (33) US 



(57) Disclosed is a reel assembly (100). The assembly includes an element 

(10) configured to rotate about a spooling axis (X). The element is 

configured to receive a linear material wrapped around a spool surface 

thereof as the element rotates about the spool axis. A housing (22, 24) 

substantially encloses the element, wherein a portion of the housing defines 

an aperture (30) configured to receive the linear material therethrough. 

A reciprocating mechanism connects to the element and 

reciprocatingly rotates the element relative to the shell about a reciprocation 

axis (Y) as the element rotates about the spool axis. 

(21) 565040 (22) 13 Jun 2006 

(54) Isoquinoline derivatives as inhibitors of RHO-kinase 

(86) PCT/EP2006/005648 (87) WO2007/000240 

(51) IPC2010.01:C07D401/12; A61K31/4725; A61P27/00; C07D217/02,22; 

C07D401/14; C07D409/14; C07D413/14; A61P11/00; C07D405/14 

(71) sanofi-aventis 

(72) Plettenburg, Oliver; Hofmeister, Armin; Kadereit, Dieter; Peukert, 

Stefan; Ruf, Sven; Ritter, Kurt; Lohn, Matthias; Ivashchenko, Yuri; Monecke, 

Peter; Dreyer, Matthias; Kannt, Aimo; 

(31) 05 05013868 (32) 28 Jun 2005 (33) EP 



(57) Disclosed is a compound of formula (I), or a pharmaceutically acceptable 

salt thereof, wherein n is 1 to 4, L is O or O-(C1-C6)alkylene, and 

wherein the rest of the substituents are as describe in the specification. 

Also disclosed is the use of the compound to treat hypertension, pulmonary 

hypertension, ocular hypertension, peripheral circulatory disorder, 

angina pectoris, cerebral vasospasm, asthma, premature birth, 

hyperaggregability of platelets, Peripheral Occlusive Arterial Disease 

(PAOD), Chronic Obstructive Pulmonary Disease (COPD), cancer development, 

erectile dysfunction, arteriosclerosis, ischemic organ failure, 

fibroid lung, fibroid liver, liver failure, fibroid kidney, renal glomerulosclerosis, 

kidney failure, organ hypertrophy, prostatic hypertrophy, complications 

of diabetes, blood vessel restenosis, atherosclerosis, cancer, cardiac 

hypertrophy, heart failure ischemic diseases; inflammation; 

autoimmune diseases; AIDS, osteopathy such as osteoporosis, brain 

functional disorder, infection of digestive tracts with bacteria, sepsis, adult 

respiratory distress syndrome, retinopathy, glaucoma, and Alzheimer's 

disease. 

(21) 565044 (22) 16 Jun 2006 

(54) Methods of purifying anti A beta antibodies with calcium chloride 

(86) PCT/US2006/024026 (87) WO2006/138737 

(51) IPC2010.01:C07K16/18; A61K39/395 

(71) Elan Pharma International Limited; Wyeth LLC 

(72) Godavarti, Ranganathan; Iskra, Timothy; 

(31) 05 691821 (32) 17 Jun 2005 (33) US 



(57) Disclosed is a method for purifying an Amyloid beta (Abeta) binding 

protein having an Fc region from a source liquid comprising the protein 

and one or more impurities, comprising the steps of: 

adsorbing the Abeta binding protein to an Fc binding agent; 

washing the Fc binding agent bound to the Abeta binding protein with a 

buffer solution containing CaCl2- at a concentration from about 0.5 M to 



about 3 M to reduce the one or more impurities; and recovering the 

Abeta binding protein from the Fc binding agent in an elution solution. 

Abeta binding proteins obtained by such methods are also disclosed. 

(21) 565272 (22) 29 Jul 2005 

(54) pH-controlled pulsatile delivery system, methods for preparation and 

use thereof 

(86) PCT/NL2005/000559 (87) WO2007/013794 

(51) IPC2010.01:A61K9/00; A61K31/00; A61K39/00; A61K47/30; A61K9/ 

20,28,50 

(71) STICHTING GRONINGEN CENTRE FOR DRUG RESEARCH 

(72) Schellekens, Reinout Cornelus Andreas; Frijlink, Henderik Willem; 



(57) Disclosed is a pH-controlled pulsatile release system (PPRS) comprising 

a core surrounded by a coating layer, wherein said core comprises 

an active substance, and wherein said coating layer comprises a 

pH-sensitive coating material wherein a swellable agent is embedded. 

Also disclosed is a coating suspension for use in the manufacture of a pHcontrolled 

pulsatile release system (PPRS), said suspension comprising 

a mixture of a pH-sensitive coating material and a swellable agent in a 

solvent or solvent mixture, wherein said coating material is soluble in 

said solvent and wherein said swellable agent is insoluble and non-swollen 

in said solvent. Also disclosed is the use of the above coating suspension 

for manufacturing a drug delivery system. 

(21) 565346 (22) 23 Jun 2006 

(54) A purified selectin ligand isolated from blue-green algae 

(86) PCT/US2006/024769 (87) WO2007/002570 

(51) IPC2010.01:A61K36/02 

(71) Desert Lake Technologies 

(72) Jensen, Gitte S; Drapeau, Christian; 

(31) 05 693808 (32) 24 Jun 2005 (33) US 

(31) 05 700882 (32) 19 Jul 2005 (33) US 



(57) Disclosed is a composition comprising a therapeutically effective 

amount of (1) a water or buffered saline extract of fresh, dehydrated, or 

preserved Aphanizomenon flos aquae, wherein the extract is enriched 

for an L-selectin ligand or a dried form thereof, and (2) an ethanol extract 

of Aphanizomenon flos aquae or a dried form thereof, in a 

pharmacologically acceptable carrier. Also disclosed is a purified selectin 

ligand isolated from a blue-green algae of the species Spirulina. Further 

disclosed is use of the purified selectin ligand as defined above in the 

manufacture of a medicament for mobilising hematopoietic stem cells in 

a subject (wherein the subject may have osteoporosis, Alzheimer's disease, 

cardiac infarction, Parkinson's disease, traumatic brain injury, 

multiple sclerosis or cirrhosis of the liver). 

(21) 565645 (22) 10 Mar 2006 

(54) Cable barrier system 

(86) PCT/US2006/008569 (87) WO2007/008258 

(51) IPC2010.01:E01F15/00 

(71) Neusch Innovations, LP 

(72) Neusch, William H; 

(31) 05 175940 (32) 6 Jul 2005 (33) US 



(57) A cable barrier system 10 for redirecting errant object like a motor 

vehicle towards a safer path. The cable barrier system a cable-release 

anchor assembly 17, a terminal end section 14 with at least one terminal 

post 20 placed next to the cable-release anchor assembly 17, a length 

of need section 16 with a number of line posts 24 spaced apart from 

each other and at least one cable having a terminal end. Each line post 

24 has an internal cavity and a slot formed along a sidewall extending 

downwards from its top end. The cable is releasably held in tension by 

the cable-release anchor assembly 17 placed next to the terminal end. 

The cable is also releasably held by the terminal posts 20 and by the line 

posts 24. The cable’s releasable connection to each of the line posts 

utilises a post-cable connector. The post-cable connector has an elon- 

gated portion forming sliding loops, with the elongated portion mainly 

inside the line post’s 24 internal cavity and the loops extending through 

the slot in the line post 24. Thus the cable’s connection to the line post 24 

is such that when the line post 24 is struck by a moving object, like a 

motor vehicle, the cable will be released from the deformed line post 24 

in a manner that allows the cable to stay in contact with the moving 

object. 

(21) 565669 (22) 20 Jul 2006 

(54) Cyclohexylamin isoquinolone derivatives as Rho-kinase inhibitors 

(86) PCT/EP2006/007140 (87) WO2007/012422 

(51) IPC2010.01:C07D217/24; A61K31/472; A61P9/12 


(72) Plettenburg, Oliver; Hofmeister, Armin; Kadereit, Dieter; Brendel, 

Joachim; Loehn, Matthias; 

(31) 05 05016153 (32) 26 Jul 2005 (33) EP 



(57) Disclosed is an isoquinoline and isoquinolone compound of formula 

(I) or formula (I’) or their pharmaceutically acceptable salts and/or 

stereoisomeric forms wherein the substituents are defined in the specification. 

Also disclosed is the use of these compounds for producing a 

medicament and a medicament comprising at least one of these compounds. 

(21) 565821 (22) 28 Aug 2006 

(54) Argatroban formulation comprising an acid as solubilizer 

(86) PCT/US2006/033432 (87) WO2007/027565 

(51) IPC2010.01:A61K9/08; A61K31/47; A61K47/12; C07D221/02 

(71) Baxter International Inc.; Baxter Healthcare S.A. 

(72) Owoo, George; Burgos, Richard A; 

(31) 05 713403 (32) 1 Sep 2005 (33) US 



(74) PETER MAXWELL & ASSOCIATES, Level 6, 60 Pitt Street, Sydney, 

NSW 2000, Australia 

(57) The disclosure relates to an aqueous, stable, injectable, sterile pharmaceutical 

solution comprising: 

a) 0.5 to 10 mg/mL 1-[5-[(ammoiminomethyl)amino]-1-oxo-2-[[(1 ,2,3,4tetrahydro-3-methyl-8-quinolinyl)sulfonyl]amino]pentyl]4-methyl-2piperidinecarboxylic 

acid hydrate (argatroban); 

b) 0.01 to 3 N acid to solubilize the argatroban; 

c) a buffering agent to maintain the solution at a pH of about 4.5 to 5.5; 

and 

d) 1 to 100 mg/ml osmotic-adjusting agent, wherein the pharmaceutical 

solution is stable for at least 24 months and is substantially free from 

dehydrated alcohol. 

Also disclosed is a method for preparing said composition. 

(21) 565968 (22) 20 Jul 2006 

(54) Security in peer to peer synchronization applications 

(86) PCT/US2006/028390 (87) WO2007/024380 

(51) IPC2010.01:G06F17/30 


(72) Jhaveri, Vivek Jawahir; Novik, Lev; 

(31) 05 211119 (32) 24 Aug 2005 (33) US 



(57) A computing system is configured as a manager in a secure peer-topeer 

data synchronization community. The system comprises a processor; 

and memory storing the following components: a tracking component 

of a data storage system, a sync component for creating sync relationships 

between folders on the computing system and folders stored 

on other computing systems in the synchronization community a sync 

application that receives user input to the computing system for communicating 

with the sync component. 

The tracking component tracks changes that occur to the data storage 

system. The sync component includes a user sync manager component 

for creating the sync relationships, creating synchronized folders, inviting 

users to join the synchronization community, accepting invitations to 

join the synchronization community, removing users from the synchronization 

community, and maintaining a membership list of each user's access 

rights to synchronized folders in the synchronization community. 

Upon receiving user input specifying that a first folder of the computing 

system is to be synchronized within the synchronization community, the 

sync application communicates the user input to the user sync manager 

of the sync component, such that the user sync manager creates an 

invitation which includes an indication that the first folder is to be synchronized 

with another folder on a second computing system in the synchronization 

community and also includes the membership list that specifies 

the access rights the user of the second computing system as well 

as at least one other user of another computing system in the synchronization 

community will have to the first folder. The user sync manager 

further sending the invitation to the second computing system such that 

in response to the user of the second computing system selecting a 

second folder with which to synchronize the first folder, a sync relationship 

is created between the first and second 15 folders such that the 

second folder stores the membership list including the access rights for 

the user of the second computing system as well as the access rights of 

the at least one other user for accessing the first folder. 

(21) 566010 (22) 4 Aug 2006 

(54) 3, 11b-cis-dihydrotetrabenazine for the treatment of an inflammatory 

disease 

(86) PCT/GB2006/002909 (87) WO2007/017643 

(51) IPC2010.01:A61K31/473; A61P19/02; A61P29/00; A61P35/00 

(71) Biovail Laboratories International (Barbados) SRL 

(72) Duffield, Andrew John; 

(31) 05 0516168 (32) 5 Aug 2005 (33) GB 



(57) Disclosed is the use of a compound for the manufacture of a medicament 

for the prophylaxis or treatment of an inflammatory disease, the 

compound being 3,11b-cis-dihydrotetrabenazine or a pharmaceutically 

acceptable salt thereof. 

(21) 566125 (22) 22 Aug 2005 

(54) Modem with acoustic coupling 

(86) PCT/EP2005/009063 (87) WO2007/022788 

(51) IPC2010.01:H04M1/215; H04M11/06 

(71) ULTRA PROIZVODNJA ELEKTRONSKIH NAPRAV D.O.O. 

(72) Urbanija, Milos; Golobic, Gregor; Chowdhury, Amor; 



(57) An interface terminal is arranged for interfacing between an electronic 

device (200) and a service provider (300). The interface terminal 

(100) comprises a data interface (110) adapted to enable data communication 

with the electronic device (200); modem means (130) enabling 

data communication between the interface terminal (100) and a terminal 

device (45) enabled for voice commutation in a mobile communications 

network (400); and data processing means (120) coupled to the data 

interface (110) and the modem means (130) for processing data received 

from either of the data interface (110) and the modem means (130) and 

for generating data to be transmitted via the data interface (110) and/or 

the modem means (130). The data is communicated between the interface 

terminal (100) and the service provider (300) via the terminal device 

(450) on a voice communication connection; and the electronic device is 

an on-board diagnostic system (200) of a vehicle, which provides diagnostic 

data comprising diagnostic information and/or sensor information. 

The data is to be transmitted to a service provider providing monitoring, 

support, and/or maintenance services for the vehicle. 

(21) 566177 (22) 22 Aug 2006 

(54) External fixation system with adjustment of ring member spacing via 

knob connected to distractor 

(86) PCT/US2006/032850 (87) WO2007/024904 

(51) IPC2010.01:A61B17/62,64 

(71) HFSC COMPANY; SYNTHES GmbH 

(72) Hearn, Jim; Maughan, Thomas J; Horan, Timothy J; Wahl, Michael J; 

(31) 05 213030 (32) 25 Aug 2005 (33) US 




(57) An external fixation system is disclosed for connecting one or more 

bone segments together to facilitate healing of bone. The system may 

include one or more rings and/or ring segments. One or more linear 

distractors and/or angular distractors may connect the rings to each other 

so as to allow for distraction and/or reduction/compression of a bone. 

Linear distractors may enable an operator to move the rings towards and 

away from each other, while angular distractors may enable an operator 

to angle the rings relative to each other. In an embodiment using angular 

distractors, one or more angular separation assemblies may be positioned 

between the rings. These separation assemblies may have joints 

which may two portions which may be angled relative to each other and 

connected directly or indirectly to the rings.; Various fasteners (e.g., nuts 

and typically knobs) and/or tightening members may configured for quick 

movement along and selective tightening to various components. Moreover, 

clamps may be attached to the rings and may engage pins, wire, 

rods, which may be inserted into bone to hold bone segments to each 

other. The components of the external fixation system may be provided 

in sets or kits so that the a surgeon may select various combinations of 

components to create an external fixation system which is configured 

specifically for the particular needs of a patient and the bone fracture/ 

deformity. 

(21) 566363 (22) 8 Sep 2006 

(54) Thread navigation 

(86) PCT/US2006/035079 (87) WO2007/030727 

(51) IPC2010.01:G06Q10/00; G06F9/46 


(72) Taboada, Roberto C; Fernandes, Bertille N; Jones, Brian M; Yap, Joe 

K; 

(31) 05 715725 (32) 9 Sep 2005 (33) US 

(31) 06 332822 (32) 13 Jan 2006 (33) US 



(57) A system for navigating messages within a thread comprises means 

for accessing the thread; means for determining a location for each message 

header within the thread; means for modifying an appearance of 

each message header; means for navigating within the thread using at 

least one navigational control that is displayed within a message header; 

and means for rendering the thread. 

The means for modifying the appearance of each message can comprises 

changing the shading of each message header. The system can further 

comprise means for tagging the thread according to an XML schema. 

(21) 566369 (22) 29 Aug 2006 

(54) Convertible cycling apparatus 

(86) PCT/IL2006/001002 (87) WO2007/031987 

(51) IPC2010.01:B62J1/16; B62B7/12; B62K13/00; B62K7/00 

(71) Taga Design & Development Limited 

(72) Barak, Shlomo; Barak, Hagai; Barak, Amit; Ken-Dror, Boaz; Heimann, 

Miky; 

(31) 05 224114 (32) 13 Sep 2005 (33) US 


(57) Cycling apparatus (10) including at least one front wheel (12) and at 

least one rear wheel (14) rotatably mounted on axles on a frame (18), a 

riding sea (20) attached to the frame (18), a drive mechanism (24) coupled 

to at least one of the wheels for driving the cycling apparatus, at 

least one handlebar post (26) attached to a portion of the frame (18), and 

a carrier member (28) attachable to the frame (18) for carrying at least 

one of a child and an object therein and movable between first and second 

attachment orientations, wherein in the first attachment orientation 

the cycling apparatus is in a rider orientation drivable by a rider sitting on 

the seat, and wherein in the second attachment orientation the cycling 

apparatus is in a stroller orientation wherein the at least one handlebar 

post (26) is arranged with respect to the carrier member (28) to form a 

pushable stroller, wherein in the stroller orientation there are two rear 

wheels (14). 

(21) 566387 (22) 20 Oct 2005 

(54) Method to predict or monitor the response of a patient to an ErbB 

receptor drug by screening for mutations in an ErbB receptor 

(86) PCT/GB2005/004036 (87) WO2007/039705 

(51) IPC2010.01:C12Q1/68 

(71) ASTRAZENECA UK LIMITED; NATIONAL CANCER CENTRE 

(72) Nishio, Kazuto; Kimura, Hideharu; Kasahara, Kazuo; 

(31) 05GB 0503823 (32) 5 Oct 2005 (33) GB 



(57) Disclosed is an ex vivo method for predicting the response of a patient 

to an ErbB receptor drug comprising detecting one or more mutations 

in an ErbB receptor wherein said method comprises the steps of:- 

(a) providing a bio-fluid sample from a patient; 

(b) extracting DNA from said sample; 

(c) screening said DNA for the presence of one or more mutations in the 

receptor using PCR and one or more techniques selected from the group 

consisting of: Single Stranded Conformation Polymorphism (SSCP); 

Restriction Fragment Length Polymorphisms (RFLPs); WAVE; Real-time 

PCR, Amplification Refractory Mutation system (ARMS); and probes in 

combination with ARMS wherein said probes comprise a single-stranded 

bi-Iabelled fluorescent sequence held in a hairpin-loop conformation by 

complementary stem sequences on the 5' and 3' ends of the probe, further 

comprising a fluorescent reporter dye attached to the 5' end and a 



quencher molecule attached to the 3' end, and wherein the hairpin loop 

is linked to the 5' end of a primer via a PCR blocker; and 

(d) predicting the response of a patient to an ErbB receptor drug based on 

the presence or absence of a mutated allele encoding said ErbB receptor. 

(21) 566755 (22) 22 Sep 2006 

(54) Safety needle with lockout mechanism via blocking member(s) that 

engage with end of hollow member proximal to user 

(86) PCT/US2006/037278 (87) WO2007/035923 

(51) IPC2010.01:A61M5/50,158 

(71) TYCO HEALTHCARE GROUP LP 

(72) Jones, Scott; Clark, George; 

(31) 05 719761 (32) 22 Sep 2005 (33) US 



(57) A safety needle is provided which includes blocking structure to maintain 

a sharp tip of a needle safely within a housing and prevent re-advancement 

of a needle from a safety needle housing. The safety needle 

includes flexible blocking members positioned on an inner needle assembly 

which are configured to engage an outer housing after the needle 

assembly has been fully retracted within the outer housing. The engagement 

is at a proximal end of the housing (opposite the needle extension 

end). 

(21) 566786 (22) 27 Sep 2006 

(54) Use of composition containing cyprodinil and dodine as a selective 

fungicide 

(86) PCT/EP2006/009403 (87) WO2007/036355 

(51) IPC2010.01:A01N43/54; A01N47/44,12,04; A01N43/ 

90,78,76,653,40,32; A01N41/06; A01N37/52,34; A01N35/04; A01P3/00 

(71) Syngenta Participations AG 

(72) Forster, Birgit; McKenzie. Duncan; Godwin, Jeremy R; 

(31) 05 05021278 (32) 29 Sep 2005 (33) EP 

(31) 05 05025915 (32) 28 Nov 2005 (33) EP 



(57) Disclosed is the use of a composition comprising Cyprodinil and 

Dodine, in addition to customary inert formulation adjuvants, for control 

of diseases on useful plants or on propagation material thereof caused 

by phytopathogens selected from Botrytis, Fusarium and 

Pseudocercosporella. 


(21) 566876 (22) 26 Sep 2006 

(54) Derivatives of 2-aminthiazoles and 2-aminooxazoles, processes for 

their preparation and their use as pharmaceuticals 

(86) PCT/EP2006/009302 (87) WO2007/039176 

(51) IPC2010.01:C07D413/12; A61K31/4245; C07D419/12; C07D277/42; 

C07D263/48; C07D271/07; A61K31/421,422,426,427 


(72) Keil, Stefanie; Urmann, Matthias; Wendler, Wolfgang; Glien, Maike; 

Chandross, Karen; Lee, Lan; 

(31) 05 05021279 (32) 29 Sep 2005 (33) EP 



(57) Disclosed are 2-phenyl-[1,2,4]oxadiazol-5-one derivatives as represented 

by formula I, wherein R1, R2, R3 and R4 are independently selected 

from the group consisting of H, halogen, alkyl, alkylene-O-alkylene- 

H, SCH3, and CN, wherein the alkyl and alkylene groups are unsubstituted 

or mono, di- or tri-substituted by F; X is -CH2- or -CH-2-CH2-; U is S or 

O; and wherein the remaining substituents are as defined herein. Also 

disclosed is the use of the compounds as defined above for the preparation 

of a medicament of the treatment and/or prevention of disorders of 

fatty acid metabolism and glucose utilization disorders. 

(21) 566877 (22) 26 Sep 2006 

(54) Phenyl-1,2,4-oxadiazolone derivatives, processes for their preparation 

and their use as pharmaceuticals 

(86) PCT/EP2006/009303 (87) WO2007/039177 

(51) IPC2010.01:A61K31/4245; C07D413/12; C07D263/32; C07D213/62; 

C07D277/24; C07D413/14; C07D213/70,78; C07D277/28; C07D213/64; 

C07D271/07; A61K31/421,422,426,427 


(72) Keil, Stefanie; Urmann, Matthias; Bernardelli, Patrick; Glien, Maike; 

Wendler, Wolfgang; Chandross, Karen; Lee, Lan; 

(31) 05021277.8 (32) 29 Sep 2005 (33) EP 



(57) Disclosed are 2-phenyl-[1,2,4]oxadiazol-5-one derivatives as represented 

by formula (I), wherein B is C(R4) or N; R1, R2, R3 and R4 are 

independently selected from the group consisting of H, halogen, alkyl, 

alkylene-O-alkylene-H, cycloalkyl, SCH3, and CN, where in the alkyl and 

alkylene groups are unsubstituted or 1- to 5-fold substituted by F; or R2 

and R3 together with the carbon atoms to which they are bonded form an 

aryl or heteroaryl ring; X is O, S, S(O), S(O)2, O-CH-2, S-CH2, CH2-O, 

or CH2-S; one of U and V is N the other is S or O; Z is a bond, alkylene, 

alkenylene, alkylidene, or alkylene-O-alkyl; A is cycioalkyl, 

heterocycloalkyl, heterocycloalkenyl or a heteroaryl ring; and wherein the 

other substituents are as described herein. Also disclosed is the use of 

the compounds as defined above for the preparation of a medicament 

for the treatment and/or prevention of disorders of fatty acid metabolism 

and glucose utilization disorders. 

(21) 567205 (22) 26 Sep 2006 

(54) Cyclic N-[1,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for 

their preparation and their use as pharmaceuticals 

(86) PCT/EP2006/009299 (87) WO2007/039173 



(51) IPC2010.01:C07D285/12; A61K31/433; A61P25/28; A61P3/10 


(72) Schoenafinger, Karl; Keil, Stefanie; Urmann, Matthias; Matter, Hans; 

Glien, Maike; Wendler, Wolfgang; 

(31) 05021785.0 (32) 6 Oct 2005 (33) EP 



(57) The disclosure relates to cyclic N-[1,3,4]-thiadiazol-2-yl-benzene 

sulfonamides of the formula (I) and to their physiologically acceptable 

salts showing PPARdelta, PPARalpha and PPARgamma agonist activity, 

in which the radicals are as defined in the specification, and pharmaceutical 

compositions comprising these compounds and processes for 

their preparations. The compounds are suitable for the treatment and/or 

prevention of disorders of fatty acid metabolism and glucose utilization 

disorders as well as of disorders in which insulin resistance is involved 

and demyelinating and other neurodegenerative disorders of the central 

and peripheral nervous system. 

(21) 567213 (22) 24 Oct 2006 

(54) Adjustable vaginal splint for pelvic floor support 

(86) PCT/IB2006/003625 (87) WO2007/049154 

(51) IPC2010.01:A61F2/00 

(71) ETHICON INC. 

(72) Astani, Aida; Peters, Burkhard; Carey, Marcus P; 

(31) 05 258441 (32) 25 Oct 2005 (33) US 

(31) 06 334966 (32) 19 Jan 2006 (33) US 



(57) Vaginal splint assemblies and methods for their use for treating various 

pelvic floor conditions are provided. One embodiment of a vaginal 

splint assembly includes a base portion having a connecting portion and 

first and second sides extending outwardly from first and seconds ends 

of the connecting portion to first and second free ends respectively. It 

further includes a plurality of apical sections each of a different size and 

each having a connecting portion and first and second sides extending 

outwardly from first and second ends of the connecting portion to first 

and second free ends respectively, and at least first and second coupling 

elements. The first coupling element is capable of securing the first free 

end of the base portion to the first free end of any one of the plurality of 

apical sections, and the second coupling element is capable of securing 

the second free end of the base portion to the second free end of the one 

apical section. 

(21) 567314 (22) 28 Sep 2006 

(54) Load balancing 

(86) PCT/US2006/038117 (87) WO2007/047066 

(51) IPC2010.01:G06F15/16; G06F17/00 


(72) Stephens, Maoni Z; Dussud, Patrick H; 

(31) 05 254649 (32) 20 Oct 2005 (33) US 



(57) A method of controlling behavior of an application is disclosed. The 

method includes: 

inspecting at least a portion of programmed code running on a processing 

device in a managed execution environment to determine that a sweep 

of memory heap is impending; 

assessing a magnitude of the impending sweep relative to a threshold 

value; 

receiving an indication that the magnitude of the impending sweep during 

execution of an application in a managed execution environment exceeds 

the threshold value; and 

redistributing execution of at least a portion of the application across an 

isolation boundary when the threshold value is exceeded. 

(21) 567380 (22) 14 Apr 2008 (23) 9 Jan 2009 

(54) A wave box unit being a device for generating electricity from sea 

shore waves 

(51) IPC2010.01:E02B9/08; F03B13/16,14,22 

(71) Peter Vivian Wardrop 

(72) Wardrop, Peter Vivian; 

(74) Peter Vivian Wardrop, 80 Beach Road, Haumoana, Hawkes Bay, 

New Zealand 

(57) Apparatus for use in converting kinetic energy from moving water to 

electrical energy, the apparatus comprising a ramped water channel, a 

water receiving unit, a turbine, and transportation means. The apparatus 

is formed such that when it is in use as a shore-based installation it 

can be transported from the shore to a body of water via the transportation 

means so that the ramped water channel enters the body of water to 

an adjustable degree such that water contacts and moves up the ramped 

channel and into the water receiving unit where it drops under gravity 

and in so doing causes the turbine to turn to facilitate the generation of 

electricity. 

(21) 567767 (22) 28 Apr 2008 

(54) Stack sealable heat shrinkable multilayered film, bags and pouches 

for packaging goods 

(51) IPC2010.01:B32B27/28,32,36; B29C55/28; C08J5/22; B32B27/08,30 

(71) Flexopack S.A. Plastics Industry 

(72) Gkinosatis, Dimitris; 

(31) 07 107035 (32) 26 Apr 2007 (33) EP 



(57) The disclosure relates to a multilayer heat shrinkable film characterized 

by a combination of desirable properties, such as high shrinkage, 

good optical properties, excellent sealability and stack sealability; it is 

further directed to a method of producing a packaged food item by using 

said film, and to the use of said film or bags and pouches made therefrom 

for packaging goods as for example food products. Particularly disclosed 



is a heat shrinkable film produced by a double bubble process, said film 

having a shrinkage of at least 10% measured according to ASTM 2732 

in water at 90 Deg C in at least one of MD, TD directions, where the film 

comprises an outer layer comprising polyester elastomer and a core layer 

comprising EVOH and/or PVDC. 

(21) 567799 (22) 27 Oct 2006 

(54) Precoding for segment sensitive scheduling in wireless communication 

systems 

(86) PCT/US2006/042058 (87) WO2007/050924 

(51) IPC2010.01:H04L5/02; H04B7/06; H04L1/06; H04L27/26; H04L25/ 

02 


(72) Gore, Dhananjay Ashok; Sampath, Hemanth; Wang, Jibing; Kadous, 

Tamer; Barriac, Gwendolyn D; 

(31) 05 731558 (32) 27 Oct 2005 (33) US 



(57) A wireless communication apparatus comprises a processor 

configured to decode signals that are received over two or more 

subcarriers of a segment of subcarriers, which is one of a plurality of 

segments of subcarriers available for communication, and to provide 

precoding information for at least one segment; and a transmitter 

configured to transmit the precoding information, wherein the transmitter 

is configured to transmit the precoding information on a feedback channel 

associated with the at least one segment. The precoding feedback 

is reported in multiple channel quality indication (CQI) channels and the 

number of used CQI channels depends on the number of available codes. 

(21) 568133 (22) 2 Nov 2006 

(54) Ringback tone preference information to assist selection of ringback 

tone 

(86) PCT/US2006/042521 (87) WO2007/058772 

(51) IPC2010.01:H04M3/42 

(71) LUCENT TECHNOLOGIES INC. 

(72) Batni, Ramachendra Prahlada; Sharma, Ranjan; 

(31) 05 272111 (32) 10 Nov 2005 (33) US 



(57) A method of ringback tone preference information to assist selection 

of ringback tone is disclosed. Ringback tone preference information, 

input by a user of a communication device, is presented to a ringback 

tone service subscriber or a proxy for the ringback tone service subscriber. 

A ringback tone is suggested to the ringback tone service subscriber 

that conforms to the preference information. The preference information 

is based on one or more likes or dislikes of the user of the 

communication device, and at least one of the likes or dislikes is a specific 

music album. 

(21) 568603 (22) 31 Oct 2005 

(54) Cylindrical biodegradable, biocompatible scleral buckle band 

(86) PCT/CN2005/001801 (87) WO2007/051345 

(51) IPC2010.01:A61F2/14; A61F9/007; A61K47/42 

(71) Life Spring Biotech Co., Ltd. 

(72) Yen, Hsiaocheng; Hsiao, Joyi; Lee, Wenhao; 

(74) A.P.T. PATENT AND TRADE MARK ATTORNEYS, 383 Goodwood 

Road, Westbourne Park, SA 5041, Australia 

(57) Disclosed is a scleral buckling band used for an ophthalmic operation, 

the band comprises a slender cylindrical structure formed by a 

biocompatible material, wherein the biocompatible material is a bio-absorbable 

polymer material; the material is biodegradable such that a buckling 

effect of the sclera resulting from implantation of the scleral buckling 

band is degraded as time elapses after implantation. Preferable materials 

for use are collagen, polyactic acid (PLA), polyglycolic acid (PGA), 

polyactic acid-glycolic acid (PLGA), polycaprolactone polyol (PCL), hyaluronic 

acid (HA) and chitosan. Further disclosed is a method of making 

said scleral buckling band. 

(21) 568655 (22) 6 Dec 2006 

(54) Stator end disk for a commutator motor and corresponding commutator 

motor 

(86) PCT/EP2006/069371 (87) WO2007/068636 

(51) IPC2010.01:H02K3/52 

(71) BSH Bosch und Siemens Hausgerate GmbH 

(72) Binder, Alfred; Ircha, Peter; Ivanak, Martin; Murnik, Jaroslav; 

(31) 2005 060 358.0 (32) 16 Dec 2005 (33) DE 

(31) 2006 007 808.8 (32) 16 May 2006 (33) DE 



(57) A stator end disk for a laminated stator core of a commutator motor 

comprising a connecting terminal 11 which has connecting elements 24 

for connecting stator winding wires and a female connector 28 with contact 

elements 25 for receiving and electrically connecting an external 

motor connector, whereby each of the connecting elements 24 is connected 

in each case to an associated contact element 25 so as to be 

electrically conducting, wherein only one connecting terminal 11 is arranged 

on the stator end disk, and that in order to electrically connect at 

least one further internal, electrical component 31 of the commutator 

motor at least one further contact element 25 assigned to the component 

31 is arranged in the female connector 28. 

(21) 568768 (22) 6 Nov 2006 

(54) Lithium polymer battery powered intravenous fluid warmer 

(86) PCT/US2006/043069 (87) WO2007/056202 

(51) IPC2010.01:H01M10/48,46,50; H02J7/00 

(71) Enginivity LLC 

(72) Cassidy, David; 

(31) 05 734108 (32) 7 Nov 2005 (33) US 



(57) An apparatus for use with a system for warming an intravenous fluid 

to be administered to a living body, which includes a case through which 

an intravenous fluid line extends, is disclosed. The apparatus includes a 

housing configured for attachment to the case. The housing includes: 

several lithium polymer cells; 



a charger connected to the lithium polymer cells; 

a heater positioned to transfer heat to the case and attached to a thermal 

fuse; 

a fluid warmer microcontroller connected to the charger and the heater; 

a spread spectrum oscillator connected to the fluid warmer microcontroller; 

a battery condition indicator and controller connected to a fluid warmer 

cover closure signal and to the fluid warmer microcontroller; 

a first order battery protection circuit connected to elements selected from 

the group consisting of: the battery condition indicator and controller, at 

least one sensor connected to at least one of the lithium polymer cells, 

a cell balance circuit connected to the at least one of the lithium polymer 

cells, and a battery disconnect switch; 

a second order battery protection circuit connected to the at least one of 

the lithium polymer cells and the thermal fuse; and 

a fluid warmer over-temperature protection to sense the temperature of 

the case during use and connected to the thermal fuse. 

(21) 568772 (22) 27 Nov 2006 

(54) Truncated analogs of the peptide pYY3-36 that are neuropeptide-2 

receptor-agonists 

(86) PCT/EP2006/068924 (87) WO2007/065808 

(51) IPC2010.01:A61P3/10 


(72) Conde-Knape Karin; Danho, Waleed; Ehrlich, George; Fotouhi, Nader; 

Fry, David C; Khan, Wajiha; Konkar, Anish; Rondinone, Cristina Martha; 

Swistok, Joseph; Taub, Rebecca Anne; Tilley, Jefferson W; 

(31) 05 748071 (32) 7 Dec 2005 (33) US 

(31) 06 855249 (32) 30 Oct 2006 (33) US 



(57) Disclosed are neuropeptide-2 receptor agonists of formula (I), wherein 

X is 4-oxo-6-(I-piperazinyl)-3(4H)-quinazoline-acetic acid (Pqa) and R1- 

R14 are amino acids as defined in the specification. The compounds 

are useful for the treatment of obesity, diabetes and other metabolic disorders. 

(21) 568829 (22) 14 Oct 2006 

(54) Decorative effect coating compositions and methods of making and 

applying same 

(86) PCT/US2006/040341 (87) WO2007/061533 

(51) IPC2010.01:C09D5/29; B05D5/06; C09D5/02 

(71) United States Gypsum Company 

(72) Negri, Robert H; Bury, Rafael; 

(31) 05 287036 (32) 22 Nov 2005 (33) US 



(57) The disclosure is generally related to a coating composition, and more 

particularly to a decorative effect coating composition capable of producing 

a multi-coloured and/or multi-shaded appearance in a single application. 

The multi-colour effect arises through multiple tinting colorants 

that are substantially immiscible and which separate into separate layers 

upon application. The colour difference between the two layers should 

be at least about 0.25 delta E units. Additional decorative effects may be 

applied through shearing the surface with a putty knife or other instrument 

while the coating composition is still in the liquid or semi-liquid state. 

(21) 568865 (22) 20 Oct 2006 

(54) Acid milk beverage comprising polydextrose and a glucide, and process 

for its preparation 

(86) PCT/JP2006/320897 (87) WO2007/055089 

(51) IPC2010.01:A23L2/38; A23C9/152; A23L2/62 

(71) Kabushiki Kaisha Yakult Honsha 

(72) Nakano, Masatoshi; Matsui, Akihisa; Kobayashi, Yukiko; Akahoshi, 

Ryoichi; 

(31) 05 326977 (32) 11 Nov 2005 (33) JP 



(57) Disclosed is an acid milk beverage comprising polydextrose and at 

least one glucide selected from glucose, fructose, sugar, trehalose, maltose, 

erythritol, sorbitol, xylitol, maltitol, lactitol, palatinose and 

galactooligosaccharide, wherein the total amount of polydextrose and 

glucide is 12.0-17.0% by mass and the beverage contains substantially 

no thickening stabilizer. Also disclosed is a process for producing the 

above beverage. 

(21) 569136 (22) 29 Dec 2006 

(54) Piperazine compounds with a herbicidal action 

(86) PCT/EP2006/070271 (87) WO2007/077201 

(51) IPC2010.01:C07D241/08; A01N37/46; C07D401/06; C07D403/06; 

C07D409/06,12; C07D413/06; C07D417/06,12; C07F5/02; C07F7/10,18; 

C07F9/6509; C07K5/065 

(71) BASF SE 

(72) Hupe, Eike; Zager, Cyrill; Witschel, Matthias; Kuhn, Toralf; Moberg, 

William Karl; Parra Rapado, Liliana; Stelzer, Frank; Vescovi, Andrea; Puhl, 

Michael; Reinhard, Robert; Sievernich, Bernd; Grossmann, Klaus; 

Ehrhardt, Thomas; Rack, Michael; 

(31) 06 06000013 (32) 2 Jan 2006 (33) EP 



(57) Disclosed is the use of piperazine compounds of formula I or of the 

agriculturally useful salts of piperazine compounds of formula I as herbicides, 

the substituents being defined in the specification.

Patent Abridgements Part 1 [2.2 MB PDF] - Intellectual Property ...

Create successful ePaper yourself

Delete template?

Save as template?